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ABSTRACT
The Perplexing Paradox of Clostridioides (Clostridium) difficile Infection (CDI) –
Analysis of Anti-Germinants As Part of CDI Prophylaxis
By
Christopher Yip
Dr. Ernesto Abel-Santos, Examination Committee Chair
Professor of Chemistry and Biochemistry
University of Nevada, Las Vegas

Clostridioides (Clostridium) difficile infections (CDI) have become the leading
cause of nosocomial antibiotic-associated diarrhea worldwide. Under normal
circumstances, bacteria found in the gastrointestinal tract provide a barrier against C.
difficile colonization. Upon antibiotic therapy, the protective barrier is lost as the
microbial community becomes depleted thus providing the opportunity for C. difficile to
colonize the human gut. Exposure to taurocholate, a bile acid produced within the
mammalian gastrointestinal tract, causes C. difficile spores to begin their transition, a
process known as germination, from metabolically dormant structures to toxin-producing
cells. As germination is required for the onset of CDI, anti-germination compounds may
serve as disease prophylactics.
CamSA, a synthetic analog of taurocholate, was previously shown to inhibit C.
difficile strain 630 spores in vitro with an IC50 of 58.3 µM. CamSA was also shown to
protect mice from strain 630-induced CDI by inhibiting spore germination in vivo without
any overt toxicity. Since antibiotic treatment is a trigger for CDI, we examined the
iii

pharmacokinetic parameters of CamSA using an antibiotic-treated mouse model. Our
data suggests that CamSA is localized primarily to the murine intestinal lumen and liver,
while systemic absorption, distribution, and degradation of CamSA is minimal. Our data
also suggests that CamSA is being recognized as a bile acid and undergoes
enterohepatic circulation. This could be important in establishing a CamSA reservoir in
our animal model. Since CamSA was found in the liver, we also evaluated a potential
interaction between CamSA and CYP3A4, a P450 isozyme involved in drug
metabolism. We observed a weak interaction between CamSA and CYP3A4.
While CamSA may be a feasible prophylactic treatment, CDI has been further
complicated by the emergence of highly virulent variants of C. difficile. CamSA,
interestingly, is inactive against C. difficile strain R20291, a hypervirulent strain of C.
difficile. To increase the scope of anti-germination therapies for CDI prophylaxis, a
library of CamSA analogs was synthesized and assayed against C. difficile strain
R20291 spores. We were able to determine structure-activity relationships (SAR) from
this chemical library. Our SAR analyses suggest shorter alkyl chains between the amide
nitrogen and the aromatic side chain, as well as more constrained ring structures, allow
for better germination inhibition of C. difficile strain R20291 spores. These SAR
analyses would be used to further develop potent anti-germinants against C. difficile in a
rationalized manner. We identified 24 anti-germinants with IC50 values between 0.35 µM
and 37 µM. Several of these compounds are equally effective against strain 630 and
account for the most potent anti-germinants reported so far against C. difficile.
The germination response difference between C. difficile strains R20291 and 630
suggests that there are strain-specific mutations that alter bile acid recognition. Indeed,
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several clinically relevant C. difficile strains have been reported to exhibit a variety of
germination responses. We attempted to elucidate the genetic basis behind the
germination variations. By generating C. difficile knockouts and comparing a subset of
phenotypically different C. difficile strains, we verified three essential germination
proteins believed to function in germinant/anti-germinant recognition. We were,
however, unable to establish a correlation between these germination proteins and the
different germination phenotypes.
Lastly, conventional CDI treatments can often lead to the development of
antibiotic-resistant C. difficile. Several clinically relevant C. difficile strains have already
shown resistance to metronidazole. While vancomycin-resistant C. difficile have not yet
been reported, the possibility of vancomycin resistance exists as shown in other species
of bacteria. Thus, we determined the frequencies at which C. difficile spores could
become resistant to our anti-germinants. We also determined the frequencies where our
anti-germinants could trigger the germination and outgrowth of C. difficile spores.
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CHAPTER 1
INTRODUCTION

1.1. Clostridioides (Clostridium) difficile Background
Clostridioides (Clostridium) difficile is a flagellated, rod shaped bacterium from
the Phylum Firmicutes1. Members of the Firmicutes generally lack an outer membrane
and therefore display a Gram-positive phenotype (Fig. 1.1)2. The Firmicutes are
typically divided into the Clostridia and the Bacilli, two taxonomic classes able to
produce dormant endospores. The Clostridia are mostly obligate anaerobes and are
unable to undergo aerobic respiration whereas the Bacilli are usually obligate or
facultative aerobes.

Figure 1.1. Gram stain of C. difficile strain 630 and E. coli. When visualized under Brightfield or light microscopy, Gram-stained bacteria appear either purple (Gram-positive) or pink
(Gram-negative) and cell morphology can be observed. Gram-positive bacteria possess a thick,
outermost peptidoglycan cell wall that retains the primary stain, crystal violet, in the presence of
Gram’s iodide. Gram-negative bacteria possess an outer membrane and a thin peptidoglycan
cell wall that is unable to retain crystal violet; Gram-negative bacteria will stain pink when
treated with safranin following standard crystal violet and Gram’s iodide exposure. C. difficile

1

cells stain purple and exhibit rod-shaped morphology. E. coli cells stain pink and also exhibit
rod-shaped morphology but typically display shorter rods, compared to C. difficile.

Clostridioides (Clostridium) difficile, was originally placed in the genus
Clostridium. This genus was proposed in 1880, with the type species being Clostridium
butyricum. The genus later became a depository for other Gram-positive, spore-forming,
anaerobic organisms3. Examination of the chromosomal DNA from members of this
genus revealed a G+C content range too broad for a single genus (~21-54%).
Development of molecular methods, such as 16S rRNA sequencing, revealed the
extensive diversity of the Clostridium genus1. A total of 19 clusters were identified with
the type species Clostridium butyricum and “true” members of the genus Clostridium
being in cluster I, and Clostridium difficile in cluster XI3. Reclassification of Clostridium
difficile was considered necessary as the phylogenetic distance between C. difficile and
C. butyricum became more apparent4.
In 2009, a proposal was made to move several organisms located in cluster XI to
the family Peptostreptococcaceae5. Another proposal was made soon afterwards to
include several members of cluster XI into genus Peptoclostridium however, tree
topology and phylogenetic depth demonstrated that this inclusion would have been too
great to encompass within a single genus1. Moreover, a request for name validation for
genus Peptoclostridium was never received by the List Editors of the International
Journal of Systematic and Evolutionary Microbiology4. In 2018, Clostridium difficile was
reclassified into genus Clostridioides with the type species being Clostridioides difficile.
C. difficile was originally thought to be a commensal bacterium when it was first
discovered in the 1930s as part of the intestinal flora colonizing healthy newborns6–8. C.
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difficile is present in the stools of approximately 30-70% of infants, and 5-15% of healthy
adults9,10. However, due to the advent of antibiotic advancements and therapies, C.
difficile was revealed to be an opportunistic pathogen and the etiological agent of C.
difficile infections (CDI)8,11.

1.2. Sporulation
1.2.1. Introduction to Sporulation
During stressful conditions, most commonly through nutrient deprivation, C.
difficile is able to undergo a complex differentiation program known as sporulation to
produce highly resistant endospores (generally referred to as spores) (Fig. 1.2)12. Most
of our understanding of C. difficile sporulation has been based largely on studies done
in other endospore-forming bacteria, such as Bacillus subtilis12. While several
sporulation-associated genes are conserved between C. difficile and other well-studied
endospore formers based on genomic comparisons, there are also a considerable
number of genetic, regulatory, and phenotypic differences (vide infra)13–15.

3

Figure 1.2. Schaeffer-Fulton endospore stain of C. difficile strain R20291. A sporulating
culture of C. difficile R20291 was washed and stained using the Schaeffer-Fulton endospore
staining method. C. difficile endospores are stained blue in the presence of malachite green,
while the vegetative cells are counterstained pink with safranin.

1.2.2. Regulation of Sporulation
The sporulation program in B. subtilis has been studied in detail16,17. In B.
subtilis, the sporulation process is activated by an intricate signaling pathway consisting
of five histidine autokinases (KinA, KinB, KinC, KinD, and KinE) and two phosphorelay
proteins (Spo0F and Spo0B)15,18–20. KinA is the major kinase responsible for initiating
the sporulation process and contains three PAS domains. PAS domains are commonly
used to monitor the overall energy level of the cell and a variety of exogeneous factors.
As such, KinA provides a link between the external environment and the initiation of
sporulation21,22.
Following phosphorylation and activation of the histidine kinases, a phosphoryl
group is relayed onto Spo0F then transferred to Spo0B (by Spo0F~P)18. Lastly,
Spo0B~P phosphorylates and activates Spo0A23. Spo0A, a master transcription factor,
regulates the expression of several genes involved in the different stages of B. subtilis
differentiation. The activity of Spo0A is dependent on its phosphorylation state21,24.
Physiological responses such as cannibalism and competence occur at low levels of
Spo0A~P, whereas elevated levels of phosphorylated Spo0A result in the induction of
sporulation.
Given the physiological importance of Spo0A’s phosphorylation state, the
kinases and phosphorelay system that contribute to Spo0A activation are tightly
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regulated20,25. Indeed, this process is regulated on multiple levels given the number of
steps required for Spo0A phosphorylation26. Sda, a protein expressed during the
initiation of DNA replication, can inhibit KinA from phosphorylating downstream targets
such as Spo0F21. Regulation by Sda in this manner serves to prevent the formation of
non-viable spores with multiple copies of the chromosome (polyploid spores)21.
Spo0F~P and Spo0A~P are subject to dephosphorylation by the RapA and
Spo0E phosphatases, respectively. RapA transcription is dependent on the ComAComP two component system, which is activated by peptides secreted into the
extracellular medium during stationary phase25,27. Regulation by ComA-ComP/RapA
may be used to prevent sporulation from competing with stationary phase processes
such as competence. RapA activity can also be regulated by PhrA peptides. These
peptides are generated from the rapA operon; inhibition of RapA by PhrA may suggest
the cessation of competence25.
If the phosphorelay system is not hindered or inactivated, Spo0A subsequently
becomes activated. Once phosphorylated, Spo0A undergoes structural rearrangements
allowing it to bind to specific DNA elements known as the 0A box. Binding of Spo0A to
0A DNA elements represses the expression of genes normally required during
vegetative growth. Simultaneously, Spo0A upregulates the expression of genes
associated with sporulation, including sporulation-specific sigma factors18,23.
During the initiation of sporulation, an asymmetrically placed septum results in a
larger mother cell and a forespore. The mother cell and forespore are morphologically
distinct, but genetically identical; these structures undergo compartment-specific
transcription programs that drive sporulation through morphological changes28. SpoIIE,
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a sporulation-specific protein, has been suggested to play a role in positioning the
septum. Deletion or mutations that target SpoIIE result in mutants that are defective in
sporulation, or cells with abnormally thick septa29.
Two sporulation specific sigma factors, sF and sE, are produced in a Spo0Adependent manner in the forespore and mother cell, respectively. Both sF and sE are
partially active until asymmetric division has been completed28. Once fully activated, sF
drives the expression of sG and SpoIIQ in the forespore (Fig. 1.3). sF also drives the
expression of SpoIIR, a protein required for sE activation and expression of ~300 genes
in the mother cell21. sE upregulates spoIIIAA-AH and genes required for the mother cell
to engulf the forespore following septum formation28,30. SpoIIQ and SpoIIIAA-AH form a
channel that bridges the mother cell and the developing forespore31. This channel is
required for the transport of various molecules to and from the forespore to activate and
regulate sporulation-specific gene products such as the sigma factor sG in the
forespore21,30,31.
Once activated, sG indirectly upregulates the transcription and activation of the
mother-cell specific sigma factor sK. sG also drives the transcription of genes required
for germination (vide infra) and for the completion of sporulation.
Factors produced by sG also traverse the SpoIIQ-SpoIIIAA-AH channel to
proteolytically activate sK. Active sK in the mother cell upregulates genes required for
cortex and coat formation28. At the completion of sporulation, the mother cell lyses and
a mature spore is released into the environment.
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Figure 1.3. Basic regulation of sporulation in B. subtilis and C. difficile. Once sporulation is
initiated, an asymmetric septum divides the larger mother cell from the smaller developing
forespore. Phosphorylated Spo0A (Spo0A~P) drives the expression of sE and sF in the mother
cell and forespore, respectively. After asymmetric division has completed, sE and sF upregulate
genes required for spore formation. Several compartment-specific molecules are able to
traverse the mother cell/forespore boundary via the SpoIIQ-SpoIIIAA-AH channel to activate
factors required for the continuation of sporulation.

1.2.3. C. difficile Sporulation
As an obligate anaerobic bacterium, the vegetative cells of C. difficile are highly
susceptible to oxygen poisoning32–34. However, in order to transmit infection and survive
in aerobic environments, C. difficile must produce oxygen-tolerant spores (vide infra)35.
The signals that trigger C. difficile sporulation have yet to be identified but
environmental stimuli such as nutrient limitation have been suggested to play a pivotal
role in this process36,37. Similar to the initiation of sporulation in B. subtilis,
phosphorylation of Spo0A is a required event for sporulation in C. difficile. Spo0A is
believed to function similarly in C. difficile as it is able to bind to the distinct 0A box
sequences, albeit the DNA binding domain of C. difficile Spo0A is able to function in the
absence of phosphorylation23. Orthologs of Spo0F, Spo0B, and the autokinases (KinA,
KinB, KinC, KinD, and KinE) do not seem to be encoded by the C. difficile genome38.
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Previous research demonstrated that C. difficile encodes putative orphan histidine
kinases, several of which are believed to affect sporulation37,38. Indeed, when one of the
putative histidine kinases (CD2492) was inactivated, the mutants displayed a
sporulation defect whereby only 4% of the population generated spores37,38. The exact
mechanism as to how Spo0A becomes phosphorylated in C. difficile remains unclear.
The absence of B. subtilis Spo0F and Spo0B orthologs may suggest that putative
histidine kinases directly phosphorylate Spo0A in C. difficile36.
Once C. difficile Spo0A becomes phosphorylated, it upregulates sigF and sigE to
drive the cascade of sporulation factors36. The sporulation process in C. difficile is
controlled similarly by the four sigma factors (sF, sE, sG, and sK) that drive sporulation in
B. subtilis. Although the sigma factor architecture between the mother cell and the
forespore is well conserved, the late sporulation sigma factors are differentially
regulated in C. difficile as compared to B. subtilis (Fig. 1.3)36,39. sG activation seems to
occur independently of sE, can occur prior to the completion of forespore engulfment,
and is solely dependent on sF36,37,39. Additionally, sK activation in the mother cell occurs
independently of sG but is directly dependent on sE36. While the crisscross regulation of
the sporulation sigma factors is reliant on SpoIIQ-SpoIIIAA-AH channel, the presence of
this channel in C. difficile may suggest the transport of other factors essential for
sporulation37.

1.2.4. Structure and Resilience of Bacterial Spores
Spores are robust structures highly resistant to desiccation, UV damage,
corrosive chemicals, extreme temperatures, and antibiotics8,40,41. Spores exhibit minimal
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metabolic activity and are therefore, usually considered dormant42,43. The spore’s
resistance results from several semi-permeable membranes, thick proteinaceous layers,
a rigid cortex, and a dehydrated core (Fig. 1.4)40,43. These characteristics have allowed
spores to remain viable over prolonged periods of time. For example, cells of Bacillus
sphaericus were reportedly revived from spores isolated from 25-40 million-year-old
amber, as well as other spore forming species from 250 million-year old salt
crystals40,44. Relevant to C. difficile pathology, the resistance afforded by the spore
allows these structures to persist indefinitely on hospital surfaces12
The innermost structure of the spore is a dehydrated core that houses the
bacterial chromosome and will later form the cytoplasm of the vegetative cell45.
Whereas the water content in growing cells comprises approximately 75-80% of wet
weight, the water content in the spore core is considerably lower (approximately 2850%)46. The core contains monovalent cations, a high concentration (up to 1 M) of
calcium ions (Ca) complexed with pyridine-2,6-dicarboxylic acid (DPA), and small acidsoluble proteins (SASP)47. The high concentration of Ca-DPA complex maintains the
spore in a dehydrated state which protects macromolecules from heat damage. SASPs,
on the other hand, are specialized proteins that compact DNA and protect the
chromosome from UV damage21,40,47,48. Indeed, in vitro studies with recombinant SASPs
have been shown to bind DNA and protect it from DNase I degradation48.
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Figure 1.4. General structure of the bacterial endospore. The innermost structure of the
endospore is the dehydrated core (white) containing the bacterial DNA, SASPs, and a high
concentration of Ca-DPA and protons. Surrounding the core is a compressed inner membrane
(dotted red line); putative Ger receptors are believed to localize to the spore’s inner membrane.
The germ cell wall (purple) surrounds the inner membrane and will later become the cell wall of
the outgrowing cell. A flexible cortex (blue) surrounds the germ cell wall to regulate osmotic
pressure resulting from the hypertonic core. Hydrolysis of the cortex is catalyzed by CLEs CwlJ
and SleB and is required for spore germination (vida infra). Surrounding the cortex is a vestigial
structure known as the outer membrane (dotted black line). Lastly, proteinaceous coats (gray)
found outermost on the spore play structural roles and provide resistance against various
degradative enzymes and chemicals.

Surrounding the spore core is a compressed and rigid phospholipid bilayer
known as the inner membrane. The inner membrane, formed from the forespore
membrane, has low water permeability consistent with maintaining the low water
content in the core40,48. Studies using FRAP (fluorescence redistribution after
photobleaching) analyses demonstrated the immobility of proteins within the inner
membrane, suggesting a gel-like state49. The rigidity of the inner membrane suggests
that this structure as the main permeability barrier that restricts small molecules from
entering the core50,51.
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Moving outward from the core, the next structural feature is the germ cell wall.
The germ cell wall is chemically and structurally similar to the peptidoglycan found in
actively-growing vegetative cells45,52. Indeed, at the completion of germination (vide
infra), the germ cell wall eventually becomes the cell wall of the outgrowing cell while
the spore’s inner membrane becomes the bacterium’s cell membrane40,52.
Encasing the germ cell wall is a thick layer of specialized peptidoglycan known
as the cortex. The cortex peptidoglycan possesses several structural modifications that
allow it to be specifically degraded during germination. Compared to the germ cell wall,
the cortex has lower levels of cross-linking, resulting in a more flexible structure. The
flexibility of the cortex contributes to the stability of the spore by regulating osmotic
pressures generated by the hypertonic core40. Cortex formation is regulated by sK and
is therefore formed by precursors produced in the mother cell that become transported
across the outer membrane of the developing forespore45. Surrounding the cortex is an
outer membrane. The outer membrane is derived from the mother cell and does not
seem to play a role in resistance, nor does it seem to act as a selective barrier40,43. The
outer membrane may, however, act as a scaffold for the spore coats (vide infra)53.
Above the outer layer are proteinaceous layers known as the spore coats. The
coats play extensive roles in the spore’s resistance to a variety of environmental insults
such as antibiotics and disinfectants40,43,54. While the exact mechanism for which the
coat layers confer protection remains unknown, the coats might act as a selective
barrier to exclude degradative enzymes and antagonistic molecules from entering the
spore. The coat morphology and composition vary considerably between different
bacterial species. In B. subtilis, the coats can be sectioned into three distinct layers
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visible by transmission electron microscopy (TEM) and ruthenium red staining. In
contrast, only two layers are apparent in Bacillus anthracis54. Approximately 80 different
proteins comprise the coat layers in B. subtilis. The proteins that comprise the coats are
most likely niche specific, mediating the spore’s dispersal within an environment or
association with a specific host54.
In some bacterial species, a glyco-proteinaceous structure called the exosporium
loosely surrounds the spore coats. While the exosporium is absent in B. subtilis, it is
present in Bacillus cereus and B. anthracis. Several publications have also suggested
the presence of an exosporium layer in C. difficile and other Clostridia55,56. Similar to
cortex and coat formation, exosporium formation is dependent on sK activation and is
formed in the mother cell concurrently with the aforementioned layers55. While the
exosporium does not seem to confer any significant resistant properties, it is believed to
facilitate attachment of the spore to its cognate host or environment36,55,56.

1.3. Germination
1.3.1. Introduction to Germination
Following dissemination into an environment, bacterial spores must transform
back into vegetative bacteria in order to complete their lifecycle. The process by which
the spore reverts back into a metabolically active, vegetative bacterium is known as
germination43,57–60. Germination is a complex, transcription-independent, biochemical
cascade of spatially- and temporally-regulated events that degrade spore-specific
structures, ultimately leading to the outgrowth of vegetative cells.
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1.3.2. The Canonical Germination Process (Nutrient Germination)
Similar to sporulation, much of what is understood about germination has been
based off B. subtilis studies. Most commonly, the process of germination is initiated by
the recognition of specific signal molecules known as germinants. Germinants often
signal the return to conditions that are supportive of vegetative growth. However, while
bacteria often respond to nutrient limitation by initiating sporulation, the signal for the
initiation of germination between different bacterial species is less conserved.
Germinants commonly include metabolites such as sugars, amino acids,
nucleosides, and salts58. The identity of the germinants, as well as their effective
concentrations, are generally tailored to a bacterium’s specific environment42. For
example, spores from Paenibacillus larvae, a honeybee pathogen, germinate in
response to L-tyrosine and uric acid. These metabolites are found at high
concentrations and co-localize only in the midgut of developing bee larvae61. On the
other hand, Paenibacillus sordellii spores, a human pathogen commonly associated
with gynecologic procedures can germinate with several different amino acids in
conjunction with bicarbonate62,63. Interestingly, bicarbonate is found at high
concentrations (up to 90mM) in female reproductive tracts, compared to other tissue
groups64. As such, bacterial spores have evolved germination responses that are
selective for their specific niche.
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Figure 1.5. General schematic of the canonical germination process. (A) Germinant
Recognition. Germinants traverse through the spore coats (gray), outer membrane (dotted
black line), cortex (blue), and germ cell wall (purple) to reach the spore’s inner membrane (red
dotted line). (B) Stage I of Germination. After germinants are recognized by their cognate
receptors, the spore releases monovalent cations (primarily H+) and Ca-DPA from the core. An
influx of water occurs following Ca-DPA release. (C) Stage II of Germination. Ca-DPA
released from the spore core triggers the activation of CLEs in the cortex. Once activated, CwlJ
and SleB degrade the cortex and the core continues to rehydrate and expands. (D) Spore
Outgrowth. The germ cell wall and core reform into the peptidoglycan cell wall and cytosol,
respectively. The newly germinated vegetative cell resumes cellular metabolism.

Germinant recognition in B. subtilis is believed to occur via proteinaceous
heterocomplexes, known as germination (Ger) receptors, found on the spore’s inner
membrane58,59. Ger receptors are encoded by a tricistron operon, a genetic region
comprising of three protein-coding genes termed the A-, B-, and C- subunits42.
The A- subunit of Ger receptors is comprised of hydrophobic and hydrophilic
domains and shares homology to late-sporulation proteins with no known function42,65.
The B- subunit is believed to be a transmembrane protein due to the presence of 10
putative transmembrane helices. Genetic evidence suggests that the B- subunit may be
involved in germinant recognition58,60,66,67. The C- subunit is likely a lipoprotein65.
Lipidation of C- subunits is required for germination42,68. Ger receptor homologs have
been identified in other species of sporulating bacteria and the essentiality of these
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receptors has been demonstrated. Knockout mutations or mutations that compromise
any of the Ger subunits result in spores that are unable to germinate42,58,59.
Germinant recognition has been shown to occur in a stereospecific manner. For
example, B. subtilis spores germinate in response to L-alanine. In contrast, D-alanine is
not a germinant but can inhibit L-alanine-mediated germination43. Moreover, point
mutations to Ger receptor subunits can alter germinant specificity and concentration
dependence43. Gain-of-function mutations with altered germinant responses have been
mapped to either the A- or B- subunits of the corresponding Ger receptors, suggesting
that both subunits may be involved in germinant recognition42,69. Similarly, single point
mutations of the C-subunit that eliminate its potential anchoring to the membrane result
in a germination null-phenotype70.
After binding to cognate germinants, the process of germination can be divided
into two stages (Fig. 1.5). The processes and signal transductions that occur between
germinant recognition and Stage I initiation have yet to be identified43. Stage I of
germination is marked by the release of ions from the spore core, predominantly in the
form of protons (H+)43. The release of H+ elevates the spore core’s pH from 6.5 to 7.758.
Following the efflux of monovalent cations, Ca-DPA is released from the spore core, a
process believed to be facilitated by the protein SpoVA 71. SpoVA proteins play a role in
DPA uptake during sporulation. However, how the SpoVA channel becomes activated
during germination and alters its function to release DPA is unknown58,71. After DPA is
released, an influx of water occurs to replace the lost Ca-DPA resulting in the partial
hydration of the core. The increase in core pH and partial core hydration serve to
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restore physiological conditions that are required for enzymatic activity and resumption
of cellular metabolism.
Stage II of germination begins with the activation of cortex-lytic enzymes (CLEs)
(Fig. 1.5). CLEs degrade muramic acid-d-lactams (MAL), found only in the cortex
peptidoglycan. Hence, the absence of muramic-d-lactams from the germ cell wall
ensures that it does not become degraded by CLEs and can be reused by the upcoming
vegetative cell58. B. subtilis encodes two partially redundant CLEs, SleB and CwlJ58.
Several studies have suggested that SleB may be packaged into spores in an active
form. Indeed, purified SleB is able to degrade cortex peptidoglycan in vitro, as well as in
decoated spores71. How SleB activity is regulated in the dormant spore remains
unknown but it is believed that YpeB, a protein required for SleB localization, may
modulate SleB’s activity71,72. The second CLE, CwlJ, is activated in a Ca-DPA
dependent manner. Hence, CwlJ is activated at the end of stage I of germination,
ensuring that this stage is completed prior to initiation of Stage II43,60,71,73. Interestingly,
DPA-less B. subtilis spores germinate spontaneously. This phenotype can be
suppressed by deletion of sleB, but not with cwlJ71. This further demonstrates that CwlJ
activation is dependent on Ca-DPA, while SleB is active independent of Ca-DPA71.
Upon CLE activation, the cortex becomes degraded (Fig. 1.5). Cortex
degradation is required for the continued influx of water to rehydrate the core. Toward
the end of Stage II, the core’s water content rises to nearly 80%, approximately equal to
that found in growing cells43. The continued hydration of the spore core results in the
expansion of the germ cell wall, resumption of cellular metabolism, and macromolecule
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synthesis. Following a lag period, ranging from 30 minutes to 24 hours, outgrowth
occurs, and vegetative cell replication resumes57.

1.3.3. Non-Nutrient Germination
The process of germination is most commonly triggered and described by the
recognition of germinants/nutrient signals (vide supra). In addition to these nutrient
signals, abiotic factors including high pressure, osmotic regulators, and chemical
surfactants, can trigger spore germination59,60. Interestingly, spores have also been
shown to germinate in response to a variety of community signals71,74.
CwlJ activation is dependent on Ca-DPA released from the spore core during
Stage I of germination. Studies have shown that exogenous Ca-DPA can also activate
CwlJ and subsequently trigger spore germination75. To wit, B. subtilis spores with
compromised expression of Ger receptors germinate poorly in response to L-alanine but
germinate normally compared to wild-type spores when exposed to Ca-DPA76,77. In
these cases, exposure to Ca-DPA bypasses Ger receptor activation and Stage I of
germination. The activation of CwlJ by exogenous Ca-DPA however, only occur at nonphysiologically high concentrations due likely to the low permeability of Ca-DPA through
the spore coats43,78,79. Germination in response to high concentrations of exogenous
Ca-DPA could serve as a quorum sensing mechanism to coordinate an orchestrated
germination response within a bacterial population.
Bacterial cell walls are comprised of muropeptide monomers that are crosslinked
to form the rigid peptidoglycan. Muropeptides differ between bacterial species; in B.
subtilis, chains of N-acetylglucosamine and N-acetylmuramic acid are attached to stem
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peptides with meso-diaminopimelic acid (m-Dpm), whereas Staphylococcus aureus
contain stem peptides with L-lysine80. Muropeptides derived from growing B. subtilis
cultures are able to trigger B. subtilis spore germination by activating PrkC, a Ser/Thr
kinase found on the spore’s inner membrane57,80. Conversely, muropeptides containing
L-lysine derived from S. aureus are unable to trigger B. subtilis germination unless B.
subtilis expresses S. aureus PrkC57,80. Through this mechanism, PrkC activation can
bypass Ger receptor activation as B. subtilis spores lacking Ger receptors can
germinate with muropeptides57,80. The use of muropeptides as a signal for germination
could suggest the return to favorable conditions, as evident by the presence of growing
bacteria in the local environment.

1.3.4. C. difficile Germination
The uniqueness and divergence of C. difficile from other sporulating bacteria is
most apparent when comparing the germination process between C. difficile and B.
subtilis81. Germination in most other sporulating bacteria, is triggered by the initial
recognition of germinants by Ger receptors. Homologs of Ger receptor genes have been
identified in other Clostridia and Bacilli. However, these genes are conspicuously absent
from the C. difficile genome42. The absence of conventional Ger receptor genes from C.
difficile may suggest that C. difficile spores respond to unique germinants82. Indeed, C.
difficile spores must detect environmental signals or metabolites in order to initiate
germination and return to vegetative growth. Work from our lab and others have shown
that C. difficile spores respond to a variety of bile acids and amino acids found naturally
in the mammalian gastrointestinal tract37,82,83. More specifically, we have pinpointed to
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taurocholate, a conjugated bile acid, as the main trigger for the germination in C. difficile
spores83,84. Similarly, chenodeoxycholate, a naturally occurring secondary bile acid, was
shown to inhibit C. difficile spore germination83,85. Since the GI tract of animals is the
only place where large concentrations of bile acids are present, this suggests that C.
difficile has adapted to replicate in the host gut.
A culmination of different studies have suggested the presence of a distinct C.
difficile germination receptor that is unrelated to the canonical Ger receptors82–85. In
2013, Francis et al. published data suggesting that bile acids are recognized by CspC, a
catalytically-inactive serine protease86. While convention Ger receptors are located on
the spore’s inner membrane, C. difficile CspC is believed to localize to the spore cortex.
In contrast to B. subtilis, C. difficile only encodes a single CLE, SleC, that
degrades the spore cortex following germinant recognition. Cortex degradation by SleC,
however, occurs prior to Ca-DPA release81. As such, CLE activity in C. difficile do not
seem to be regulated in a manner similar to other Bacilli or Clostridia. Following cortex
degradation, the osmotic constrains placed on the spore inner membrane are relieved
allowing for the subsequent release of Ca-DPA from the spore core87.

1.4. Germination and its Relevance to CDI
CDI begins with the ingestion of C. difficile spores that are contaminating the
environment, most commonly hospital surfaces. Upon entering the mammalian
gastrointestinal tract, the spores are exposed to two different fates dependent on the
host. In one scenario, prior to antibiotic treatment, commensal and symbiotic
gastrointestinal microbiota provide a barrier against C. difficile colonization by occupying
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nutrient-rich niches. Upon antibiotic therapy, however, this protective barrier is lost as
the microbial community becomes depleted, thus providing the opportunity for C. difficile
to colonize the human gut. As germination from a metabolically dormant C. difficile
spore to a toxin-producing C. difficile cell is required for the onset of CDI, the
germination process plays a pivotal role in C. difficile pathogenesis.
Bile acids are produced by the liver, stored in the gallbladder, and secreted into
the duodenum where they play key roles in lipid metabolism. Primary bile acids are
synthesized from cholesterol through a series of enzymatic reactions, and exist primarily
as cholate and chenodeoxycholate in humans88,89. These primary bile acids usually
become conjugated with either taurine or glycine to increase their solubility (Fig.
1.6)88,90. Conjugated primary bile acids are continually secreted into the duodenum
where a vast majority becomes reabsorbed and recycled back to the liver88,90.
Approximately 3% of the bile acid pool enters the small intestine where they undergo a
series of biochemical transformations catalyzed by gastrointestinal microbiota88,89,91.
Glycochenodeoxycholate, for example, is hydrolyzed at the amide bond by bacterial bile
salt hydrolases resulting in chenodeoxycholate and glycine. Primary bile acids can be
further processed by microbial dehydroxylases to form secondary bile acids88,90–92.
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Figure 1.6. Bile acid metabolism in the GI tract. Primary bile acids, such as
chenodeoxycholate and cholate, are synthesized from cholesterol in the liver. Primary bile acids
are then conjugated with either glycine or taurine to generate conjugated primary bile acids and
secreted into the duodenum. Gastrointestinal microbiota found in the lower small intestine
produce bile salt hydrolases that deconjugate the glycine and taurine moieties from the primary
bile acids. In the cecum and large intestine, primary bile acids are dehydroxylated by several
species of endogenous bacteria, generating secondary bile acids. Cholate, cholate derivatives,
and glycine (outlined in green) promote C. difficile spore germination. Chenodeoxycholate
(outlined in red) is a competitive inhibitor of C. difficile germination. Secondary bile acids (dotted
line), such as lithocholate and deoxycholate, are antagonists of C. difficile spore outgrowth and
vegetative growth.

Prior to antibiotic treatment, mouse ileal contents contain mostly conjugated and
unconjugated primary bile acids and a low concentration of secondary bile acids (Fig.
21

1.6). Deconjugation of conjugated primary bile acids reduces the concentration of
taurocholate in the upper gastrointestinal tract, limiting C. difficile spores’ ability to
germinate. In parallel, bile salt hydrolases increase the concentration of
chenodeoxycholate found in the small intestine. Whereas taurocholate triggers C.
difficile spore germination, chenodeoxycholate is a competitive inhibitor of taurocholatemediated germination85. As C. difficile spores transit into the cecum, they encounter a
high concentration of secondary bile acids89. Secondary bile acids, such as
deoxycholate and lithocholate, are antagonists of C. difficile spore outgrowth and
vegetative growth, thereby preventing intestinal colonization by C. difficile (Fig.
1.6)82,89,92.
During and post-antibiotic therapy, the abundance of gastrointestinal microbiota
within an individual decreases, potentially leading to a reduction in bile salt hydrolases.
A reduction in bile salt hydrolases results in elevated levels of taurocholate and
decreased levels of chenodeoxycholate in the ileum. This change in the bile acid pool
provides an environment conductive of C. difficile spore germination. Moreover, the
decreased microbial diversity also reduces the abundance of bile acid dehydroxylases,
which leads to a decrease in secondary bile acid production. The absence of
chenodeoxycholate, deoxycholate, and lithocholate permits C. difficile spore
germination and subsequent outgrowth, and toxin-producing cell multiplication93.
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1.5. Clostridioides difficile Infection (CDI)
1.5.1. CDI Diagnosis and Symptoms
CDI is defined by symptoms of diarrhea in combination with a stool test that is
positive for C. difficile or C. difficile toxins, colonoscopic or histopathologic identification
of pseudomembranous colitis94. Disease severity can be categorized as mild, severe, or
complicated. The severity of CDI is based on a range and rubric of symptoms. Mild
cases of CDI are defined solely by the presence of diarrhea10. Patients with severe CDI
exhibit elevated white blood cell counts (>15,000 cells/mm3), diarrhea, and in some
cases abdominal tenderness10. In extremely severe (complicated) cases of CDI,
patients can exhibit pseudomembranous colitis (PMC), fever >38.5°C, hypotension,
increased blood cell count (>35,000 cells/mm3), and organ failure. In patients with
complicated CDI, PMC can often devolve into a condition known as toxic megacolon
which can lead to the rupture of the colon. With extremely severe and complicated
cases of CDI, patients are frequently admitted into intensive care and the presence of
toxic megacolon and organ failure can often result in death10.

1.5.2. Significance
C. difficile infections have become the leading cause of nosocomial antibioticassociated diarrhea worldwide36,37. In the United States alone, there are approximately
500,000 cases annually with associated costs estimated to be about $6.3 billion in
treating the disease8,95–97. The costs associated with treating CDI are expected to rise
further due to the increasing number of CDI incidences98.
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CDI is also a highly recurrent disease: recurrences within 8 weeks of an initial
episode is approximately 15-25% with associated fatalities estimated to be 9.3%97,99.
The subsequent risk of recurrence following a second episode of CDI is further
increased to approximately 65%100. Moreover, CDI recurrence can occur by reestablishment of the original infecting strain, or a different strain of C. difficile101.
CDI has been associated primarily with patients that have recently undergone
antibiotic exposure. Commonly used antibiotics such as macrolides, third generation
cephalosporins, penicillins, and fluoroquinolones, are most frequently associated with
the onset of CDI. Elderly and immunocompromised individuals are also highly
susceptible to CDI due to their close association with antibiotic use. Other CDI
susceptible groups include patients undergoing chemotherapy, gastric acid suppression
therapy, or patients that recently undergone certain surgical procedures (vide infra)97.
More recently, community-acquired CDI has been reported in patients at low risk for
CDI102. As such, CDI has a broad range of targets and continues to be a growing
concern.

1.5.3. Emergence of Hypervirulent C. difficile Strains
Recently, new strains of C. difficile have begun to emerge, leading to deadly CDI
outbreaks. These so called “hypervirulent” strains of C. difficile are generally
characterized by increased rates of sporulation or toxin production. Some hypervirulent
strains also produce additional toxins not expressed by common clinical strains (vide
infra)103. BI/NAP1/027 strains are the most common and notorious hypervirulent C.
difficile isolates. These strains have been associated with either severe or complicated
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cases of CDI and are also resistant to several classes of antibiotics including
fluoroquinolines104–106. Furthermore, hypervirulent strains have been associated with
outbreaks in low risk individuals that have not been exposed to antibiotics. The recent
and continued emergence of hypervirulent C. difficile strains has further complicated
CDI management in clinical settings103,105,107,108.

1.5.4. C. difficile Toxins
The symptoms and pathology associated with CDI are mainly due to the action of
two major C. difficile toxins, TcdA and TcdB. Indeed, several non-toxigenic C. difficile
strains exist and do not elicit disease, pointing to toxin production and activity as the
etiological link to CDI symptoms109. C. difficile’s ability to produce toxins is heavily
dependent on resource availability. When carbon sources and other essential nutrients
are readily available, toxin expression is inhibited. In contrast, toxin production is
upregulated during stationary phase growth when resources are low. This type of
regulation suggests that C. difficile virulence is employed to improve nutrient
availability8,110.
The genes encoding TcdA and TcdB are found within a 19.6 kb region on the
chromosome known as the pathogenicity locus (PaLoc). PaLoc also houses genes that
encode for TcdR, an alternative sigma factor, TcdC, an anti-sigma factor that interacts
directly with TcdR, and TcdE, a putative holin that is involved with toxin release from the
bacterial cell111.
During vegetative growth, CodY, a global regulator, binds to the tcdR promoter
and inhibits TcdR production. CodY binding only occurs in the presence of GTP thereby
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providing a link between resource availability and toxin production. When resources are
depleted, the GTP concentration drops and CodY leaves the tcdR promoter, allowing
production of the sigma factor. Even then, toxin production can be downregulated by the
interaction of TcdC with TcdR, that results in a decreased affinity of TcdR for the RNA
polymerase holoenzyme112. If toxin production is ready to proceed, TcdR binds to the
RNA polymerase holoenzyme to upregulate tcdA, tcdB, and tcdE expression113.
Interestingly, some hypervirulent strains of C. difficile with mutations in tcdC have
exhibited increased virulence due likely to dysregulated, higher toxin expression113,114.
TcdA and TcdB are isozymes that have four functional domains: an N-terminal
glucosyltransferase domain (GTD), an autoprocessing domain, a pore-forming and
delivery domain, and a C-terminal binding domain108,110,115. The C-terminal binding
domains allow the toxins to recognize and interact with different sugar and protein
moieties found on the host cell surface110. TcdB binds to chondroitin sulfate
proteoglycan 4 (CSPG4) and poliovirus receptor-like 3 (PVRL3) found on the surface of
intestinal epithelial cells. TcdA binds to glycoprotein 96 and sucrase isomaltase found
on human colonocytes8,115. Once these toxins are bound to their cognate substrates,
they become internalized by host cell endocytosis. Acidification of the endosome
causes the toxins to undergo conformation changes. These changes allow the toxins to
traverse the endosomal membrane and enter the host cytosol. In the cytosol, the toxins
undergo autoprocessing, releasing and activating the N-terminal GTD domain110.
Activated GTD then transfers glucose to several crucial Rho proteins. Rho proteins play
essential roles in regulating the host cell’s cytoskeleton. Glycosylation of Rho proteins
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result in their inactivation which causes cytopathic effects including disruption of tight
junctions and increased epithelial permeability8,111,116.
In addition to TcdA and TcdB, some strains of C. difficile also produce a third,
unrelated toxin. Clostridium difficile transferase (CDT) is a ribosyltransferase that can
bind to lipolysis-stimulated lipoprotein receptor (LSR), and is encoded by two genes
(cdtA and cdtB) located at a genetic region termed CdtLoc8,117–119. Once translocated
into the host cytosol, CDT ribosylates actin. Low concentrations of CDT induce
microtubule protrusions from the host-cell membrane, facilitating C. difficile adherence.
At high CDT concentrations, ribosylation activity inhibits actin polymerization, resulting
in cytoskeleton collapse118. The ability of C. difficile to adhere to host cells by CDT may
facilitate the toxic effects of TcdA and TcdB, leading to more severe disease119. Patients
with CDI caused by these CDT-expressing strains have also been shown to be at a
higher risk of CDI recurrence108. Indeed, strains that express CDT have been correlated
with more severe outcomes of CDI119. While only a small percentage of C. difficile
strains express CDT, the hypervirulent 027 ribotypes are amongst these strains120. The
environmental signals that regulate or lead to CDT expression have not yet been
elucidated100.

1.5.5. Transmission
Patients with CDI continually shed large quantities of C. difficile spores and
vegetative cells in their feces (Fig. 1.7)121. Exposure to oxygen results in a significant
loss in viability for the C. difficile vegetative cells. However, the spores’ innate resilience
allows them to persist indefinitely under normal atmospheric conditions. This results in
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C. difficile contaminating different environments such as hospital surfaces, personnel,
and equipment122. Moreover, C. difficile has been isolated from different animals and
animal products and various organisms can act as potential reservoirs for the
transmission of C. difficile spores123,124.

Figure 1. 7. The C. difficile infection cycle. Following ingestion of C. difficile spores (blue
circles), spores transit through the gastrointestinal tract of a mammalian host where they can
germinate and outgrow into toxin producing, vegetative C. difficile cells (red ovals). CDI patients
continually excrete C. difficile cells and spores in their feces. C. difficile spores that were shed
from a CDI patient can re-infect the original host or be transferred to different hosts through the
oral-fecal route. Vegetative C. difficile cells do not survive under aerobic conditions or the acidic
gastric environment and rarely elicit disease.

Once in the environment, C. difficile is most commonly transferred to different
hosts through the oral-fecal route (Fig. 1.7). Ingestion of vegetative C. difficile cells
rarely elicits disease since they are killed by the acidic gastric environment. However,
patients undergoing gastric acid suppression are at an increased risk of CDI possibly
due to more viable C. difficile cells in the host121. Ingested C. difficile spores on the
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other hand, are able to survive passage through the GI tract where they are then able to
germinate inside the host and, given the appropriate conditions, cause disease92,125.

1.5.6. Current Treatments
Treatments for CDI require thorough and rigorous regimens that include
decontamination of the local environment along with antibiotic therapy. Complete
decontamination is often difficult due to C. difficile’s ability to form highly resistant
spores. Hypochlorite has been shown to reduce the frequency of CDI, assumingly by
reducing the viability of C. difficile spores. Several guidelines suggest the use of an
unbuffered 1:10 dilution of hypochlorite as high concentrations are often corrosive or
toxic126. However, the use of chlorine-based decontaminants often requires the
subsequent use of neutralization solutions. Alternative approaches for decontamination
include the use of UV light or gaseous hydrogen peroxide. However, the costeffectiveness and efficacy of these approaches against C. difficile spores still remain
unclear100.

1.5.6.1. Antibiotics
Initial and mild CDI cases are usually treated with metronidazole (Fig. 1.8).
Metronidazole is a nitroaromatic pro-antibiotic that is used to treat various anaerobic
infections. Metronidazole has also been used as part of prophylaxis to reduce
postoperative infections127. Due to metronidazole’s low molecular weight, it is able to
enter C. difficile’s cytoplasm through passive diffusion. In anaerobic bacteria, flavodoxin
and ferredoxin act as electron acceptors when pyruvate becomes oxidatively
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decarboxylated128. However, in the presence of metronidazole, the nitro group on the
imidazole ring of metronidazole acts as the terminal electron acceptor. Reduction of the
nitro group results in a nitroso free radical that targets DNA. Since only anaerobic
bacteria are able to activate metronidazole, only bacterial DNA subsequently undergoes
oxidative damage resulting in numerous single stranded and double stranded
breaks8,128.
While metronidazole was considered the first line antibiotic for the treatment of
CDI, several clinically relevant C. difficile strains have shown resistance to
metronidazole127. Additionally, metronidazole treatment usually fails in patients with
severe disease and the use of metronidazole beyond the first CDI recurrence is not
recommended due to the risk of azole metabolite neurotoxicity129,130.

Figure 1. 8. Structures of antibiotics commonly used to treat CDI.

Recent guidelines have elevated oral vancomycin over metronidazole as the
preferred antibiotic of choice in CDI treatment (Fig. 1.8)99,129,131. Vancomycin is a large,
amphiphilic, broad-spectrum antibiotic that inhibits peptidoglycan maturation in Gram30

positive bacteria8,128. Moreover, vancomycin can also inhibit outgrowth of C. difficile
spores. Vancomycin, when administered orally, is absorbed minimally by the intestines,
and can be found at high concentrations in the gut and feces suggesting that
vancomycin co-localizes at the site of infection. Although vancomycin resistance exists,
it has not yet been reported in C. difficile128,129.
Metronidazole and vancomycin treatments can continue to suppress the
gastrointestinal microbiota, ultimately leading to CDI recurrence after cessation of antiCDI treatment8,132. Fidaxomicin, a newer anti-CDI treatment, is active against C. difficile
and shows minimal activity against several commensal bacterial species found in the
mammalian gut (Fig. 1.8)133. Fidaxomicin is a naturally occurring antimicrobial that
inhibits bacterial RNA polymerase, effectively preventing and terminating
transcription134. Compared to other RNA polymerase inhibitors that prevent the initiation
and elongation steps, fidaxomicin halts transcription by binding to RNA polymerase prior
to DNA separation128,131. Interestingly, fidaxomicin has been shown to inhibit spore
production and, similar to vancomycin, can prevent the outgrowth of C. difficile
spores8,134–136. While fidaxomicin demonstrates higher efficacy and lower rates of
recurrence when compared to both metronidazole and vancomycin, it still leads to
recurrence in approximately 13% of patients130. Furthermore, the cost of fidaxomicin is
substantially higher than vancomycin, making it a less attractive form of CDI
treatment137.
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1.5.6.2. Alternative Forms of Treatment
Due to the paradox of treating CDI with antibiotics and the subsequent high rates
of recurrence, several non-antibiotic and prophylactic regimens have been proposed
and developed to treat CDI8. One of the major alternative approaches used to treat
severe and recurrent CDI is fecal microbiota transplantation (FMT)138. FMT introduces
stools from a healthy donor into the colon of a CDI patient139. This procedure aims to
restore the natural gut flora that was disrupted by antibiotic use. Re-establishment of
commensal and symbiotic gut bacteria could shift the bile acid pool to concentrations
that prevent C. difficile spore germination or outgrowth. FMT has demonstrated
exceptionally high rates of success (77-100%) and is more cost effective in treating
recurrent CDI than vancomycin or fidaxomicin8,139. While the use of FMT has
demonstrated compelling evidence as a treatment for CDI, the aesthetics of FMT is
often unpalatable to patients. More problematic, a subset of patients that underwent
FMT following CDI also developed gastrointestinal disorders including abdominal
cramping, constipation, and irritable bowel syndrome140. Recently, several deaths have
been attributed to FMT. These deaths have been attributed to opportunistic pathogens
present in the stool from the donor141. Due to these issues, the FDA recently cancelled
all clinical trials involving FMT.
TcdA and TcdB are the two major etiological agents associated with the
symptoms and pathology of CDI. Hence, targeting these toxins could serve to control
the course of CDI8. Previous studies have demonstrated the use of antibodies to
inactivate TcdA and TcdB, thereby preventing the toxin-mediated morbidity associated
with CDI142. Recently, actoxumab and bezlotoxumab, two human monoclonal
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antibodies, were developed against TcdA and TcdB, respectively143. Actoxumab and
bezlotoxumab bind to the C-terminal regions of TcdA and TcdB, and prevent the toxins
from interacting with their cognate receptors on host cell surfaces144. Bezlotoxumab was
found to be effective against CDI in mice, hamsters, and piglets and advanced onto
human trials143,145. As of 2016, Bezlotoxumab (Zinplava) has been approved for human
use by the FDA. While anti-toxins are effective against CDI symptoms, anti-toxins
against CDT have not yet been reported. Moreover, anti-toxins play no role in inhibiting
C. difficile colonization and may need to be used in conjunction with other forms of
treatment8.
The development of a C. difficile vaccine has been an ongoing effort for the past
two decades. Since TcdA and TcdB are the main determinants of CDI, they have been
the target of numerous attempts for vaccine development 146. Administration of the C.
difficile toxoids, derived from a strain that is hyper-productive for both TcdA and TcdB,
conferred protection in hamsters134. Following intramuscular injection and rectal
immunization, however, no anti-TcdA antibodies were found in the feces147. This
suggests that circulating antibodies were responsible for eliciting protection and that
passive immunization may be possible. Further studies demonstrated a vaccine
developed by Sanofi Pasteur not only protected hamsters from CDI, but was also able
to increase IgG titers in these animals148. However, other vaccine targeting C. difficile
toxins have failed during clinical trials.
Vaccine development has been geared primarily toward C. difficile toxins.
Several studies have also focused on targeting surface antigens expressed by C.
difficile. C. difficile vegetative cells contain three intricate carbohydrate structures
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termed PSI, PSII, and PSIII149. When inoculated with PSII, antibodies were raised
against the surface antigen in mice and rabbits. However, the protective efficacy of
these antibodies and the use of PSII as a vaccine remains unknown147. While vaccines
that target surface antigens and vaccines developed from inactivated toxins may reduce
the symptoms of CDI, asymptomatic colonization by C. difficile still occurs. The
presence of a C. difficile reservoir could potentiate disease following vaccination
cessation and depletion of circulating antibodies.

1.5.6.3. Prophylaxis
Since the germination of C. difficile spores inside a host is required for
subsequent toxin production and the establishment of disease, one approach to CDI
management could be by blocking spore germination. Anti-germination therapy has
been proposed, representing a new paradigm in CDI treatment and prophylaxis150.
Cholate-derived molecules, such as taurocholate and deoxycholate, are able to trigger
the germination of C. difficile spores. Chenodeoxycholate and other
chenodeoxycholate-based molecules, such as lithocholate, were shown to inhibit C.
difficile spore germination by competing with taurocholate83,85.
The ability of chenodeoxycholate to inhibit C. difficile spore germination
juxtaposes in vivo scenarios where non-antibiotic treated individuals do not develop
disease92. However, when antibiotic-treated animals were administered a 50 mg/kg oral
gavage of chenodeoxycholate, these animals developed moderate to severe CDI signs
following C. difficile spore challenge151. Furthermore, a single 300 mg/kg dose of
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chenodeoxycholate resulted in immediate death, presumably due to chenodeoxycholate
precipitation upon interaction with gastrointestinal liquids.
Several chenodeoxycholate analogs were later identified and proved to be more
efficacious than chenodeoxycholate at inhibiting C. difficile spore germination in vitro93.
Ursodeoxycholate, a minor secondary bile acid and stereoisomer of
chenodeoxycholate, was recently shown to be active against a panel of clinically
relevant C. difficile strains152. Ursodeoxycholate was also able to treat ileal pouchitis
associated with recurrent CDI, but was unable to prevent CDI in hamsters153,154.
Stoltz et al. later published data on compounds that were potent inhibitors of C.
difficile germination. These compounds also contained modifications that limited their
intestinal absorption, allowing them to effectively co-localize with C. difficile spores in
the intestinal lumen155. Interestingly, these compounds were effective at preventing the
germination of a NAP1 hypervirulent strain of C. difficile. The efficacy of their most
potent compounds, however, remains unknown against other C. difficile strains.
The Abel-Santos lab started a structure-activity relationship (SAR) study to
understand how C. difficile spores recognize bile acids84. In this process, CamSA, a
synthetic bile acid analog, was shown to be a potent inhibitor of C. difficile strain 630
spore germination in vitro (Fig. 1.9). Furthermore, a single 50 mg/kg dose of CamSA
was able to completely protect mice from strain 630-induced CDI by inhibiting spore
germination in vivo even when challenged with an unnaturally massive C. difficile spore
inocula150,151. CamSA alone could not protect hamsters from CDI but could double the
mean time of death156. However, when used in conjunction with suboptimal
concentrations of vancomycin, CamSA could protect hamsters from CDI. Similar to the
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study and compounds developed by Stoltz et al., the efficacy of CamSA against other
C. difficile strains remains unknown.
A previous study conducted by Heeg et al. demonstrated that C. difficile isolates
exhibit a range of germination responses when treated with either taurocholate or
chenodeoxycholate157. Further studies by Thanissery et al. demonstrated that the
efficacy of C. difficile anti-germinants are, indeed, strain dependent152. Thus, the genetic
diversity of C. difficile strains presents a substantial challenge in developing antigerminants effective against a broad spectrum of C. difficile isolates.

Figure 1. 9. Structures of CamSA and compound 12a. CamSA, a potent germination inhibitor
of C. difficile 630 in vitro and in vivo, is a meta-aminobenzene sulfonic acid derivative of cholate.
Compound 12a is an aniline derivative of cholate and a potent germination inhibitor of C. difficile
630 and R20291 germination in vitro.

1.6. Research Aims
CamSA, a metanilic acid derivative of taurocholate, was previously shown to
inhibit the germination of C. difficile strain 630 spores both in vitro and in vivo84,150,151.
To be effective in humans, CamSA and other anti-germinants, should demonstrate not
only efficacy, but low toxicity, negligible drug-drug interactions, and low intestinal
absorption. Low intestinal absorption will allow these compounds to co-localize with C.
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difficile spores in the gastrointestinal tract, hence preventing the germination process in
vivo. Furthermore, low absorption will also prevent systemic distribution of CamSA,
lowering the possibility of side-effects and host toxicity. Previous in vitro data (vide
supra) suggested that CamSA is retained in the intestines. These studies also
suggested that CamSA might be actively transported into the lumen by P-glycoproteins
(P-gp) due to the high permeability from the basolateral chamber151.
Thus, the first aim of this study was to examine how bile acid analogs behave in
vivo using the murine model of CDI. To investigate the pharmacokinetic parameters,
antibiotic-treated mice were administered a single dose of CamSA. CamSA and CamSA
byproducts were then quantified from feces, blood, and tissue groups at different time
points. Our data suggests that CamSA is localized primarily to the murine intestinal
lumen and liver. In this antibiotic-treated model, systemic absorption, degradation, and
distribution of CamSA is minimal. Since CamSA was detected in the liver, we also
assayed for a potential interaction between CamSA and CYP3A4, a major liver enzyme
involved in drug metabolism.
While CamSA may be a feasible prophylactic treatment, CDI has been further
complicated by the emergence of hypervirulent strains of C. difficile. Interestingly, we
found that CamSA is inactive against C. difficile strain R20291, a hypervirulent strain of
C. difficile41. The second aim of this study was to identify anti-germinants that would be
active against hypervirulent strains of C. difficile. For this purpose, a library consisting of
approximately 200 cholate analogs with side chain modifications was synthesized by
our collaborators. We subsequently assayed these compounds for anti-germination
activity against C. difficile strain R20291 spores Upon screening the bile acid library, we
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identified compound 12a, an aniline derivative of cholate (Fig. 1.9). Compound 12a has
an IC50 value of 1.8 µM against strain R20291, representing an anti-germinant that is
225 times more potent than the natural germination inhibitor, chenodeoxycholate.
Compound 12a was also more effective than CamSA at preventing C. difficile 630 spore
germination. From this chemical library, our collaborators determined quantitative
structure activity relationships (QSAR). QSAR analyses suggested that active antigerminants occupied smaller molecular volumes and were more hydrophobic than their
inactive counterparts. In our hands, we also determined structure-activity analyses from
a limited subset of cholate analogs. Our SAR analyses suggest shorter alkyl chains
between the amide nitrogen and the aromatic side chain, as well as more constrained
ring structures, allow for better germination inhibition of C. difficile strain R20291 spores.
SAR analyses from this study would allow for the rational design of more potent antigerminants as part of CDI prophylaxis.
The germination response difference between C. difficile strains R20291 and 630
suggests that C. difficile strains may recognize and respond to germinants differently.
Indeed, several clinically relevant C. difficile strains have been reported to exhibit a
variety of germination phenotypes. In the third aim of this study, we attempted to
elucidate the genetic basis behind C. difficile germination variation. Through a series of
genetic knockouts, natural mutant enrichments, and by comparing a subset of
phenotypically different C. difficile strains, we verified three essential germination
proteins believed to function in germinant/anti-germinant recognition. We were,
however, unable to establish a correlation between these germination proteins and the
different germination phenotypes. Through this study, we also investigated the
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frequencies of anti-germinant resistance, as well as the frequencies in which C. difficile
spores could germinate in response to our anti-germinants.
Through these studies, we expect to identify potent anti-germinants effective
against C. difficile. We hypothesize that these anti-germinants would be used as part of
CDI prophylaxis following systematic characterization in vitro and in vivo. These
compounds could also be used as molecular probes to identify germination variations
between different C. difficile strains.
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CHAPTER 2
PHARMACOKINETIC PARAMETERS OF CAMSA AND CAMSA ANALOGS
2.1. Background
2.1.1. Pharmacokinetics overview
Pharmacokinetic (PK) analysis is essential to understanding the fate of drugs
through living organisms and is required as part of drug discovery and development158.
PK analyses specifically determine how drug candidates are processed in vivo159.
Following oral administration, drugs must survive the challenging and changing
environments of the gastrointestinal tract. Subsequently, drugs may be subject to
metabolism by various degradative and detoxifying enzymes. Metabolism of these
drugs (vide infra) can frequently lead to inactivation but, in some cases, also produce
metabolites with adverse side effects. The fate of a drug in vivo can be determined
following four major parameters: absorption, distribution, metabolism, and excretion
(ADME) (Fig. 2.1)158–160. In vitro assays can often be used to predict ADME parameters
prior to in vivo testing. Furthermore, some PK analyses can include in vitro and in vivo
assays to evaluate drug toxicity (ADME-Tox).
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Figure 2.1. Fate of administered drugs. Pharmaceutical and candidate drugs administered
orally can be absorbed into the bloodstream from the small intestine. Drugs are often subject to
metabolism primarily by the liver. Drug and drug byproducts can be distributed systemically or
excreted.

The gastrointestinal epithelium is a dynamic system consisting of various
differentiating, proliferating, and functioning cells. The inner wall of the small intestine is
covered by a layer of cells that form a rate-limiting, selective barrier against the
systemic distribution of metabolites and xenobiotics161. Our ability to fully study this
system has been hindered by the limited availability of human intestinal epithelial cell
lines. Moreover, while animal models for this system exist, major differences have been
observed between at least humans and rodents162. Human colon adenocarcinoma
(Caco-2) cells have been used widely as an in vitro surrogate model to evaluate the
absorption and transport of drug candidates across the intestinal epithelium161,163. Caco2 cells, when cultured onto support filters, can differentiate and form monolayers that
are structurally and functionally similar to the intestinal epithelium. Furthermore, Caco-2
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cells also express various enzymatic and transporter systems, including apical efflux
mechanisms163.
A large number of drug candidates often fail the later stages of drug development
resulting from unexpected human metabolism. Metabolism of drug candidates can often
produce byproducts that lack efficacy in vivo or molecules that elicit unfavorable side
effects164. Cytochrome P450s (CYPs) represent a family of enzymes responsible for the
biotransformation of many environmental toxins and endogenous compounds165,166.
CYPs can detoxify xenobiotics and decrease drug efficiency through a series of
oxidation reactions. These CYP-catalyzed reactions can also increase drug effects or
produce toxic byproducts, such as the generation of carcinogenic compounds from noncarcinogenic precursors160,165. Altogether, CYPs are often implicated in several
scenarios where drug candidates become ineffective in vivo, as well as cases where
adverse drug effects and toxicity occur164.
Screening for CYP-drug interactions at earlier stages of drug development could
eliminate toxic or inactive molecules in vivo164. A number of in vitro approaches have
been developed to screen for CYP metabolism. These approaches include colorimetric-,
radiometric- or fluorescent-based assays164,167. Fluorescent-based assays utilize
substrates that are metabolized by P450 isozymes, generating a highly fluorescent
byproduct. Assessment using these assays is based on a candidate drug’s ability to
either inhibit P450 isozyme activity or to compete with the fluorogenic substrate’s
binding site, whereas the latter suggests that the candidate drugs may be a substrate
for a specific P450 isozyme164,167.
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2.1.2. Bile acid metabolism
Bile acids are amphipathic molecules produced in the liver and stored in the
gallbladder. Bile acids are subsequently released from the gallbladder into the small
intestine, and function to facilitate the digestion and absorption of lipids and liposoluble
xenobiotics168. The concentration of bile acids in the intestinal lumen often vary but can
reach millimolar levels169.
Primary bile acids are synthesized from cholesterol through a series of enzymatic
reactions, and exist mainly as cholate or chenodeoxycholate in humans88,89. These
primary bile acids become conjugated with either glycine or taurine moieties prior to
secretion from the gallbladder. Once conjugated, the bile acids become more water
soluble but are also less permeable to cell membranes, allowing them to be retained
primarily in the intestines90,170.
Following secretion into the small intestine, a majority (~95%) of the bile acids
are reabsorbed either passively, or actively by ileal enterocytes171,172. Bile acids
absorbed in this manner are deposited into the portal bloodstream, where they become
partly bound to albumin88. Bile acids in the portal vein are transported back to the liver
for uptake by hepatocytes91,173. This movement of bile acids between the liver and the
intestines, termed enterohepatic circulation, plays an essential role in bile acid recycling
and homeostasis174. Although absorption of bile acids from the small intestine is an
efficient process, bile acid uptake by hepatocytes during enterohepatic circulation is
imperfect. Indeed, while bile acids are found primarily in the liver and intestines,
approximately 0.5 mg can also be found in systemic circulation due to spill over from
enterohepatic circulation88,175.
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Bile acids in the small intestine are subject to processing and metabolism by the
gastrointestinal microbiota (Fig. 2.2). These bacterially-catalyzed reactions can occur
on the steroid backbone, or at the C-24 side chain91. In the small intestine, several
species of bacteria express bile salt hydrolases (BSHs) that deconjugate the C-24 side
chain moieties. Glycocholate, a conjugated primary bile acid, can be hydrolyzed by
BSHs resulting in glycine and cholate. Following deconjugation, the resulting bile acids
can be absorbed by the small intestine, transported back to the liver, re-conjugated, and
reused170.

Figure 2.2. Bile salt diversity before and after bacterial biotransformation. BSHs remove a
majority of the taurine and glycine moieties from conjugated bile salts released from the
gallbladder. Additional bacterial enzymes convert the primary bile salts into secondary bile salts
in the lower gastrointestinal tract. “Other” bile salts refer to oxidized forms and β-isomers of
secondary bile salts. Values were obtained and adapted from Ridlon et al. 2006. CA, cholate;
CDCA, chenodeoxycholate; DCA, deoxycholate; LCA, lithocholate; UDCA, ursodeoxycholate.

Approximately 5% of the total bile acids released from the gallbladder can
escape enterohepatic circulation and enter the large intestine. Bile acids that enter the
large intestine can be dehydroxylated, oxidized, or undergo epimerization catalyzed by
commensal bacteria91,92,174. One of the most important bile acid transformations is
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dehydroxylation at the C-7 position of the steroid backbone. These reactions are
catalyzed by bacterial 7α-dehydroxylases and convert the primary bile acids cholate and
chenodeoxycholate to the secondary bile acids deoxycholate and lithocholate,
respectively173,176. Interestingly, bacterial 7α-dehydroxylases can only utilize
unconjugated bile acids as substrates177–179. Secondary bile acids are still subject to,
albeit limited, enterohepatic circulation. Following transport back to the liver, secondary
bile acids can be re-conjugated and re-secreted. Humans, however, lack the ability to
re-hydroxylate the C-7 position180.
The bile acid pool is defined as the population of bile acids found circulating in
the liver, intestine, gallbladder, and enterohepatic circulation174. While bile acids may be
found in systemic circulation, their small amounts are generally disregarded and not
included as part of the bile acid pool. Bile acids can often be lost in the feces if they
escape enterohepatic circulation. Moreover, bile acids that spill over into systemic
circulation can be captured and filtered out by the kidneys and excreted in the urine.
The fate of bile acids can also be altered by the gastrointestinal microbiota.
Unconjugated bile acids bind to transport sites in the small intestine with lower affinity
and thus pass more frequently into the large intestine, ultimately leading to excretion in
the feces. Similarly, deoxycholate and lithocholate, two highly toxic secondary bile acids
produced as a result of bacterial metabolism, are absorbed poorly into enterohepatic
circulation. As such, enterohepatic circulation and metabolism by endogenous bacteria
can often alter the fate of bile acids and the composition of the bile acid pool.
Bile acids, in addition to their many physiological functions, can often exhibit
deleterious effects166. Some bile acids have been shown to alter DNA synthesis during
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liver regeneration, suggesting a relationship between bile acids, cell proliferation, and
carcinogenic effects178. Additionally, bile acids can induce apoptosis in hepatocytes by
activation of the Fas death receptor181. The cytotoxic effects of bile acids could also be
due to their amphipathic nature and high concentrations, allowing them to exhibit
detergent-like properties. Altogether, bile acid regulation is an essential process that
dictates the delicate balance between physiological functions and pathological effects.
Bile acid sulfation is an essential process used to eliminate excess or toxic bile
acids from the body, thereby regulating the concentration of certain bile acids within the
bile acid pool91,178. A group of mammalian enzymes, called sulfotransferases, transfer a
sulfonate group (SO3-) from 3’-phosphoadenosine-5’-phosphosulfate to a substrate’s
hydroxyl, amino, or carboxylate group176,182. In humans, mono-sulfated bile acids are
the most common, with only a small proportion of poly-sulfates. Of the mono-sulfates,
sulfation occurs primarily at the 3-OH position, followed by the 7-OH position. Monosulfation at the 3-OH and 7-OH positions also occurs predominantly in rats and
hamsters182.
Importantly, the sulfation process produces bile acids that are less toxic and also
more water soluble183. Sulfated bile acids are also less prone to intestinal absorption
and absorption by hepatocytes173. As such, the limited absorption of bile acids from the
small intestine can restrict enterohepatic circulation. Moreover, sulfated bile acids that
enter enterohepatic circulation are captured inefficiently by hepatocytes. Sulfated bile
acids that spill over into systemic circulation are often excreted into the urine following
capture by the kidneys. Thus, bile acid sulfation can limit the recycling of bile acids,

46

ultimately altering their fates, and shifting the bile acid population toward fecal and renal
excretion183.
Sulfation has substantial effects on the composition of the bile acid pool. Sulfated
bile acids are often resistant to deconjugation by bacterial BSHs and other microbial
transformations that would normally occur in the small intestine182. Interestingly, in one
study, bile acid desulfation was observed when sulfated bile acids were incubated with
large intestinal contents; bile acid desulfation was not observed using small intestinal
contents182. Following transit into the large intestine, these bile acids can be desulfated
and deconjugated where absorption is minimal.
The physiological effects of the sulfation process can be best demonstrated with
the secondary bile acid lithocholate. Lithocholate is highly insoluble and one of the most
toxic bile acids180,182. Following intestinal absorption, lithocholate is transported back to
the liver where it becomes sulfated and re-conjugated183,184. Following secretion into the
small intestine, 3-sulfo-lithocholate is eventually lost in the feces due to limited intestinal
absorption, both from being sulfated and conjugated91,182. Indeed, significant quantities
of 3-sulfo-lithocholate, along with other sulfated bile acids can be found in the ceca of
humans184.

2.1.3 Effect of bile acid analogs on C. difficile germination and prevention of CDI
Following ingestion by a mammalian host, C. difficile spores eventually enter the
small intestine where they are exposed to a variety of chemical signals. Taurocholate, a
conjugated primary bile acid, is the most important chemical signal required for C.
difficile spore germination. The gastrointestinal microbiota often provide a barrier
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against C. difficile colonization by metabolizing taurocholate. Bile acid metabolism by
the microbiota can also generate chenodeoxycholate-derived bile acids that are
antagonists of C. difficile spore germination. Following antibiotic exposure, the
gastrointestinal microbiota becomes depleted leading to higher levels of the
taurocholate germinant and lower levels of the chenodeoxycholate anti-germinant.
Thus, antibiotic exposure frequently results in the mammalian gastrointestinal tract to be
conductive of C. difficile spore germination, outgrowth, and vegetative growth.
CamSA, a meta-aminobenzene sulfonic acid derivative of cholate, is a synthetic
inhibitor of taurocholate-mediated C. difficile spore germination84,151. Significantly, the
anti-germination activity of CamSA conferred complete protection from murine CDI,
even when animals were dosed with an unnaturally massive inoculum of C. difficile
spores150. CamSA alone could not completely prevent the onset of disease in the more
susceptible hamster model of CDI however, under the same conditions, CamSA
doubled the mean time of death of infected hamsters 156. Given the in vivo differences
between the murine and hamster models, CamSA may be subjected to differential
processing between the two organisms.
Complete protection from CDI signs in the murine model of CDI required only a
single 50 mg/kg dose of CamSA150,151. This is an intriguing result since CDI onset
occurs over the course of days for individual mice, indicating potential timing differences
with in vivo spore germination. Furthermore, we have shown that spores are retained in
the intestine of mice for up to 3 days post-challenge. We also observed that hamsters
can be protected by CamSA for up to 16 days before developing disease156. Hence
CamSA seems to affect CDI onset for days after dosage.
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In order to prevent the onset of CDI, anti-germination compounds should ideally
remain in the gastrointestinal tract and be retained in the intestinal lumen where they
co-localize with C. difficile spores. As such, it would be favorable for the anti-germinants
to display low systemic absorption. Previous studies using Caco-2 monolayers
suggested that CamSA would be retained in the intestinal lumen151. Even more,
differential uptake across the monolayer suggests that any systemic CamSA might be
actively transported back into the intestinal lumen. At the end of this assay, 100%
CamSA was recovered, demonstrating that CamSA is not metabolized by epithelial
cells.
Since CamSA has a structure that closely resembles conjugated bile acids, it is
possible that processes affecting the composition of the bile acid pool could also
influence CamSA’s pharmacokinetic parameters. Distribution of CamSA into peripheral
tissues needs to be evaluated in order to fully understand CamSA’s bioavailability158,185.
Given the likelihood that CamSA is retained in the intestinal lumen, we expect that
systemic distribution of CamSA would be minimal. CamSA’s poor bioavailability would
become an important measure to ensure that it does not circulate outside the intestinal
lumen where it could elicit adverse effects to other organs. Enterohepatic circulation
could potentially recycle CamSA following absorption from the intestinal lumen and
movement to the liver and gallbladder. Since hepatocyte uptake during enterohepatic
circulation is not an absolutely efficient process, spillover of CamSA into systemic
circulation and subsequent distribution to other tissue and organ groups is a
possibility88. Sulfation of CamSA could also occur. The sulfation process could further
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highlight the possibility that CamSA is retained in the intestinal lumen, partitioned into
the feces, and eventually eliminated from the body.
In order to be effective at preventing CDI, CamSA should be stable throughout
the gastrointestinal tract and resist chemical and structural modification. CamSA could
be hydrolyzed into cholate and metanilic acid (mSA) by bacterial BSHs. Bifidobacterium
longum and Lactobacillus gasseri are two bacterial species found endogenously within
the mammalian gut and are common test strains of BSH production. When incubated
with growing cultures of B. longum and L. gasseri, approximately 80% of CamSA was
hydrolyzed after 24 hours151. These conditions, however, are not physiological, since
following antibiotic treatment, the population of BSH-producing bacteria would be
depleted. CamSA could also be dehydroxyated to the 7- and or 12-deoxy analogs in the
large intestine following deconjugation.
To determine the ADME-Tox parameters for CamSA, we used a series of in vitro
and in vivo assays. Our in vitro assays suggest a weak interaction between CamSA and
CYP3A4. At this point, however, we are unable to determine if this interaction results
from CamSA inhibiting CYP3A4 activity, or if CamSA is an alternative substrate for
CYP3A4. Using an antibiotic-treated mouse model for CDI, our data shows that CamSA
is localized primarily to the murine intestinal lumen and liver. In this model, we also
show that systemic absorption, metabolism, and distribution of CamSA is minimal.
Interestingly, the fact that CamSA is found in the liver and is absent from systemic
circulation could suggest that CamSA is subjected to recycling by enterohepatic
circulation.
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2.2. Materials and Methods
2.2.1. General Comments
CamSA, 7-deoxy-CamSA, and 12-deoxy-CamSA were synthesized and purified
by the Abel-Santos laboratory at the University of Nevada, Las Vegas. Cholic acid and
metanilic acid were purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA).
The Vivid™ CYP3A4 Green Screening Kit (Cat # P2857) was purchased from Thermo
Fisher Scientific (Waltham, MA, USA). RP-HPLC separation was conducted using a
PRP-1 column (Cat # 79422) purchased from Hamilton Company (Reno, NV, USA).
HPLC analyses and mass spectra were obtained using an Expression-L compact mass
spectrometer (CMS) purchased from Advion (Ithaca, NY).

2.2.2. Animal Preparation
Animal protocols were performed in accordance with the Guide for Care and Use
of Laboratory Animals outlined by the National Institutes of Health. The protocols were
reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at
the University of Nevada, Las Vegas. Weaned female C57BL/6N mice were purchased
from Charles River Laboratories (Wilmington, MA, USA) and housed in groups of five
mice per cage at the University of Nevada, Las Vegas animal care facility. All water,
food, bedding, and cages were sterilized prior to contact with animals. Upon arrival at
the facility, the mice were quarantined and allowed to acclimate for one week prior to
experimentation. Animal manipulations were performed in a biosafety level 2 laminar
flow hood.
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2.2.3. CDI Animal Model
The murine CDI induction model used in this study was adapted from procedures
published by Theriot et al186. Briefly, mice were given cefoperazone (0.5 mg/ml) and
allowed to drink the antibiotic water ad libitum for at least 5 days prior to CamSA
administration. The antibiotic water was refreshed every three days, or as needed. On
the day of administration, mice were given 50 mg/kg CamSA via oral gavage, then
individually caged with enrichment. The mice remained on antibiotic water throughout
the duration of the experiment.

2.2.4. Feces Sample Preparation
Following CamSA administration, total mouse feces from each cage was
collected every 2 h for the first 24 h, then periodically over the course of a week. The
samples were stored at 4°C until use. At the time of processing, feces from each
individual cage was resuspended with water and vortexed until completely
homogenized. The suspension was centrifuged at 21,130 x g for 5 minutes to pellet
down insoluble fecal matter. The supernatant, containing CamSA, was filtered through a
0.2 µm PES syringe filter to remove particulates. The resulting filtrate was stored at
room temperature until separation and quantification by HPLC-MS.

2.2.5. Liver and Blood Sample Preparation
Following CamSA administration, animals were sacrificed 4, 12, 22, 32, and 120
hours post-CamSA administration. The livers were collected and stored at 4°C until use.
At the time of processing, livers from each time point was mixed with water and
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homogenized using a tissue grinder. The suspension was mixed with 1 volume (v/v) of
acetonitrile (ACN) and vortexed to precipitate soluble proteins. The sample was then
centrifuged at 21,130 x g for 5 minutes to pellet down precipitated proteins and insoluble
matter. The supernatant, containing CamSA, was filtered through a 0.2 µm nylon
syringe filter to remove particulates. The resulting filtrate was stored at 4°C until
separation and quantification by HPLC-MS.
Blood was collected from sacrificed animals by heart puncture and stored at 4°C
until use. At the time of processing, a 25 µl aliquot of blood sample was mixed with
water and centrifuged at 21,130 x g for 5 minutes. The serum/supernatant was filtered
through a 0.2 µm PES syringe filter to remove particulates. The resulting filtrate was
stored at 4°C until separation and quantification by HPLS-MS.

2.2.6. Detection of CamSA and mSA from Mice
Processed mouse feces, liver, and blood preparations were subjected to reversephase high-performance liquid chromatography (Table 2.1). Briefly, 10 µl of sample was
injected and separated using a polystyrene divinylbenzene (PSDVB) column (4.1 x 250
mm; 7 µm). Separations were carried out using an isocratic elution of 40% ACN, 5 mM
ammonium acetate, and 0.1% formic acid with a flow rate of 1.3 ml/min.
Elution of CamSA and mSA was monitored by fluorescence at 254 nm. Mass
spectrometer (MS) detection was operated in the negative ionization mode following
electrospray ionization (ESI) (Table 2.2). The areas of peaks corresponding to the
molecular weights of CamSA and mSA were determined and quantified using Data
Express (Advion).
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Parameter
Column

Value
Hamilton PRP-1 (4.1 x 250 mm, 7 µm)

Solvent A

Water (5mM ammonium acetate, 0.1% formic acid)

Solvent B

ACN (5mM ammonium acetate, 0.1% formic acid)

Flow rate

1.3 ml/min

Column temp.

Ambient
10 µl

Injection vol.

Table 2.1. HPLC conditions.

Parameter

Value

Ionization mode

ESI

Source voltage

+3500 V; -2500 V

Capillary voltage

120 V

Source gas temp.

250°C

Capillary temp.

250°C

Scan range (m/z)

100-600

Table 2.2. MS conditions.

2.2.7. Interaction of CamSA with CYP3A4
To test for an interaction between CamSA and CYP3A4, the Vivid™ CYP3A4
Green Screening Kit (Thermo Fisher Scientific) was used. Briefly, 40 µl aliquots of
CamSA and taurocholate standards were added to 96-well clear bottom, black plates
containing P450 BACULOSOMES® (baculovirus-infected microsomes) expressing an
isozyme of CYP3A4. The plates were incubated at RT for 10 minutes to allow the test
compounds to interact with CYP3A4 in the absence of enzyme turnover. As a control for
CYP3A4 inhibition, microsomes were treated with 10 µM ketoconazole, a known
inhibitor of CYP3A4187. Following the addition of the Vivid® Substrate to each well,
fluorescence (excitation, 485 nm; emission 520 nm [appropriate wavelengths for the
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unbound substrate]) was measured every minute for 1 h. CamSA and taurocholate were
resuspended in deionized (DI) H2O. All experimental conditions were performed in
triplicate and the final volume in each well was 100 µl.

2.3. Results and Discussion
2.3.1. Metabolism of CamSA by Gastrointestinal Microbiota
(This study was performed by A. Howerton as part of her Ph. D. thesis
dissertation)
Previous work demonstrated that CamSA was stable when incubated in artificial
gastric and intestinal juices151. CamSA, however, was susceptible to deconjugation
when incubated with growing cultures of B. longum and L. gasseri151. In order for
CamSA to be effective at preventing C. difficile spore germination, CamSA should
remain unmodified during transit through the gastrointestinal tract. Under more
physiological conditions, CamSA was slowly hydrolyzed by the gastrointestinal
microbiota of heathy mice (Fig. 2.3). The gastrointestinal microbiota from antibiotictreated mice, however, were unable to hydrolyze CamSA. In fact, it took 96 hours to
degrade 50% of CamSA by the gut microbiota of antibiotic-treated mice.
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Figure 2.3. Hydrolysis of CamSA under physiological conditions. Under physiological
conditions, CamSA is slowly hydrolyzed into cholate and metanilic acid (mSA) by the
gastrointestinal microbiota of healthy mice but is stable against the microbiota of antibiotictreated mice. CamSA was incubated with feces collected from mice before antibiotic-treatment
(black bars), or 1-day post-antibiotic treatment (white bars). The data represent the averages
from five independent measurements (n = 5), and error bars represent the standard deviations.

2.3.2. Efficacy of CamSA Metabolites in the Prevention of Murine CDI
(This study was performed by A. Howerton as part of her Ph. D. thesis
dissertation)
CamSA metabolites were assayed for their ability to prevent CDI by inhibiting C.
difficile strain 630 spore germination in vivo. When challenged with strain C. difficile
strain 630 spores, CamSA treated mice developed little to no signs of CDI. In contrast,
mice treated with a mixture of cholate and mSA to mimic the deconjugation of CamSA
developed severe CDI and reached clinical endpoint 48 hours post-challenge (Fig. 2.4).
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The effect of CamSA dehydroxylation was also examined. Mice treated with 12-deoxyCamSA developed similar symptoms as mice treated with the mixture of cholate and
mSA and reached clinical endpoint 48 hours post-challenge. Interestingly, mice treated
with 7-deoxy-CamSA developed only moderate CDI. These data suggest that CamSA,
and not its metabolites, is responsible for CDI prevention.

Figure 2.4. Effect of CamSA metabolites on CDI severity in spore challenged mice.
CamSA could be deconjugated and/or dehydroxylated by the gastrointestinal microbiota. To test
for the effect of CamSA metabolites, mice were treated with DMSO (black bars), cholate + mSA
(gray bars), 12-deoxy-CamSA (diagonal-dashed bars), 7-deoxy-CamSA (checkered bars), or
CamSA (white bars). Clinical endpoint (dashed line) was set at > 6 in the CDI severity
scale150,151. Mice treated with 12-deoxy-CamSA or a mixture of cholate and mSA developed
severe CDI signs (score > 6) similar to DMSO-treated animals and reached clinical endpoint 48
hours post-challenge. In contrast, mice treated with 7-deoxy-CamSA developed only moderate
CDI signs. CamSA treated mice developed little to no signs of CDI.
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2.3.3. Separation, Detection, and Quantification of mSA and CamSA
A previous method using 60% methanol, 5mM ammonium acetate, and 0.1%
formic acid was developed allowing metanilic acid (mSA) and CamSA to elute at
approximately 1 minute and 45 seconds, and 4 minutes and 40 seconds, respectively
(data not shown). CamSA’s long elution time using this method hindered data
acquisition of multiple samples in a timely manner. Instead, an HPLC method that
utilized 40% acetonitrile in place of methanol (outlined in Table 2.1) allowed for
sufficient separation of mSA and CamSA, with an elution time difference of
approximately 1 minute per sample (Fig. 2.5). In our hands, we were able to detect
CamSA and mSA signals down to approximately 70 ng.
Cholate, the other byproduct of CamSA deconjugation, was not analyzed by this
method due to several reasons. Cholate is a primary bile acid found naturally in the
gastrointestinal tract of mice and results from gut microbiota metabolism. As such,
quantification of cholate as a byproduct of CamSA degradation would not be accurate.
In any case, if CamSA was deconjugated, mSA and cholate would be produced at 1:1
molar ratios and quantification of mSA would allow us to directly calculate how much
cholate was formed from CamSA. Lastly, cholate is not UV active. Hence, we would not
be able to monitor the elution of cholate by absorption at 254 nm, in a manner similar to
mSA and CamSA.
Following separation by RP-HPLC, mSA and CamSA were ionized by ESI, then
quantified by MS. Formation of an ionized species is a pre-requisite for MS analyses.
The presence of a sulfonate functional group in both mSA and CamSA allowed both
compounds to be ionized by the loss of a proton. The peak areas corresponding to each

58

compound’s molecular weight were determined and plotted against concentration,
allowing for a standard curve to be generated (Fig. 2.4).
Because cholate lacks conjugated bonds, it does not absorb light at 254 nm.
Nevertheless, the mass for cholate can be detected by ESI-MS. As expected for its
more non-polar structure, cholate eluted 2 minutes after CamSA, thus ensuring that its
presence will not interfere with either the CamSA or mSA signal.

Figure 2.5. Separation of mSA and CamSA by RP-HPLC. Chromatogram depicting the
separation of mSA and CamSA. A 10 µl aqueous sample consisting of 250 µM mSA and 125
µM CamSA was separated using a PSDVB (4.1 x 250 mm, 7 µm) column. The separation was
carried out using an isocratic elution of 40% ACN, 5mM ammonium acetate, and 0.1% formic
acid with a flow rate of 1.3 ml/min. Elution of mSA and CamSA were monitored by absorption at
254 nm. mSA eluted after 1 minute and 15 seconds while CamSA eluted after 2 minutes and 15
seconds. The separation time between mSA and CamSA is approximately 1 minute. Cholate is
not UV active and cannot be monitored by absorption at 254 nm. When monitored by ESI-MS,
cholate eluted 2 minutes after CamSA.
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Figure 2.6. Representative standard curves. The standard curves were constructed by
plotting the peak areas corresponding to the molecular weights of either (A) mSA or (B)
CamSA against their known, calculated quantities. Following separation by RP-HPLC, the
samples were ionized by ESI and the masses corresponding to each analyte was determined by
MS.

2.3.4. Metabolism and Excretion of CamSA
Since CamSA could prevent CDI in the mouse model, we hypothesized that
CamSA should be found primarily in the intestinal lumen where it co-localizes with C.
difficile spores. Hence, we expect that CamSA would be eventually excreted in the
feces. After administration, we recovered approximately 30% of the total dosed CamSA
from feces over the course of a week (Fig. 2.7 and 2.8). This was quantified by
observing the m/z (mass to charge ratio) corresponding to CamSA’s molecular weight
(573.75 g/mol). Using our antibiotic-treated mice as a model, we expected the
deconjugation of CamSA to be minimal following depletion of the gut flora. Indeed, no
mSA was observed in the feces at any timepoint during the course of these
experiments.
It is possible that endogenous murine metabolites present in feces could interfere
with the quantification of CamSA and/or mSA. To test for this possibility, fecal samples
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from naïve mice (not treated with CamSA) were subjected to HPLC-MS, under the
same conditions developed for the separation and detection of CamSA and mSA. As
expected, we observed no peaks at the expected location of our analytes.
Surprisingly, a trend corresponding to CamSA’s localization to the intestinal
lumen was not readily apparent. We expected a sharp rise shortly after CamSA
administration, where the concentration of CamSA should have been highest in feces,
with CamSA concentrations tapering off over time. Instead, we observed an oscillating
pattern/wave function when total CamSA (Fig 2.6) or the ratio of CamSA to feces
weight (Fig 2.7) was plotted against time. Interestingly, this oscillating pattern was
previously described by Roth et al., suggesting the enterohepatic circulation of
ochratoxin A in mice188.

Figure 2.7. Total CamSA quantified from mouse feces. Mouse feces was collected at predetermined time points following CamSA administration. CamSA was extracted from the feces
and quantified by measuring the m/z ratio corresponding to CamSA’s molecular weight following
ESI-MS. No CamSA was observed in feces up to four hours post oral gavage. The data
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represent the averages from five independent measurements (n = 5), and error bars represent
the standard deviations.

Figure 2.8. Total CamSA quantified per feces weight.

2.3.5. Absorption and Distribution of CamSA
Given that only 30% of the dosed CamSA was recovered from mouse feces, we
rationalized that CamSA could be absorbed from the intestinal lumen and distributed to
other tissue and organ groups. Blood and liver samples were collected at predetermined time points and analyzed for CamSA. From the liver samples, we were able
to recover approximately 3% of the total dosed CamSA (Fig. 2.9). We were, however,
unable to recover or detect a CamSA signal from blood or kidney samples (N. Okada,
unpublished data).
Although the amount of CamSA recovered from the liver was 10-fold less
compared to what was recovered from feces, the presence of CamSA in the liver is still
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a very interesting result. The lack of CamSA signal found in the blood could suggest
that CamSA is being transported to the liver by a mechanism that bypasses systemic
absorption and circulation. These data strongly suggest, in conjugation with the
oscillating pattern of CamSA found in the feces, that CamSA undergoes enterohepatic
circulation (Fig. 2.7 and 2.8).

Figure 2.9. Total CamSA quantified from mouse liver. Mice were sacrificed at predetermined time points following oral gavage and their livers were collected. CamSA was
extracted from the livers and quantified by measuring the m/z ratio corresponding to CamSA’s
molecular weight following ESI-MS. Minimal amounts of CamSA, representing approximately
3% of the total dosed CamSA, was found in the liver.

2.3.6. Interaction of CYP3A4 with CamSA
The liver functions primarily to detoxify various xenobiotics and endogenously
occurring compounds from the body. These detoxification reactions are catalyzed by
CYP family of enzymes. CYP3A4, a P450 isozyme, is the most abundant P450 found in
the human liver. Previous studies have identified interactions between CYP3A4 and bile
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acids166,189,190. Given that CamSA was found in the liver, we wanted to determine if
CamSA interacted with CYP3A4.
The interaction of CamSA with CYP3A4 was determined using P450
BACULOSOMES® expressing CYP3A4164. The CYP3A4 isozyme converts a “blocked”
Vivid Substrate® dye into a highly fluorescent byproduct in aqueous solutions. Nontoxigenic compounds, or compounds that do not interact with CYP3A4, are unable to
inhibit CYP3A4 activity and can therefore result in highly fluorescent readouts under
these assays164. Comparatively, toxigenic compounds, such as ketoconazole, inhibit
CYP3A4 activity and therefore sequester the formation of fluorescent byproducts187.
This system has a distinct advantage over human liver microsomes such that only a
single P450 isozyme is expressed.
Under our conditions tested, we detected a weak interaction between CamSA
and CYP3A4. Through these initial assays however, we were unable to differentiate
whether this interaction occurred through inhibition of CYP3A4 activity, or if CamSA
served as an alternative substrate for CYP3A4. Under the assumption that CamSA
could inhibit CYP3A4 activity, the IC50 value was determined (IC50 = 0.59 ± 0.09 mM)
(Fig. 2.10). While under the assumption that CYP3A4 was inhibited by CamSA, the IC50
value represented concentrations well above what is necessary to completely inhibit C.
difficile spore germination in vitro84. The effect of taurocholate on CYP3A4 activity was
also determined. Comparatively, an even weaker interaction between CYP3A4 and
taurocholate was observed. CYP3A4 was less susceptible to inhibition by taurocholate
(IC50 = 5.99 ± 0.28 mM) when assayed under similar conditions (Fig. 2.10). These
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results are consistent with previous data describing an interaction of bile acids with
CYP3A4166,189,190.

Figure 2.10. Effect of CamSA and taurocholate on CYP3A4 activity. BACULOSOMES®
expressing CYP3A4 were assayed for their ability to convert a non-fluorescent, Vivid
Substrate® into a highly fluorescent byproduct in the presence of (A) CamSA or (B)
taurocholate. Toxigenic compounds can inhibit CYP3A4 activity and therefore inhibit the
production of a fluorescent signal. Water was used as a positive control for the reaction. As a
control for inhibition, CYP3A4 was incubated with ketoconazole at a final concentration of 10
µM187.

2.4. Conclusions
CamSA, a synthetic taurocholate analog, was previously demonstrated to be a
potent inhibitor of C. difficile strain 630 spore germination in vitro. Significantly, CamSA
was also able to protect mice from CDI even when dosed with an unnaturally massive
inoculum of C. difficile spores. CamSA alone, however, was unable to prevent the onset
of disease in the hamster model of CDI but could double the mean time of death. Given
the differences of responses, CamSA may be subject to different fates in vivo.
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In order for CamSA to be effective at preventing C. difficile spore germination in
vivo, CamSA should exhibit several characteristics. At a minimum, CamSA should
remain unmodified during transit though the gastrointestinal tract. A previous study
performed by Howerton et al. demonstrated that CamSA is stable against artificial
gastric and intestinal juices, but can be hydrolyzed in the presence of bacteria
expressing bile salt hydrolases151. To address CamSA’s stability under more
physiological conditions, CamSA was incubated with feces collected from mice before
and after antibiotic treatment. Under these conditions, CamSA was more stable to the
gut microbiota of antibiotic-treated mice than to the gut microbiota of non-antibiotic
treated mice (Fig. 2.3). Furthermore, we confirm that CamSA, and not its metabolites, is
responsible for preventing CDI onset (Fig. 2.4). These data are encouraging since our
proposed anti-germination therapy would be administered to high risk CDI patients
undergoing antibiotic treatment.
Since our anti-germination compounds would likely be administered to patients
undergoing antibiotic treatment, we initially sought to elucidate CamSA’s
pharmacokinetic parameters using an antibiotic-treated mouse model. Since CamSA
was able to prevent CDI onset by inhibiting C. difficile spore germination in vivo, we
hypothesized that CamSA should co-localize with C. difficile spores and be excreted
into the feces150. We were able to recover approximately 30% of the total dosed CamSA
over the course of a week (Fig. 2.7 and 2.8). CamSA did not exhibit excretion kinetics
similar to most drugs where there is first a rapid increase in drug concentration followed
by an exponential decline as the drug is metabolized and/or excreted. Instead, CamSA
was retained in the animal’s intestines for up to a week
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Given that CamSA is retained in the mouse intestines up to a week postadministration, CamSA could be absorbed into systemic circulation and subsequently
distributed to other organ and tissue groups where a reservoir of CamSA can be
established. We were able to recover approximately 3% of the total dosed CamSA from
5 pre-determined time points. Even though the amount of CamSA found in the liver is
approximately 10-fold less than what was observed in the feces, this is still a very
interesting result.
The presence of CamSA in the liver could suggest that CamSA is absorbed from
the intestinal lumen and subsequently distributed. However, previous studies using an
in vitro Caco-2 assay for intestinal permeability suggested that CamSA has limited
intestinal permeability and should be retained in the intestinal lumen151. Moreover, a
ratio of the apparent permeability coefficients between the apical and basolateral
chambers further suggests that CamSA is actively pumped into the intestinal lumen. In
accordance with the Caco-2 permeability data, we were unable to detect or quantify
CamSA from the blood.
The presence of CamSA in the liver and absence from the bloodstream suggests
a mechanism whereby CamSA can bypass systemic circulation and localize to the liver.
A majority of bile acids (representing approximately 95% of the total bile pool) are
absorbed from the ileum and colon through the mesenteric vein and transported to the
liver sinusoids through the portal vein191. Therefore, CamSA’s distribution to the liver
could have occurred primarily by enterohepatic recycling. For our liver samples, the
portal vein was also collected and included in all liver sample preparations. These data
suggest that CamSA is recognized as a bile acid and transported to the liver by
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enterohepatic circulation. The wave pattern observed for CamSA’s recovery against
time further supports our hypothesis that CamSA undergoes enterohepatic circulation
(Fig. 2.7 and 2.8).
By recirculating between the liver and intestines, CamSA can be retained in the
mouse for an astonishing 7 days post-administration. Hence, enterohepatic recycling
allows CamSA to be present in the intestines for extended periods of time after an initial
dosage. This would explain why a single CamSA dose is sufficient to protect mice from
CDI, even though spores remain in the colon for three days after challenge150. It also
explains why hamsters remain protected for days after the last dose of CamSA and
vancomycin were administered even though spores were still detected in the animal
feces156.
The liver serves as the body’s major detoxification organ. As such, the presence
of CamSA in the liver prompted us to study whether CamSA could interact with
members of the P450 family of enzymes. Since CYP3A4 is the most abundant P450
found in the liver and has also been shown to interact with other bile salts, we assayed
CYP3A4 against CamSA. Using a fluorescence-based assay, we were able to identify a
weak interaction between CYP3A4 and CamSA. These assays, however, cannot
distinguish if the apparent interaction occurred through inhibition of CYP3A4, or if
CamSA served as an alternative substrate for CYP3A4. Assuming that CamSA could
inhibit CYP3A4 activity, the IC50 value was determined (IC50 = 0.59 ± 0.09 mM). While
high concentrations of bile acids can inhibit CYP3A4 activity leading to cytotoxicity and
other downstream cytopathic events, the highest CamSA concentration found in the
liver from our timepoints was calculated to be approximately 70 µM. Compared to the
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calculated IC50 value, we do not expect CamSA to significantly affect CYP3A4 activity.
While the concentration of CamSA in the liver of hamsters treated for 30 consecutive
days with a 300 mg/kg dose of CamSA is unknown, these animals displayed no adverse
physiological or behavioral effects156,166. Microscopic examination of the colons from
these hamsters also exhibited no histological anomalies and were indistinguishable
from untreated animals.
Considering we only recovered approximately 35% of the total CamSA
administered, one major question that remains unanswered is: where is the remaining
65% of CamSA? Our data acquisition is based solely on signals pertaining to mSA or
CamSA, Therefore, any modifications to mSA or CamSA that led to different elution
times or different m/z ratios were not quantified. While we expect CamSA metabolism
and degradation by the gastrointestinal microbiota to be minimal in our antibiotic-treated
mouse model, CamSA may be modified by the mammalian host. Bile acid sulfation is an
essential process used to eliminate excess or toxic bile acids from the body91,178. Other
modifications, not limited to host processes, can also include amidation,
dehydroxylation, and epimerization. The sulfated, amidated, and dehydroxylated forms
of CamSA could be present in mouse feces, however an HPLC-MS method for
separating and quantifying these compounds has not yet been developed. While the
separation patterns and elution times for these potential CamSA metabolites can be
estimated, the lack of standards hinders the absolute identification and quantification of
the compounds from mice. Moreover, our liver and blood experiment provided more
qualitative data, than quantitative. Our pre-determined time points for harvesting the
liver and blood samples were based on our feces data. By only collecting a limited
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number of samples, we could have potentially missed important concentration changes
at time points we did not look into. Finally, there is also the possibility that a majority of
the dosed CamSA will be found in the chyme and gastrointestinal liquids. However,
from this study, we did not quantify CamSA from the chyme.
The presence of CamSA in the liver raises additional questions. At this point, we
still do not know if CamSA is metabolized by CYP3A4, or if CamSA can inhibit CYP3A4
activity. Moreover, the effect of CamSA metabolites on CYP3A4 activity is unknown.
During re-establishment of the gastrointestinal microbiota, CamSA could be
subsequently deconjugated and dehydroxylated. Cholate and mSA, or the deoxyCamSA variants could ultimately affect CYP3A4 activity.
In conclusion, the fate and pharmacokinetic parameters of CamSA using an
antibiotic-treated mouse model was determined. From this study, our data suggests that
CamSA is localized primarily to the intestinal lumen and liver. In this model, we also
show that systemic absorption, metabolism, and distribution of CamSA is minimal.
Interestingly, the fact that CamSA is found in the liver and is absent from systemic
circulation could suggest that CamSA is subjected to recycling by enterohepatic
circulation. By recirculating between liver and intestines, a CamSA reservoir was
established in the mouse for up to 7 days post administration. Enterohepatic recycling
allows CamSA to be present in the intestines for extended periods of time after an initial
dosage, potentially preventing CDI relapse and recurrence resulting from any residual
C. difficile spores present within the host.
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CHAPTER 3
IN VITRO CHARACTERIZATION OF SPORE GERMINATION INHIBITORS AGAINST
CLOSTRIDIOIDES DIFFICILE STRAIN R20291
Parts of this work were previously published as:
Yip, C.*, Sharma, S. K.*, Esposito, X. M., Sharma, P. V., Simon, M. P., Abel-Santos,
E. & Firestine, S. M. The Design, Synthesis, and Characterizations of Spore
Germination Inhibitors Effective against an Epidemic Strain of Clostridium
difficile. J. Med. Chem. 61, 6759-6778 (2018).

My contributions to this article were to prepare C. difficile strain R20291 spores
for in vitro assays and to test the cholate analogs for biological activity.

3.1. Background
Metabolically dormant C. difficile spores do not elicit disease, but instead act as
infectious vehicles. As such, CDI symptoms ultimately results from toxins produced by
the vegetative C. difficile cell following spore germination. Since the germination of C.
difficile spores is required for disease onset, we reasoned that anti-germinants may play
a role in CDI prophylaxis.
The germination process is most commonly initiated by the recognition of key
molecules, termed germinants. Germinants commonly include various metabolites such
as amino acids, salts, and sugars. The identity of these germinants and their effective
concentrations are species dependent42,82. Germinants in Bacillus subtilis are sensed by
proteinaceous GerA, GerB, and GerK heterocomplexes found on the spore’s inner
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membrane. Homologs of these receptors are found in most Bacilli and Clostridia and
result in a variety of germination responses. Interestingly, homologs of these Ger
receptor family of proteins are absent in C. difficile. This suggests that C. difficile Ger
receptors may be too divergence from other sporulating bacteria, or that C. difficile may
respond to novel environmental cues82,84.
C. difficile spores germinate and form colonies inefficiently on commonly used,
nutrient-rich media. Pre-incubation of C. difficile spores with bile acids have been shown
to increase colony formation. Raibaud et al. reported that addition of 1% sodium
taurocholate to media can increase the recovery of C. difficile spores, presumably by
triggering germination192. Sorg and Sonenshein later demonstrated that taurocholate,
along with glycine, were sufficient to trigger C. difficile germination, whereas
taurocholate or glycine alone could not82,193. Work from our lab confirmed the
requirement of taurocholate as a germinant and found that other amino acids can also
act as co-germinants for C. difficile spores84. Sorg also found that chenodeoxycholate, a
naturally occurring bile acid, can inhibit C. difficile spore germination85. Our lab further
showed that chenodeoxycholate is a competitive inhibitor of taurocholate-mediated
germination with an IC50 of 235 µM83,151.
Although bile acids can affect C. difficile spore germination, their effects can vary
between different C. difficile strains. Heeg et al. previously described the germination
profiles from various C. difficile isolates157. Spores from different strains, when
incubated in media alone, or media supplemented with either taurocholate or
chenodeoxycholate, displayed a range of germination phenotypes and responses.
The ability of taurocholate, in conjunction with amino acids, to increase C. difficile
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recovery could suggest two possible mechanisms in which C. difficile spore germination
is triggered. Taurocholate is a bile acid involved in the emulsification of fats. As such, it
is possible that taurocholate could trigger C. difficile spore germination by
permeabilizing the spore membrane. This, however, proved not to be the case as
detergents and other bile acids were unable to germinate C. difficile spores83. The corequirement for glycine, an amino acid with no known membrane-disrupting activity,
suggests that C. difficile spores could be recognizing taurocholate and glycine using
unknown receptor(s). Indeed, kinetic evidence suggests the presence of putative
binding sites where taurocholate binding must first take place, before binding of glycine
can occur83.
Genetic analyses conducted by Francis et al. recently suggested that C. difficile
uses a soluble pseudoprotease, CspC, to directly sense bile acids86. Indeed, both C.
difficile cspC knockout and targetron mutants are unable to germinate in response to
taurocholate33,194. Moreover, a single point mutation in CspC (glycine 457 to arginine,
G457R) permitted C. difficile spores to germinate in response to chenodeoxycholate,
whereas chenodeoxycholate would normally act as a competitive inhibitor of
germination86. Additional point mutations in CspC have been established that can
hyper- and hypo-sensitize C. difficile spores to taurocholate195.
Following germinant identification, mechanistic information of the germinant
binding site can often be determined using a series of chemical analogs. Thus,
molecules that closely resemble germinants can be developed to inhibit the germination
process by competing for a substrate binding site. B. subtilis spores, for example,
germinate in response to L-alanine, but can be inhibited by D-alanine196. Likewise,
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whereas Bacillus anthracis spores germinate in response inosine, the germination
process can be blocked by 6-thioguanosine, a nucleoside analog. As discussed above,
chenodeoxycholate, a natural bile acid, was shown to inhibit C. difficile spore
germination by competing with taurocholate for a putative binding site83,85. Indeed, the
physiological concentrations of chenodeoxycholate relative to taurocholate would
prevent C. difficile spores from germinating inside healthy hosts92,93.
While chenodeoxycholate can inhibit C. difficile spore germination, its use as it
pertains to CDI prophylaxis has been hampered. Chenodeoxycholate is highly insoluble
in physiological systems and is also rapidly absorbed and recycled back to the liver,
thereby limiting its ability to interact with C. difficile spores. In our hands, a 300 mg/kg
dose of chenodeoxycholate by oral gavage resulted in immediate death in mice,
presumably by precipitation of chenodeoxycholate upon interaction with saliva and
gastric juice151.
The ability of chenodeoxycholate to inhibit C. difficile spore germination prompted
further identification and development of anti-germination molecules against C. difficile.
Indeed, Sorg and Sonenshein developed several methyl ester derivatives of
chenodeoxycholate that were able to inhibit C. difficile spore germination more
effectively than chenodeoxycholate93. While these compounds successfully inhibited C.
difficile spore germination in vitro, the use of these compounds in vivo would be
challenging because of their susceptibility to chemical and enzymatic hydrolysis93,155.
The effects of ursodeoxycholate, a stereoisomer of chenodeoxycholate, have also
been studied.
When dosed continually over the course of at least seven months, ursodeoxycholate
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was able to treat pouchitis associated with recurrent CDI by inhibiting C. difficile spore
germination in vivo153. However, similar to chenodeoxycholate, ursodeoxycholate is
actively absorbed into enterohepatic circulation. While ursodeoxycholate is effective
against spores from multiple C. difficile strains in vitro, ursodeoxycholate has not yet
been tested for its ability to protect animals from CDI caused by these strains.
More recently, Stoltz et al. published data demonstrating the efficacy of two
synthetic bile acids, 20β and 21β, against a NAP1 hypervirulent strain of C. difficile.
Interestingly, these compounds also contained modifications that limited their intestinal
absorption, allowing them to effectively co-localize with C. difficile spores155. However,
the effectiveness of these compounds against other C. difficile strains and protective
efficacy in animals remains to be determined155.
Quantitative structure-activity relationships (QSAR) are used in medicinal
chemistry to predict biological activity based on chemical structures. Specifically, QSAR
are quantitative regression models that relate the structures and functional groups
within chemical compounds to a corresponding, measurable activity197. Using these
analyses, our lab previously demonstrated that a putative glycine receptor requires both
a free carboxylate and free amino group84. These analyses suggested that the putative
glycine receptor utilizes a narrow hydrophobic binding site to selectively exclude bulky,
hydrophilic amino acids from binding. From these data however, we were unable to
identify amino acid analogs that were able to compete with glycine in order to inhibit C.
difficile spore germination84.
Since we were unable to identify amino acid analogs that inhibited C. difficile
spore germination, our lab subsequently developed a series of cholate-based analogs
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as inhibitors of C. difficile spore germination. From these efforts, we found that CamSA,
a synthetic bile acid analog of taurocholate, inhibited C. difficile strain 630 spore
germination in vitro with an IC50 value of 58.3 µM84. Remarkably, CamSA was also able
to prevent infection in antibiotic-treated mice challenged with C. difficile spores150,151.
CamSA, in conjunction with suboptimal concentrations of vancomycin, was also able to
prevent CDI in the highly susceptible hamster model156.
Our first anti-CDI compound, CamSA, albeit effective against C. difficile strain
630, was unable to prevent spore germination of C. difficile strain R20291, a
BI/NAP1/027 hypervirulent strain. As a consequence, CamSA was unable to protect
mice from C. difficile strain R20291 infections (Phan et al., data not published). Given
the increasing prevalence of hypervirulent C. difficile strains in hospital-settings, we
wanted to explore bile acid analogs with anti-germination activity against hypervirulent
C. difficile strain R20291 spores.
During this initial study, a bile acid library consisting of cholate analogs with
modifications along the side chain/amide region was synthesized by our collaborators in
the Firestine lab at Wayne State University (Fig. 3.1). Compounds from this chemical
library were assayed at the University of Nevada, Las Vegas to identify potent inhibitors
of C. difficile strain R20291 spore germination. The chemical library could also be
screened for compounds that activate C. difficile spore germination. This alternate
method would allow for the identification of functional groups that are not only are
required for binding to the taurocholate receptor but, could also activate the germination
process.
Using QSAR and molecular modeling analyses, compounds able to inhibit C.
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difficile strain R20291 spore germination provided mechanistic information of structural
features and functional groups essential for germinant binding. These analyses can
then be used to elucidate the spatial and chemical environment of putative germinant
binding sites.
Upon screening a library of approximately 200 taurocholate analogs, this study
has identified bile acid compounds that are over 1,000-fold more effective at inhibiting
spore germination than the natural inhibitor, chenodeoxycholate. To our knowledge,
several compounds identified in this study are the most potent anti-germinants
described to date against C. difficile spores.

Figure 3.1. Generic structure of bile acid analogs used in this study. Positions 3, 7, 12, and
24 on the cholic acid backbone are labeled. Positions 3, 7, and 12 represent the most common
regions for in vivo enzymatic modification. The side chain region that was modified in the Wayne
State library is highlighted in yellow.

3.2. Materials and Methods
3.2.1. General Comments
Taurocholate, chenodeoxycholate, and glycine were purchased from SigmaAldrich Corporation (St. Louis, MO). Bile acid analogs were synthesized and provided
by Prof. Steven Firestine’s laboratory at Wayne State University, MI. All bile acid
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analogs were dissolved in DMSO. Glycine was dissolved in deionized water (DIH2O). C.
difficile strain 630 was obtained from the American Type Culture Collection (ATCC). C.
difficile strain R20291 was a kind gift from Prof. Nigel Minton at the University of
Nottingham, UK.

3.2.2. C. difficile Culturing and Growth Conditions
Frozen stocks of C. difficile strain R20291 and strain 630 were streaked onto prereduced BHIS (BHI supplemented with 0.5% yeast extract, 0.1% L-cysteine, and 0.05%
sodium taurocholate) plates and incubated overnight at 37°C in an anaerobic
environment (10% CO2, 10% H2, and 80% N2) to yield single colonies. Liquid cultures of
C. difficile were prepared by inoculating degassed BHIS (BHI supplemented with 5
mg/ml yeast extract) broth with a single C. difficile colony and incubated overnight. For
solid media, agar was added to a final concentration of 1.5% (w/v).

3.2.3. C. difficile Visualization by Phase Contrast Microscopy
C. difficile inocula were resuspended in DIH2O, pelleted and resuspended in 50
µl of DIH2O. 5 µl of each sample was placed onto a glass slide. A No. 1 glass coverslip
was placed on top of the inoculum and pressure was applied briefly to produce a
monolayer suspension. The sample was then visualized using a 100x phase contrast,
oil immersion objective.

3.2.4. Schaeffer-Fulton Endospore Stain
C. difficile inocula were resuspended in DIH2O, pelleted, and resuspended in 50
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µl of DIH2O. 10 µl of each sample was spotted onto a glass slide and heat fixed with a
Bunsen burner. Blotting paper was placed onto the fixed sample and heated periodically
over the course of 5 minutes with the continual addition of a 5% malachite green
solution. The slide was then rinsed with DIH2O to decolorize the vegetative cells and to
remove excess malachite green. A 2.5% safranin solution was then added to
counterstain the vegetative C. difficile cells. The vegetative cells (pink) and spores
(blue) were visualized under 100x light microscopy using an oil immersion objective.

3.2.5. Spore Preparation and Purification
Aliquots (200 µl) from an overnight C. difficile culture were spread onto prereduced BHIS plates and incubated for 7 days to allow for sporulation. The resulting
bacterial lawns were harvested by flooding the plates with ice-cold DIH2O. The samples
were pelleted by centrifugation at 8,800 xg and the supernatants were decanted. This
wash procedure was repeated three times. Spores were then purified by density
centrifugation through a 20% to 50% Histodenz gradient. After discarding the Histodenz
solution, the spore pellet was washed three times with DIH2O, resuspended in a sodium
thioglycolate solution (0.5 g/l), and stored at 4°C until further use. To determine spore
purity, samples were visualized by phase contrast microscopy (Fig. 3.2) or stained
using the Schaeffer-Fulton technique (Fig. 3.3), as described above. Spores used in all
experiments were more than 95% pure as determined by microscopy following
Schaeffer-Fulton staining.
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Figure 3.2. Phase contrast microscopy of purified, un-germinated C. difficile strain
R20291 spores. Un-germinated spores are highly refractile structures and appear phase bright
when observed by phase contrast microscopy. Phase bright spores display a glowing halo
surrounding them, in addition to a white internal core. Upon germination, rehydration of the
spore core results in loss in refractivity. Germinated spores appear as phase dark and lose the
glowing halo. Vegetative cells also appear as phase dark but can be easily differentiated from
germinated and un-germinated spores by morphological differences.

Figure 3.3. Schaeffer-Fulton endospore stain of purified C. difficile strain R20291 spores.
A 10 µl aliquot of a C. difficile strain R20291 spore suspension was heat fixed onto a glass slide.
The slide was processed following the Schaeffer-Fulton endospore stain (refer to section
2.2.3.2). The heating process allows the water-soluble malachite green to permeate into the
spore. Spores are thus stained blue in the presence of malachite green. Vegetative cells are
counter stained with safranin and will appear red.
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3.2.6. C. difficile Spore Germination
Spore germination is a dynamic process that can be monitored by observing the
physiological changes that occur following germinant recognition (refer to section 1.3.2).
Optical density changes, along with Ca-DPA release and degradation of cortex
peptidoglycan, are the result of the different stages of germination. As such, spore
germination can be measured by real-time or end-point assays.

3.2.6.1. Optical Density Assay
C. difficile spores were washed three times with DIH2O, then heat shocked at
68°C for 30 min to kill any vegetative cells that may have been present within the spore
suspension. This process also activates spores to become more responsive to
germinants198,199. After the spores were heat shocked, the samples were cooled to room
temperature, washed an additional three times with DIH2O, and finally resuspended in
0.1 M sodium phosphate buffer (88 mM NaH2PO4, 12 mM Na2HPO4, pH 6.0)
supplemented with 5 mg/ml sodium bicarbonate at the time of use. Spore suspensions
were diluted to an optical density at 580 nm (OD580) of approximately 1.0.
To test for C. difficile spore germination, 180 µl aliquots of the diluted spore
suspension were added to 96-well clear plates containing taurocholate and glycine, at a
final concentration of 6 mM and 12 mM, respectively. Following the addition of the spore
suspension, the OD580 was measured every minute for 2 h.
To test for compounds able to prevent C. difficile spore germination, wells
containing taurocholate and glycine were supplemented with increasing concentrations
of an experimental compound. Aliquots (180 µl) of the diluted spore suspension were
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added and spore germination was monitored, as described. As a negative control, 180
µl aliquots of the diluted spore suspension were treated with neat DMSO. All
experimental conditions were performed in triplicate and the final volume in each well
was 200 µl.

3.2.6.2. Ca-DPA Release Assay
C. difficile spore were prepared as previously described (refer to section 3.2.5.1)
with the following modifications. After the spores were heat shocked, the samples were
cooled to room temperature, washed an additional three times with DIH2O, and finally
resuspended in 10 mM Tris-HCl, pH 7.0. Spore suspensions were diluted to an OD580 of
approximately 1.0.
Aliquots (35 µl) of TbPV (250 µM TbCl3, 250 µM pyrocatechol violet (PV), 10 mM
HEPES, pH 7.0) were added to 96-well clear bottom, black plates containing
taurocholate and glycine, at a final concentration of 6 mM and 12 mM, respectively. To
test for C. difficile spore germination, 30 µl aliquots of the diluted spore suspension were
added to the 96-well clear bottom, black plates. Following the addition of the spore
suspension, Ca-DPA release (excitation, 270 nm; emission 545 nm [appropriate
wavelengths for the DPA-Tb3+ complex]) was measured every minute for 2 h.
To test for compounds able to prevent C. difficile spore germination, wells
containing TbPV, taurocholate, and glycine were supplemented with increasing
concentrations of an experimental compound. Aliquots (30 µl) of the diluted spore
suspension were added and spore germination monitored, as described. As a negative
control, 30 µl aliquots of the spore suspension were treated with neat DMSO. All
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experimental conditions were performed in triplicate and the final volume in each well
was 150 µl.

3.2.7. Calculation and Analysis of Spore Germination and Inhibition
To quantitatively assess the effect of bile acids on C. difficile spore germination,
we relied primarily on optical density assays. We used Ca-DPA release assays as
confirmation tests for germination. Changes in absorbance at OD580 during optical
density assays (section 3.2.5.1) or fluorescence intensity during Ca-DPA release
assays (section 3.2.5.2) were monitored using a Tecan Infinite M200 96-well plate
reader (Tecan Group, Männedorf, Switzerland).
Relative OD580 values were obtained by normalizing the data using the OD580
obtained at time zero [relative OD580 = OD580(t)/OD580(t0)]. The rates of spore
germination were calculated from the initial linear slopes of the germination curves. The
percent germination was obtained by comparing treated samples to the taurocholate
and glycine controls, where the rates of spore germination were set to 100%. The
percent germination for each bile acid analog treatment was plotted against
concentration, and the data was fitted using a four-parameter logistic function to obtain
the half maximal inhibitory concentration (IC50). Similarly, the percent germination can
be plotted against titrations of taurocholate and fitted using a four-parameter logistic
function to obtain the half maximal effective concentration (EC50).

3.3. Results and Discussion
3.3.1. Spores from C. difficile strains R20291 and 630 Germinate Similarly in
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Response to Taurocholate
Bacterial spores are highly refractive structures that contain a large depot of CaDPA. During germination, the spore core rehydrates, and the cortex and the spore coats
become degraded. During germination, Ca-DPA is released from the core and the spore
rehydrates. The cortex and spore coats also become degraded. These events result in
the loss of refractility, and a decrease in optical density over time. Thus, spore
germination using optical density assays were based on decreases in OD580 over time.
Alternatively, spore germination can be measured over time based on fluorescence
intensity increases associated with DPA forming a complex with a TbPV indicator.
C. difficile spores show inter-strain variability in their germination response
toward bile acids157. Hence, prior to screening a bile acid library, we wanted to
determine if treatment with taurocholate resulted in different germination efficiencies
between C. difficile strains R20291 and 630. The germination rates for R20291 and 630
spores at various concentrations of taurocholate were determined based on optical
density assays. From this, we were able to identify the EC50 for taurocholate while
keeping glycine at a constant, saturating concentration (Fig. 3.4)83. The EC50 for
taurocholate against R20291 and 630 was 9.8 ± 0.1 mM and 9.5 ± 2.1 mM,
respectively. These data suggest that R20291 and 630 spores exhibit similar
germination responses when exposed to taurocholate.
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Figure 3.4. EC50 calculations for taurocholate against (A) C. difficile strain 630 and (B) C.
difficile strain R20291 spores. The rates of germination for C. difficile spores at various
concentrations of taurocholate was determined by optical density with glycine kept constant at a
final concentration of 12mM. The percent germination was determined and plotted against
concentration. The data was fitted using a four-parameter logistic function to obtain EC50 values.

3.3.2. CamSA is Inactive against Hypervirulent C. difficile strain R20291 Spores
CamSA was shown to be a potent inhibitor of C. difficile strain 630 spore
germination in vitro (IC50 of 58.3 µM)84. CamSA was also able to prevent CDI in mice by
inhibiting C. difficile strain 630 spore germination150,151. The similar germination
response to taurocholate between strain R20291 and strain 630 spores led us to
question if CamSA would be equally effective against a hypervirulent strain of C. difficile
(Fig. 3.4). CamSA, however, was unable to prevent the germination of C. difficile strain
R20291 spores even at a final concentration of 125 µM, double the reported IC50 value
of CamSA against C. difficile strain 630 (Fig. 3.5). Indeed, the germination rates of
CamSA-treated C. difficile strain R20291 spores, in both optical density and DPA
release assays, were indistinguishable from untreated controls.
It is possible that CamSA could prevent strain R20291 spore germination but
85

may require high millimolar concentrations. Since the aim of this study was to identify
spore germination inhibitors in the low micromolar range, higher concentrations of
CamSA were not tested. However, parallel work in the lab showed that CamSA was
unable to inhibit C. difficile strain R02921 spore germination even at 1 mM final
concentration (J. Phan, data not shown). Stoltz et al. also demonstrated that CamSA
was unable to inhibit the germination of a NAP1 isolate, under their conditions tested155.

Figure 3.5. Germination assay of C. difficile strain R20291 spores. C. difficile strain R20291
spores treated with 6 mM taurocholate and 12 mM glycine () represent 100% germination. As
a control, spores were treated with DMSO () and represent 0% germination. Treatment of
spores with 125 µM CamSA (£), did not prevent the germination of C. difficile strain R20291
spores in either (A) optical density assays or (B) DPA release assays. The data represent the
averages from three independent measurements and error bars represent the standard
deviations. For clarity, the graphs represent data collected at 2-minute intervals and only the
first 50 minutes are shown.

3.3.3. Chenodeoxycholate Inhibits C. difficile strain R20291 Spore Germination
Since CamSA was unable to prevent the germination of C. difficile strain R20291
spores, we wanted to determine if the natural inhibitor, chenodeoxycholate, would be
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active against this strain. Chenodeoxycholate was able to weakly inhibit strain R20291
spore germination with an IC50 of 450 ± 44 µM (Fig. 3.6 and 3.7). Even then,
chenodeoxycholate is approximately 2-fold worse of an inhibitor of strain R20291
spores than for strain 630 spores151.

Figure 3.6. Effect of chenodeoxycholate on C. difficile strain R20291 spore germination.
C. difficile strain R20291 spores were treated with taurocholate and glycine () to a final
concentration of 6 mM and 12 mM, respectively. This control was set to represent 100%
germination. As an additional control, spores were treated with DMSO () and was set to
represent 0% germination. Spores, in the presence of taurocholate and glycine, were treated
with varying concentrations of chenodeoxycholate. Final concentrations of chenodeoxycholate
tested at 2.25 mM (r), 1.75 mM (¯), 0.5 mM (£), and 0.25 mM (Í) are shown. The data
represent the averages from three independent measurements and error bars represent the
standard deviations. For clarity, only select concentrations are shown. Moreover, the graph
represents data collected at 2-minute intervals and only the first 60 minutes are shown.
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Figure 3.7. IC50 calculation of chenodeoxycholate against C. difficile strain R20291
spores. C. difficile strain R20291 spores were treated with a fixed concentration of taurocholate
and glycine, as previously described, and incubated with chenodeoxycholate at various
concentrations. The percent germination for each treatment was determined and plotted against
concentration. The data was fitted using a four-parameter logistic function to obtain IC50 values.

3.3.4. Biological Activity of Bile Acid Analogs
We undertook a two-step process to rank anti-germination compounds that were
effective against the R20291 hypervirulent C. difficile strain. Given the insoluble nature
of many bile acids, the compounds were first assessed for solubility at a final
concentration of 125 µM. This concentration represented the lowest concentration
where chenodeoxycholate showed minimal anti-germination activity against strain
R20291 spores. Compounds that were insoluble at this concentration were deprioritized and not tested further.
Calculating IC50s for all 200 compounds would be a time-consuming and
daunting task. To screen for the most active compounds, we ran preliminary tests and
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assayed each compound at a single concentration of 125 µM. The percent germination
for each experimental compound was obtained by comparison to untreated, germinating
spores (100% germination). Compounds that exhibited a percent inhibition greater than
40% were prioritized and their IC50 values were determined. Of the approximate 200 bile
acid analogs tested, 39 compounds ultimately passed both criteria for solubility and antigermination efficacy.
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Table 3.1. Biological activity of N-Aromatic (Phenyl and Heterocyclic) Cholan-24-amides
against C. difficile strain R20291 spores. C. difficile strain R20291 spores were treated with
taurocholate and glycine to a final concentration of 6 mM and 12 mM, respectively; this
represents 0% inhibition. Percent (%) inhibition corresponding to each compound was reported
with standard deviations. IC50 values were calculated for compounds that were able to inhibit
germination >40%. All test compounds were resuspended in 100% DMSO and assayed at a
final concentration of 125 µM. N/A: not applicable.
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Table 3.2. Biological activity of N-Benzyl and N-Pyridinemethyl Cholan-24-amides against
C. difficile strain R20291 spores. C. difficile strain R20291 spores were treated with
taurocholate and glycine to a final concentration of 6 mM and 12 mM, respectively; this
represents 0% inhibition. Percent (%) inhibition corresponding to each compound was reported
with standard deviations. IC50 values were calculated for compounds that were able to inhibit
germination >40%. All test compounds were resuspended in 100% DMSO and assayed at a
final concentration of 125 µM. N/A: not applicable.
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Table 3.3. Biological activity of N-Alkyl Cholan-24-amides against C. difficile strain
R20291 spores. C. difficile strain R20291 spores were treated with taurocholate and glycine to
a final concentration of 6 mM and 12 mM, respectively; this represents 0% inhibition. Percent
(%) inhibition corresponding to each compound was reported with standard deviations. IC50
values were calculated for compounds that were able to inhibit germination >40%. All test

92

compounds were resuspended in 100% DMSO and assayed at a final concentration of 125 µM.
N/A: not applicable.

3.3.5. Structure-Activity Analyses of Bile Acid Analogs
We initially screened a chemical library that consisted of approximately 70 bile
acid analogs (Tables 3.1, 3.2, and 3.3). QSAR analysis of this initial library would later
act as a foundation to design subsequent bile acid analogs. From this first chemical
library, we discovered compound 12a to be a potent germination inhibitor of C. difficile
strain R20291 spores. Astoundingly, compound 12a was able to completely inhibit C.
difficile strain R20291 spore germination at concentrations as low as 6.25 µM (Fig. 3.8).
When assayed at 4.68 µM, the percent inhibition for compound 12a was calculated to
be 84.3% ± 1.9%. This value was comparable to the un-germinated DMSO control
where the percent inhibition was calculated to be 90.7 ± 2.3%. When percent
germination was plotted against the log concentration of compound 12a, the data
revealed an IC50 value of 1.8 ± 0.11 µM, the most potent inhibitor of any C. difficile strain
spore germination so far reported (Fig. 3.9). Compound 12a was also 7-fold more active
against C. difficile strain 630 as an anti-germinant than CamSA (J. Phan, data not
shown).
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Figure 3.8. C. difficile strain R20291 spore germination is inhibited by compound 12a. C.
difficile strain R20291 spores were treated with taurocholate and glycine () to a final
concentration of 6 mM and 12 mM, respectively; this represents 100% germination. As an
additional control, spores were treated with DMSO () and was set to represent 0%
germination. Spores, in the presence of taurocholate and glycine, were treated with compound
12a at varying concentrations; final concentrations of compound 12a tested at 6.25 µM (r),
2.34 µM (¯), and 0.78 µM (£) are shown. The data represent the averages from three
independent measurements and error bars represent the standard deviations. For clarity, only
select concentrations are shown. Moreover, the graph represents data collected at 2-minute
intervals and only the first 60 minutes are shown.
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Figure 3.9. IC50 calculation of compound 12a against C. difficile strain R20291 spores. C.
difficile strain R20291 spores were treated with taurocholate and glycine at a final concentration
of 6 mM and 12 mM, respectively, and incubated with compound 12a at various concentrations.
The percent germination for each treatment was determined and plotted against concentration.
The data was fitted using a four-parameter logistic function to obtain IC50 values.

Compound 12a is a phenyl derivative of CamSA in which the sulfonate group
was removed. Generally, structural modifications that include the loss or gain of
functional groups can result in either improved or decreased biomolecular interactions.
These modifications can be subsequently used to identify the mechanisms that allow an
interaction between our anti-germinants and the taurocholate binding site.
An initial global analysis of the active compounds performed by the Firestine lab
was unable to generate clear QSAR analyses. A number of bile acid analogs were
insoluble during our biological evaluations and were therefore not included in these
analyses. Hence, potentially active compounds could have been removed from this
analysis due to solubility, not activity. This effectively reduces the number of candidates
necessary to be able to establish a defined SAR trend. To circumvent this issue, a
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structural alignment of active versus inactive or weakly active compounds was
established.
A preliminary size comparison of the active versus inactive molecules suggested
that active compounds occupied smaller volumes than inactive molecules. All active
compounds were able to fit within the molecular volume of a phenyl ring. Likewise, the
molecular surfaces of inactive agents were generally larger. This analysis could suggest
smaller molecules are able to fit within the taurocholate binding site, whereas the size of
larger molecules can preclude them from binding. Similarly, the effect of hydrophobicity
on anti-germination activity was also examined. Alignment of active versus inactive
compounds suggested that hydrophobic side chains were more active than side chains
containing polar or hydrophilic functional groups. We performed a more detailed SAR
analysis from the similarly, limited subset of analogs. Our SAR analyses suggest at
least two additional structure-activity relationships.

3.3.5.1. Effect of Alkyl Chain Length
The effect of the alkyl chain length between the amide nitrogen and the cyclic
side chain was first evaluated. The amide nitrogen and the cyclic side chain of
compound 12a is separately by a distance of approximately 1.5 Å - this is the shortest
distance out of the alkyl linkage series and also our most active compound. Compounds
14a and 15f have a methylene and ethylene bridge separating the amide nitrogen and
phenyl ring, respectively. These changes progressively increase the distance between
the nitrogen and the aromatic ring.
Increasing the length of the alkyl chain from compound 12a to compound 14a
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with the addition of a methylene bridge resulted in 3-fold decrease in anti-germination
activity. Further increasing the length between the nitrogen and phenyl ring with the
addition of an ethylene bridge (compound 15f) completely abolishes anti-germination
activity (Fig. 3.10). These data suggest that shorter distances between the nitrogen and
the phenyl ring is required for our anti-germinants to be recognized by the taurocholate
receptor. The effect of alkyl chain length is also apparent where benzyl- analogs (Table
3.2) were all inactive compared to compounds found in Table 3.1.
Interestingly, this SAR analysis mirrors a previous study evaluating the effect of
spore germination activation of alkyl chain length between the amide nitrogen and the
sulfonate group of taurocholate84. The side chain of taurocholate has two methylenes
bridging the amide nitrogen and the sulfonate group. CAAMSA, a taurocholate analog in
which the alkyl linkage between the sulfonate and amide nitrogen was shortened to a
single carbon, exhibited germination rates comparable to the taurocholate control84. In
contrast, CAAPSA, a taurocholate analog with three methylene groups separating the
amide nitrogen and sulfonate, was unable to trigger germination. Together, these data
demonstrate the importance of the distance separating the amide nitrogen with the side
chain, with shorter distances being essential for recognition by the putative taurocholate
receptor.
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Figure 3.10. Structure activity relationship – alkyl chain length.

3.3.5.2. Effect of Side Chain Flexibility
We also evaluated the apparent effect of the side chain’s constraints and/or
planarity (Table 3.3). The side chain of compound 12a contains a rigid, planar ring that
results from the pi conjugation system. Removal of the aromaticity of compound 12a
system results in a saturated cyclohexane side chain (compound 15a). Contrary to the
phenyl ring of compound 12a, the cyclohexane substituent of compound 15a can adopt
boat/chair conformations that deviate from the planarity of the aromatic ring. Compound
15a exhibited a 2-fold decrease in anti-germination activity compared to compound 12a.
To assess whether aromaticity or rigidity was more important for optimal
germination inhibition, we tested increasingly smaller cyclic rings as side chains.
Decreasing the number of carbons in the cyclohexane ring resulted in the cyclopentane
(compound 15b) and cyclopropane (compound 15c) analogs. Interestingly, the antigermination activity exhibited by these two analogs was restored compared to
compound 15a, and was comparable to compound 12a (Fig. 3.11).
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Both cyclopentane and cyclopropane are constrained structures and their
carbons are thus forced into a more planar configuration. We hypothesize that rigid or
constrained structures may be important for recognition by the putative taurocholate
receptor. Although cyclopentane and cyclopropane lack conformational rigidity resulting
from a pi conjugation system, as observed with the phenyl ring in compound 12a, these
molecules exhibit considerable angle, torsional, and steric strain. Thus, these structures
are limited in free rotation to reduce the torsional strain that would result from bond
eclipsing.

Figure 3.11. Structure activity relationship – side chain flexibility

3.3.5.3. Synergism of Alkyl Chain Length and Side Chain Flexibility
We wanted to further validate our claims on the effect of alkyl chain length and
side chain rigidity on anti-germination activity. As such, we examined the potential
additive effects and synergisms between the two previous SAR analyses. Similar to
compound 12a, the cyclic side chain of compound 15c was separated from the amide
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nitrogen by an approximate 1.5 Å. Compounds 15c and 15d both contain a highly
strained cyclopropane ring but differ in that compound 15d has a methylene between
the amide nitrogen and the cyclopropane ring. Complementary to our alkyl chain SAR
analysis of compound 12a analogs, increasing the alkyl chain length in the cyclopropyl
series apparently decreased the percent inhibition by approximately 10%. However, a
more quantitative analysis showed no significant difference in compound potency as
observed by their IC50 values.
The side chain of compound 15e has the same number of carbons as compound
15d, but the ring constrains have been removed allowing for free rotation of all the
bonds. In line with our second SAR analysis, the percent inhibition for compound 15e
was approximately 2-fold lower than compound 15d. The effect of side chain rigidity was
also observed when comparing the IC50 values for compounds 15d and 15e. Compound
15e was 6-fold less effective compared to its ring-constrained counterpart, compound
15d. This SAR analysis could suggest that while shorter alkyl chains and more rigid side
chains account for more potent anti-germinants, side chain rigidity may have a more
dominant effect over alkyl chain length.
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Figure 3.12. Structure activity relationship – synergy between alkyl chain length and side
chain flexibility.

3.3.5.4. Effect of Electron Donating and Electron Withdrawing Groups
The presence of the sulfonate group may preclude CamSA from accessing the
putative taurocholate binding site. Since loss of the electron withdrawing sulfonate
group resulted in the highly potent compound 12a analog, we also examined the effects
of electron donating and other electron withdrawing groups on the aromatic side chain.
The position of electron donating groups on the aromatic ring, as expected,
yielded a range of activities. Methoxy substitution at the ortho position resulted in
compound 12b. Compound 12b was the most potent compound from the methoxy
substitution series of analogs and exhibited a 5-fold decrease in activity compared to
compound 12a. Methoxy substitution at the meta and para positions resulted in
compounds 12c and 12d, respectively. Compound 12c was approximately 40-fold less
effective than compound 12a, while 12d was almost completely inactive as an antigerminant. Furthermore, compound 12e, a disubstituted analog with methoxy groups at
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the ortho and para positions of the aromatic ring, exhibited no activity. These data may
suggest that electron donating groups are only tolerated at the ortho position of the
aromatic ring.
Interestingly, replacement of CamSA’s sulfonate group with an electron
withdrawing fluorine group resulted in compound 12g. We also assayed other fluorine
substituted analogs. Compound 12g exhibited 8-fold less activity than compound 12a
and was our weakest compound from the fluorinated series. Compound SKS-IX-21
contains a fluorine group at the ortho position and is our most potent substituted
aromatic compound. Compound SKS-IX-21 was approximately 4-fold weaker than
compound 12a. Compound SKS-VIII-42C was approximately 5-fold weaker than
compound 12a and contained a fluorine group at the para position. The activity of these
compounds could suggest that electron withdrawing groups facilitate an interaction with
the taurocholate-binding site. Together, these data may also suggest that substitution at
the ortho position is well tolerated while the meta and para positions are not. Fluorine
substitution may also have a dominant role in anti-germinant development.

3.3.6. New Generation of C. difficile Spore Germination Inhibitors
Based on our recently published QSAR and molecular modelling analysis, a new
group of cholate-based compounds were designed and tested for anti-germination
activity against C. difficile strain R20291 spores. From this new screen, we found that
compound SKS-IX-01C (Fig. 3.13), an indoline derivative of cholate, was able to inhibit
C. difficile strain R20291 spore germination at concentrations comparable to compound
12a. When assayed at 6.25 µM, the percent inhibition was calculated to be 15.8 ±
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0.95% (Fig. 3.14). When percent germination was plotted against the log concentration
of compound SKS-IX-01C, the IC50 value was calculated to be 1.15 ± 0.34 µM (Fig.
3.15).
The strong anti-germination activity of compound SKS-IX-01C was surprising and
counterintuitive. On the basis of compound SKS-IX-01C’s activity, it does not seem
necessarily true that smaller molecules potentiate more active compounds. This
contradicts the QSAR analyses performed by our collaborators. Re-evaluation of the
compounds corresponding to QSAR trends could suggest that inactive compounds
exhibited larger molecular surfaces due to their bulky, polar groups. Hence, larger
molecules may exhibit activity in the absence of polar functional groups.
The physical properties of indoline seem to be in line with our other SAR
analyses. Relevant to compound SKS-IX-01C, the indoline side chain is bonded directly
to the amide nitrogen. Moreover, the planar, heterocyclic rings of indoline have little
rotation due to the pi conjugation system. The activity of the indoline analog is
consistent with our second SAR analysis suggesting the importance of side chain
rigidity.

Figure 3.13. Structure of compound SKS-IX-01C.
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Figure 3.14. C. difficile strain R20291 spore germination is inhibited by compound SKSIX-01C. C. difficile strain R20291 spores were treated with taurocholate and glycine () to a
final concentration of 6 mM and 12 mM, respectively; this represents 100% germination. As an
additional control, spores were treated with DMSO () and was set to represent 0%
germination. Spores, in the presence of taurocholate and glycine, were treated with SKS-IX-01C
at varying concentrations; final concentrations of compound SKS-IX-01C tested at 12.5 µM (r),
6.25 µM (¯), and 1.25 µM (£) are shown. The data represent the averages from three
independent measurements and error bars represent the standard deviations. For clarity, only
select concentrations are shown. Moreover, the graph represents data collected at 2-minute
intervals and only the first 60 minutes are shown.
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Figure 3.15. IC50 calculation of compound SKS-IX-01C against C. difficile strain R20291
spores. C. difficile strain R20291 spores were treated with taurocholate and glycine at a final
concentration of 6 mM and 12 mM, respectively, and incubated with compound SKS-IX-01C at
various concentrations. The percent germination for each treatment was determined and plotted
against concentration. The data was fitted using a four-parameter logistic function to obtain IC50
values.

Since the anti-germination activity of compound SKS-IX-01C was comparable to
compound 12a, this has allowed us to develop additional compounds with modifications
along the indoline backbone. From this, we identified compound ARS-I-16C as our most
potent C. difficile anti-germinant to date (Fig. 3.16). Compared to compounds 12a and
SKS-IX-01C where germination was completed inhibited at concentrations as low as
6.25 µM and 25 µM, respectively, compound ARS-I-16C was able to completely inhibit
C. difficile strain R20291 spore germination at 2.5 µM (Fig. 3.17). When percent
germination was plotted against the log concentration of compound ARS-I-16C, the data
revealed an IC50 value of 0.35 ± 0.04 µM (Fig. 3.18).
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Figure 3.16. Structure of compound ARS-I-16C.

Compound ARS-I-16C is a 5-fluoro-indoline derivative of cholate. The physical
and chemical properties of compound ARS-I-16C are seemingly consistent with our
SAR analyses. Similar to SKS-IX-01C, the planar and rigid indoline side chain of ARS-I16C is bonded directly to the amide nitrogen. Our SAR analyses also suggested the
potential of fluorine groups in facilitating an interaction with the taurocholate binding site.
Indeed, addition of a fluorine group to the indoline side chain further increased the
activity of our compound.

Figure 3.17. C. difficile strain R20291 spore germination is inhibited by compound ARS-I16C. C. difficile strain R20291 spores were treated with taurocholate and glycine () to a final
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concentration of 6 mM and 12 mM, respectively; this represents 100% germination. As an
additional control, spores were treated with DMSO () and was set to represent 0%
germination. Spores, in the presence of taurocholate and glycine, were treated with ARS-I-16C
at varying concentrations; final concentrations of compound ARS-I-16C tested at 1 µM (r), 0.5
µM (¯), and 0.25 µM (£) are shown. The data represent the averages from three independent
measurements and error bars represent the standard deviations. For clarity, only select
concentrations are shown. Moreover, the graph represents data collected at 2-minute intervals
and only the first 60 minutes are shown.

Figure 3.18. IC50 calculation of compound ARS-I-16C against C. difficile strain R20291
spores. C. difficile strain R20291 spores were treated with taurocholate and glycine at a final
concentration of 6 mM and 12 mM, respectively, and incubated with compound ARS-I-16C at
various concentrations. The percent germination for each treatment was determined and plotted
against concentration. The data was fitted using a four-parameter logistic function to obtain IC50
values.

3.4. Conclusions
Taurocholate acts as the main driving force for CDI progression by triggering the
germination of C. difficile spores in vivo. As the process of germination is required for
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the onset of CDI, the use of bile acid analogs as anti-germinants has represented a new
paradigm shift in the treatment and prevention of CDI. Moreover, the increasing
prevalence of hypervirulent C. difficile strains has incited an additional need to develop
preventive and alternative approaches for managing CDI.
We previously demonstrated the efficacy of CamSA, a synthetic taurocholate
analog, to be an effective inhibitor of C. difficile strain 630 spore germination. CamSA
was approximately four times more active as an anti-germinant than the natural inhibitor
chenodeoxycholate when tested in vitro.
CamSA was also able to prevent disease in both antibiotic mice and hamsters
when challenged with an inoculum of C. difficile spores, suggesting that CamSA may
also be preventing spore germination in vivo150,151,156. Indeed, following CamSA
administration and C. difficile spore challenge, C. difficile spores can be quantitatively
recovered from the feces of CamSA-treated mice151. However, given the advantages of
CamSA described thus far, CamSA has an IC50 value in the micromolar range and is
unable to inhibit the germination of a BI/NAP1/027 hypervirulent strain of C. difficile.
To broaden the scope of anti-germination therapies against C. difficile, a
chemical library consisting of cholate analogs with side chain modifications was
designed and synthesized. This chemical library was assayed against C. difficile strain
R20291 spores in hopes of identifying potent anti-germinants effective against a
hypervirulent strain of C. difficile. The synthesis and screening of the chemical library,
containing approximately 200 compounds tested, occurred in a stepwise manner. An
initial library consisting of approximately 70 compounds were screened for activity
against C. difficile strain R20291 spores and suggested structural and chemical
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modifications that increased anti-germination activity. Results obtained from the initial
library screen was used to design the synthesis of subsequent libraries.
We identified compound 12a, an aniline derivative of cholate, to be the most
potent anti-germinant from this initial series. Compound 12a has an IC50 value of 1.8 µM
against C. difficile strain R20291, representing an anti-germinant that is 250-fold more
potent than chenodeoxycholate, the natural germination inhibitor. Compound 12a was
also active against C. difficile strain 630 with an IC50 value of 8.2 µM, representing an
anti-germinant that is 7-fold more active than CamSA (J. Phan, data not shown).
With compound 12a being our most potent compound identified thus far,
compounds from this series were examined in an attempt to establish SAR analyses.
Analogs that deviate from compound 12a could be used to identify functional groups
required for binding to the taurocholate receptor. QSAR analyses of all the compounds
from this series, performed by our collaborators, suggested that smaller and more
hydrophobic compounds exhibited more activity compared to their larger, more polar
counterparts. In addition to the QSAR analyses performed by our collaborators, our
more narrow analysis of selected compound data suggests the alkyl chain linkage
between the amide nitrogen and cyclic side chain, as well as the rigidity of the side
chain, are important for anti-germination activity; shorter alkyl chains and more
constrained cyclic side chains allow for more potent compounds. Moreover, the
presence of fluorine in the side chain could potentiate binding of the anti-germinants to
the taurocholate receptor.
During subsequent rounds of anti-germinant design and synthesis, we identified
compound SKS-IX-01C to be more potent than compound 12a. Compound SKS-IX-01C
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is an indoline derivative of cholate and has an IC50 value of 1.2 µM, representing an
anti-germinant almost 400-fold more potent than chenodeoxycholate. In line with our
QSAR and SAR analyses, compound SKS-IX-01C has a short distance between the
side chain ring and the amide group. Furthermore, the hydrophobic indoline rings lack
flexibility due to the presence of a pi conjugation system. However, in contrast with our
QSAR analyses suggesting that smaller compounds exhibit more activity than larger
compounds, indoline has a larger molecular surface/size compared to compound 12a’s
phenyl ring. We argued that the global QSAR analyses were established with the limited
number of compounds. Inactive molecules exhibited larger molecular surfaces due to
the presence of polar groups. Thus, larger hydrophobic groups might still act as potent
inhibitors of C. difficile spore germination.
Identification of an active compound with an indoline side chain allowed us to
design additional analogs, where modification of indoline could act as a framework for
more potent compounds. From these modifications, we identified compound ARS-I-16C,
a 5-fluoro-indoline derivative of cholate. Compound ARS-I-16C is our most potent antigermination compound identified in this study against strain R20291 spores identified.
Astoundingly, compound ARS-I-16C was able to completely inhibit strain R20291 spore
germination at 2.5 µM. The IC50 value for this compound was calculated to be 0.35 µM,
representing an anti-germinant that is over 1,000-fold more potent than
chenodeoxycholate, and 5-fold more potent than compound 12a, our initial lead
compound. Compound ARS-I-16C also exhibited physical and chemical properties in
agreement with our QSAR and SAR analyses. Indeed, the side chain of compound
ARS-I-16C is largely nonpolar and is connected directly to the amide nitrogen. The in
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vitro effects of compound ARS-I-16C have not yet been determined against spores from
other C. difficile strains.
Fluorine is a very electronegative element. As such, it will have a strong electronwithdrawing effect on the aromatic indoline ring. While addition of the fluorine group to
the indoline side chain increases polarity, the electron-withdrawing positive effect of
fluorine substitution may have a dominant effect over compound polarity. It would be
interesting to screen indoline ring analogs with other electron-withdrawing and electron
donating groups for their activity against C. difficile spores.
The chemical library outlined in this study has only accounted for the effects of
the side chains off the cholate amide scaffold. Indeed, modifying the cholate backbone
can have substantial effects on C. difficile spore germination. Whereas cholate can
trigger C. difficile spore germination, removal of the hydroxyl group at position 12 from
cholate produces chenodeoxycholate, a bile acid that can inhibit the C. difficile spore
germination process. Epimerization of the hydroxyl group at position 7 of
chenodeoxycholate produces ursodeoxycholate, a bile acid with similar anti-germination
efficacy in vitro. Removal of the hydroxyl group at position 7 from chenodeoxycholate
produces lithocholate, a bile acid that not only inhibits the germination process but can
also inhibit vegetative cell outgrowth and replication. The C-24 amides of our
compounds will also need to be considered during the design and development of future
analogs. Amides are highly susceptible to hydrolysis and thus need to be modified to
ensure our compounds remain stable in vivo.
Our QSAR analyses suggested that hydrophobic compounds were generally
more active than their hydrophilic/polar counterparts. Thus, we could continue to modify

111

cholate analogs to become more hydrophobic by altering the side chain region, or the
cholate backbone. The downside is that, a majority of our most active compounds are
already sparingly soluble in aqueous solutions. As an example, whereas CamSA is
minimally soluble in aqueous solutions, the loss of the polar sulfonate group rendered
compound 12a to be extremely insoluble under the same conditions.
To ameliorate the solubility issues of bile acid analogs, pro-drug versions of these
compounds can be designed. Compound SKS-IX-50C, a pro-drug version of compound
12a, was formulated allowing for potential in vivo testing (Fig. 3.19). Compound SKSIX-50C contains polar carboxylate groups attached to esters at positions 3, 7, and 12 of
the cholate backbone. Under in vivo conditions, we expect the esters to be cleaved by
gastrointestinal esterases and lipases, generating compound 12a at the site of action.
As expected, the anti-germination activity of compound SKS-IX-50C was reduced
significantly compared to compound 12a, when assayed under similar in vitro
conditions. Perhaps with the increased solubility of this pro-drug, it is now unable to bind
effectively to the taurocholate receptor. The efficacy of the prodrug in vivo has not yet
been determined.

Figure 3.19. Structure of compound SKS-IX-50C
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The increasing prevalence of hypervirulent C. difficile strains has incited a dire
need to develop additional anti-germinants more potent than any of its predecessors.
The use of this chemical library consisting of approximately 200 side chain analogs of
cholate, has allowed us to study a physical interaction between our anti-germinants and
spores from a hypervirulent strain of C. difficile. These interactions can dictate trends
necessary for the further development of anti-germinants. Within this study, we
identified a total of 24 anti-germinants with IC50 values between 0.35 µM and 37 µM
against strain R20291. Several of these compounds are equally effective against strain
630 and, to our knowledge, several compounds identified in this study are the most
potent anti-germinants described to date against C. difficile spores.
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CHAPTER 4
GERMINATION VARIANTS OF CLOSTRIDIOIDES DIFFICILE
4.1. Background
The germination process is most commonly initiated by the recognition of key
molecules, termed germinants, and is required for the onset of disease in sporulating,
pathogenic bacteria. Germinants commonly include various metabolites such as amino
acids and sugars. Most germinant recognition is believed to occur via proteinaceous
heterocomplexes, known as germination (Ger) receptors, found on the spore’s inner
membrane58,59. The identity and composition of the germinants are often tailored to a
bacterium’s specific environmental niche and has been shown to occur in a
stereospecific manner42,43.
Ger receptor homologs have been identified in most Bacilli and Clostridia200. The
number of Ger receptor operons varies between different bacterial species, as do the
germination responses. For example, all sequenced strains of Clostridium perfringens
encode a single Ger receptor, GerK, which allows for the recognition of KCl and Lasparagine201. In contrast, B. subtilis encodes three Ger receptors. The B. subtilis GerA
receptor allows for the recognition and subsequent germination in response to Lalanine. B. subtilis GerB recognizes a mixture of amino acids and fructose, while GerK
seems to recognize glucose42,69. The stereospecific requirement of these germinants
has been demonstrated in B. subtilis, where GerA-mediated germination can be
inhibited by D-alanine. Interestingly, inhibition by D-alanine in B. subtilis can be relieved
by mutations in gerB, which suggests cooperativity between the Ger receptors69,202.
Despite the germination requirement to complete its lifecycle and to initiate
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disease, all sequenced strains of C. difficile lack homologs to the classical Ger receptor
proteins34,36. The absence of conventional Ger receptor genes may suggest that C.
difficile Ger receptors are too divergent from other sporulating bacteria and may also
suggest that C. difficile spores respond to unique germinants82–84. Indeed, preincubation of C. difficile spores with bile acids have been shown to increase colony
formation; un-treated C. difficile spores germinate inefficiently and form few colonies
onto nutrient-rich media192. Further examination of bile acids led to the discovery that
taurocholate was sufficient to increase C. difficile spore recovery, suggesting that
taurocholate may be a C. difficile-specific spore germinant82.
Taurocholate is a bile acid involved in the emulsification of fats and facilitates the
uptake of fatty acids. Thus, taurocholate could non-specifically triggering germination by
solubilizing the spore membrane. However, treatment of C. difficile with detergents or
surfactants such as sodium dodecyl sulfate (SDS) or Triton X-100 could not germinate
C. difficile spores83. The co-requirement of glycine, an amino acid with no known
membrane-disrupting activity, further suggests C. difficile spores directly bind to
taurocholate and glycine. Indeed, kinetic evidence demonstrates the sequential
requirement where taurocholate must be bound first, prior to the binding of glycine83.
Lastly, chenodeoxycholate, another natural bile acid produced within the gastrointestinal
tract was shown to be a competitive inhibitor of taurocholate-mediated spore
germination83,85. These lines of evidence suggest C. difficile spores utilize an unknown
receptor to recognize and bind to taurocholate, and subsequently undergo germination.
Recently, Francis et al. utilized ethyl methanesulfonate (EMS)-mediated
mutagenesis to identify a putative C. difficile spore germination receptor responsible for
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sensing bile acids86. Whole genome sequencing of C. difficile mutants unable to
germinate in response to taurocholate identified several single nucleotide
polymorphisms (SNPs) in the cspBAC locus. Furthermore, eight of the ten mutants
contained SNPs in cspC and thus, could suggest that C. difficile likely uses CspC, a
subtilisin-like protease, to recognize bile acid germinants86,92. TargeTron inactivation of
cspC also resulted in germination deficient mutants, demonstrating the essentiality of
CspC as it pertains to germination. Interestingly, a G457R point mutation in CspC
resulted in C. difficile spores able to germinate in response to chenodeoxycholate,
suggesting that CspC may be directly involved in sensing bile acids. Moreover, a series
of point mutations in CspC were generated and resulted in either hypo- or hypersensitivity to taurocholate195.
Interestingly, the genome of C. difficile is comprised of several mobile
elements14. These mobile elements have been suggested to play an extensive role in
acquiring resistance and virulence genes and can function to increase the overall
genetic variability. Indeed, a recent study identified 86 distinct ribotypes from a pool of
705 total isolates203. The genetic diversity of C. difficile strains has also led to an
abundance of phenotypic differences. Several hypervirulent strains of C. difficile have
exhibited increased resistance to several pharmaceutically relevant antibiotics and have
been associated with more severe cases of disease.
Strain-to-strain germination variability also has been reported in C. difficile157.
While chenodeoxycholate could inhibit the germination of a clinical C. difficile isolate, a
range of inhibition efficacies was observed when chenodeoxycholate was assayed
against a panel of C. difficile isolates. Moreover, as discussed in the previous chapter,
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while CamSA was effective against C. difficile strain 630, CamSA was inactive against
R20291, a hypervirulent strain of C. difficile.
In this study, we attempted to provide a genetic basis for the recognition of bile
acids. We initially determined if other Csp proteins were required for germination and
thus generated several knockout mutations. Mutants with clean deletions of any Csp
proteins (CspA, CspB, CspC) were unable to germinate in response to taurocholate,
had no defects in spore production, and were unable to elicit disease in antibiotictreated hamsters even when administered high spore titers. Under the assumption that
bile acid recognition occurs by CspC, we sequenced cspC from eight C. difficile strains
that show different germination phenotypes. We were, however, unable to establish a
correlation between cspC and the different germination phenotypes. Lastly, we
designed a series of screens and enrichments used to identify natural mutants that are
resistant to our proposed anti-germination therapies. We also looked to identify natural
mutants that could potentially germinate in response to our synthetic anti-germination
compounds.

4.2. Materials and Methods
4.2.1. General Comments
Taurocholate and glycine were purchased from Sigma-Aldrich Corporation (St.
Louis, MO). Bile acid analogs were synthesized and provided by Prof. Steven
Firestine’s laboratory at Wayne State University. All bile acid analogs were dissolved in
DMSO. Glycine was dissolved in deionized water (DIH2O). The bile acid analogs were
synthesized and provided by Dr. Steven Firestine at Wayne State University.
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4.2.2. Bacterial Strains and Growth Conditions
C. difficile strain 630 was obtained from the American Type Culture Collection
(ATCC). C. difficile strain 630 was purchased from the American Type Culture
Collection (ATCC). C. difficile strains CDC38, DH1834, R20291, 05-1223-046, 7004578,
8085054, and 9001966 were kind gifts from Prof. Nigel Minton at the University of
Nottingham. C. difficile strain 630∆erm ∆pyrE, pMTL-YN3, and pMTL-YN1C were kind
gifts from Dr. Aimee Shen at Tufts University. C. difficile strain 630∆erm ∆pyrE is an
erythromycin-sensitive derivative of strain 630 carrying a deletion in pyrE, which
encodes for orotate phosphoribosyltransferase, required for uracil prototrophy204. pMTLYN3 was used for knockouts in C. difficile strain 630∆erm ∆pyrE, and pMTL-YN1C was
used for complementations. C. difficile strains CDC38, DH1834, R20291, 05-1223-046,
7004578, 8085054, 9001966, and 630∆erm ∆pyrE were routinely cultured at 37°C in an
anaerobic environment (10% CO2, 10% H2, and 80% N2).
C. difficile strains were grown on BHIS (BHI supplemented with 0.5% yeast
extract, 0.1% L-cysteine, and 0.05% sodium taurocholate) plates. BHIS plates were
supplemented with thiamphenicol (10 to 15 µg/ml), kanamycin (50 µg/ml), and cefoxitin
(8 µg/ml), where appropriate. Allele-coupled exchange was performed on CDMM (1%
Casamino acids, 0.05% L-tryptophan, 0.05% L-cysteine, 35.2 mM Na2HPO4, 59.5 mM
NaHCO3, 15.4 mM NaCl, 302 µM (NH4)2SO4, 177 µM CaCl2, 98.4 µM MgCl2, 50.6 µM
MnCl2, 4.2 µM CoCl2, 33.1 µM FeSO4, 0.8% glucose, 0.0001% D-biotin, 0.0001%
calcium-D-pantothenate, 0.0001% pyridoxine) plates supplemented with 5 µg/ml uracil
and 2 mg/ml 5-fluoroorotic acid (CDMMUFOA) as needed.
E. coli Mach1 T1 (Invitrogen) was used for subcloning, and E. coli CA434 (E. coli
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HB101 harboring pRK24) was used for conjugations. E. coli was cultured in LuriaBertani (LB) medium, supplemented with chloramphenicol (25 µg/ml) and ampicillin
(100 µg/ml), where appropriate, and routinely cultured at 37°C with shaking at 225 rpm.
For solid media, agar was added to a final concentration of 1.5% (w/v).

4.2.3. Spore Preparation and Purification
Frozen stocks of C. difficile strain R20291 and derivatives of C. difficile strain 630
were streaked onto pre-reduced BHIS plates and incubated overnight at 37°C in an
anaerobic environment to yield single colonies. Liquid cultures of C. difficile were
prepared by inoculated degassed BHIS (BHI supplemented with 5 mg/ml yeast extract)
broth with a single C. difficile colony and incubated overnight.
Aliquots (200 µl) of an overnight C. difficile strain R20291 culture were spread
onto pre-reduced BHIS plates and incubated for 7 days to allow for sporulation. C.
difficile strain 630 derivatives do not sporulate efficiently on BHIS and are therefore
sporulated onto pre-reduced 70:30 (6.3% Bacto peptone, 1.1% Brain heart infusion,
0.4% protease peptone, 0.2% yeast extract, 0.03% L-cysteine, 9.8 mM tris base, 5.3
mM (NH4)2SO4) plates instead. Thus, 200 µl aliquots from cultures of C. difficile strain
630 derivatives were spread onto pre-reduced 70:30 plates and incubated for 7 days to
allow for sporulation.
The resulting bacterial lawns were harvested by flooding the plates with ice-cold
DIH2O. The samples were pelleted by centrifugation at 8,800 x g and the supernatants
were decanted. This wash procedure was repeated three times. Spores were then
purified by density centrifugation through a 20% to 50% Histodenz gradient. After
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discarding the Histodenz solution, the spore pellet was washed three times with DIH2O,
resuspended in a sodium thioglycolate solution (0.5 g/l), and stored at 4°C until further
use. To determine spore purity, samples were visualized by phase contrast microscopy
or stained using the Schaeffer-Fulton technique, as described previously. Spores used
in all experiments were more than 95% pure as determined by microscopy following
Schaeffer-Fulton staining.

4.2.4. Optical Density Assay
C. difficile spores were washed three times with DIH2O, then heat shocked at
68°C for 30 min to kill any vegetative cells that may have been present within the spore
suspension. This process also activates spores to become more responsive to
germinants198,199. After the spores were heat shocked, the samples were cooled to room
temperature, washed an additional three times with DIH2O, and finally resuspended in
0.1 M sodium phosphate buffer (88 mM NaH2PO4, 12 mM Na2HPO4, pH 6.0)
supplemented with 5 mg/ml sodium bicarbonate at the time of use. Spore suspensions
were diluted to an optical density at 580 nm (OD580) of approximately 1.0.
To test for C. difficile spore germination, 180 µl aliquots of the diluted spore
suspension were added to 96-well clear plates containing taurocholate and glycine, at a
final concentration of 6 mM and 12 mM, respectively. Following the addition of the spore
suspension, the OD580 was measured every minute for 2 h. As a negative control, 180 µl
aliquots of the diluted spore suspension were treated with neat DMSO. All experimental
conditions were performed in triplicate and the final volume in each well was 200 µl.
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4.2.5. End-point Ca-DPA Release Assay
C. difficile spores were prepared as previously described (refer to section 4.2.4)
with the following modifications. After the spores were heat shocked, the samples were
cooled to room temperature, washed an additional three times with DIH2O, and finally
resuspended in 10 mM Tris-HCl, pH 7.0. The spore suspensions were diluted to an
OD580 of approximately 1.0.
To test for C. difficile spore germination, 900 µl of the diluted spore suspension
was incubated with 100 µl of a germinant solution. Following incubation, 30 µl aliquots
of the spore sample was added to 96-well clear bottom black plates containing 85 µl of
10 mM Tris-HCl, pH 7.0 and 35 µl of TbPV (250 µM TbCl3, 250 µM pyrocatechol violet
(PV), 10 mM HEPES, pH 7.0). Following the addition of the spore sample, Ca-DPA
release (excitation, 270 nm; emission 545 nm [appropriate wavelengths for the DPATb3+ complex]) was measured.
The percent germination for these assays were calculated relative to a boiled
sample of C. difficile spores. Briefly, 900 µl of the diluted spore suspension was added
to 100 µl of DIH2O. The sample was boiled for 2 h to release all the core Ca-DPA,
representing 100% germination. As a negative control, 900 µl aliquots of the spore
suspension were treated with neat DMSO. All experimental conditions were performed
in triplicate and the final volume in each well was 150 µl.

4.2.6. General Molecular Biology Comments
Primers were ordered from Integrated DNA Technologies (IDT; Coralville, IA).
Genomic DNA was extracted using Wizard® Genomic DNA Purification Kit according to
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the manufacturer’s protocol (Promega). PCR products and amplicons were purified
using QIAquick PCR Purification kit according to the manufacturer’s protocol (Qiagen;
Hilden, Germany). PCRs were conducted using Phusion Hot Start II DNA Polymerase
(Thermo Fisher; Waltham, MA). BenchTop 1 kb and 100 bp DNA ladders were
purchased from Promega (Madison, WI).

4.2.6.1. E. coli Strain Construction
To construct the pMTL-YN3 constructs carrying deletions of cspA, cspB, cspC, and
cspBA, the following PCRs were performed using the appropriate primers (Table 4.1).
For the ∆cspA construct, primer pair 1025 and 1027 was used to amplify an 870 bp region
upstream of cspA and primer pair 1026 and 1028 was used to amplify a 675 bp region
downstream of cspA. For the ∆cspB construct, primer pair 1029 and 1032 was used to
amplify a 719 bp region upstream of cspB and primer pair 1030 and 1031 was used to
amplify a 969 bp region downstream of cspB. For the ∆cspC construct, primer pair 1005
and 1007 was used to amplify an 809 bp region upstream of cspC and primer pair 1006
and 1008 was used to amplify a 924 bp region downstream of cspC. For the ∆cspBA
construct, primer pair 1019 and 1021 was used to amplify a 725 bp region upstream of
cspBA and primer pair 1020 and 1022 was used to amplify a 702 bp region downstream
of cspBA. The amplicons were purified and fused together using splicing by overlap
extension PCR (SOE-PCR) for each construct, respectively (Figure 4.1)205,206.
The resulting PCR products were ligated into AscI- and SbfI-digested pMTL-YN3
using Gibson Assembly and transformed into chemically competent E. coli Mach1
T1207,208. The resulting plasmids were confirmed by sequencing using primer pair 1000
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and 1001 and transformed into CA434.

Figure 4.1. C. difficile gene deletions. Deletions of cspB, cspA, cspC, and cspBA from the
cspBAC operon in C. difficile 630∆erm ∆pyrE. Each construct generates a putative nonfunctional, small polypeptide of the respective knockout.

123

Primer Name

Sequence

1000

pMTL-YN3 Sequencing Forward

1001

pMTL-YN3 Sequencing Reverse CTTTTTTAGCCGCTAAAACGGCCGG

GAGTATAATTAATCATACTAAATTCTATAATTTTCTTTTCTGTAAATTTC

1002

cspBA Flanking Forward

GTTTTAAATATGCGTCAATTTCAAGTTGCA

1003

cspC Flanking Forward

GCGTTCTTTACTAGAGGGTTATGTATAACG

1004

cspC Flanking Reverse

TTTAGATACTCTAGATGTTCTTATCCATCC

1005

∆cspC Forward AscI

CAATTGTTCAAAAAAATAATGGCGGCGCGCCAAGACGAGGAAGAATTATCATTAGAACTT

1006

∆cspC Reverse SbfI

AGCAAGGCAAGACCGATCGGGCCCCCTGCAGGTATATAAAGGGACGAAAGACTATTACTC

1007

∆cspC SOE Forward

ATAATTTATCAAGGTGATATAGAATCTGCCGGGATTTTAAATTTAAAAAATACGATTCAA

1008

∆cspC SOE Reverse

TTGAATCGTATTTTTTAAATTTAAAATCCCGGCAGATTCTATATCACCTTGATAAATTAT

1018

cspBA Flanking Reverse

CACACCAGCACTACTCAATATATTAAAAGT

1019

∆cspBA Forward AscI

GTCAATTGTTCAAAAAAATAATGGCGGCGCGCCTTATTTTTTGAGAAGCCAAGAAAAAAT

1020

∆cspBA SOE Foward

GAAGTCGAGGTGATTATAATAAATTATGAAGTTAGAGGAATGTTTGATGTTTTAAGATAG

1021

∆cspBA SOE Reverse

CTATCTTAAAACATCAAACATTCCTCTAACTTCATAATTTATTATAATCACCTCGACTTC

1022

∆cspBA Reverse SbfI

CAAGGCAAGACCGATCGGGCCCCCTGCAGGAAAATCTGAAACACTGTAATTTATCCTTCC

1023

cspA Flanking Forward

ATGAGGGCAATTAAATTTATTTTAGATAGG

1024

cspA Flanking Reverse

ACCAGCACTACTCAATATATTAAAAGTATC

1025

∆cspA Forward AscI

AATTGTTCAAAAAAATAATGGCGGCGCGCCGGAGGTCATAAAAGGATTAGGCTTCAAAAT

1026

∆cspA SOE Forward

GATATGGGATATAGAAGTATTAATAAGTCATAGGAGGGATTTATGGAAAAATCTTATTGT

1027

∆cspA SOE Reverse

ACAATAAGATTTTTCCATAAATCCCTCCTATGACTTATTAATACTTCTATATCCCATATC

1028

∆cspA Reverse SbfI

CAAGGCAAGACCGATCGGGCCCCCTGCAGGAAAATCTGAAACACTGTAATTTATCCTTCC

1029

∆cspB Forward AscI

GTCAATTGTTCAAAAAAATAATGGCGGCGCGCCGGATATTTAAAGTTATTTTTTGAGAAG

1030

∆cspB Reverse SbfI

AGCAAGGCAAGACCGATCGGGCCCCCTGCAGGAACATATGGTATTATTCCAGATGTATGT

1031

∆cspB SOE Forward

ACATTAATAATAATTTTAGAAGTCGAGGTGTTTAAAGATGAGGAAAATAGTTATAAGTTT

1032

∆cspB SOE Reverse

AAACTTATAACTATTTTCCTCATCTTTAAACACCTCGACTTCTAAAATTATTATTAATGT

1033

cspB Flanking Forward

AGACTTCGTCAATTTTCTACTAGAATAGAT

1034

cspB Flanking Reverse

ATATTCAGTCCCCTCTAAATCAAATAAACC

Table 4.1. Primers used for csp knockout studies.

4.2.6.2. C. difficile Strain Construction
E. coli CA434 cultures harboring pMTL-YN3 knockout constructs were grown for
6 h, pelleted at 2,500 x g for 5 min, and the supernatant was discarded. The E. coli
pellet was transferred into the anaerobic workstation and gently resuspended in 1 ml of
a C. difficile strain 630∆erm ∆pyrE that had been growing for 5 h under standard
culturing conditions. The conjugation mating mixtures were then spotted (7 x 100 µl)
onto pre-reduced BHIS lacking taurocholate. Following 16 h incubation, the conjugation
mating mixtures were harvested into 1 ml of PBS, and 100 µl of the cell suspensions
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were spread onto BHISTKC (BHIS plates containing 10 µg/ml thiamphenicol, 50 µg/ml
kanamycin, and 8 µg/ml cefoxitin) plates.
The largest colonies that grew on BHISTKC after 72 h incubation were picked and
restreaked onto BHISTUCK15 (BHISTKC containing 15 µg/ml thiamphenicol). The largest
putative transconjugant clones were passaged an additional two times on BHISTUCK15.
Transconjugants grown after three rounds of BHISTUCK15 were picked and restreaked
onto CDMM plates supplemented with 5 µg/ml uracil and 2 mg/ml 5-fluoroorotic acid
(CDMMUFOA). Colonies that formed on CDMMUFOA were restreaked and screened for the
knockout genotype by PCR. Knockout mutants were also screened for wild-type
contamination.
Pure knockout strains were complemented using pMTL-YN1C to restore uracil
prototrophy. Briefly, pMTL-YN1C was conjugated into C. difficile and single site
integrants were grown on three passages of BHISTUCK15, as described previously.
Transconjugants grown on BHISTUCK15 were picked and restreaked onto CDMM lacking
uracil to select for recombinants that restored the pyrE allele at the native locus.

4.2.6.3. CspC Sequencing
Regions flanking the CspC gene from C. difficile strains CDC38, DH1834,
R20291, 05-1223-046, 630, 8085054, and 9001966 were amplified using primer pair
1043 and 1050 to generate an 1821 bp amplicon. Similarly, regions flanking the CspC
gene from C. difficile strain 7004578 were amplified using primer pair 1051 and 1050 to
generate a 2014 bp amplicon. The amplicons were purified and DNA was quantified by
Nanodrop. CspC was sequenced by Genewiz using primers 1043, 1044, 1045, 1046,
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1047, 1048, 1049, and 1050 (Table 4.2). Sequencing results were translated and
aligned using Benchling.

Table 4.2. Primers used for C. difficile cspC sequencing

4.2.7. C. difficile spore plating assays
C. difficile strain R20291 spores were washed three times with DIH2O, then heat
shocked at 68°C for 30 min to kill any vegetative cells that may have been present
within the spore suspension. This process also activates spores to become more
responsive to germinants198,199. After the spores were heat shocked, the samples were
cooled to room temperature, washed an additional three times with DIH2O, then diluted
to an OD580 of approximately 1.0 with DIH2O.
To identify the frequencies of C. difficile strain R20291 spore germination, the
spore suspensions were serially diluted with DIH2O, then 100 µl of each sample was
plated onto BHIS, BHIS containing 0.93 mM taurocholate, or BHIS containing 10 µM of
a bile acid. Colony forming units (CFUs) were determined after 24-48 hours.
Alternatively, the frequencies of C. difficile strain R20291 spore germination
could be determined by loss of wet heat resistance as a consequence of core re126

hydration. Aliquots (900 µl) of the diluted spore suspension were incubated with bile
acids and 12 mM glycine. Following incubation at room temperature, the spore samples
were incubated at 68°C for 30 minutes to kill any germinated spores. After the spores
were heat shocked, the samples were cooled to room temperature, serially diluted with
DIH2O, then 100 µl of each sample was plated onto BHIS containing 0.93 mM
taurocholate to recover the spore population that did not germinate.

4.2.8. Enrichment of C. difficile individuals able to germinate with compound 12a
C. difficile strain R20291 spores were prepared described as above. The spore
suspensions were serially diluted with DIH2O, then 100 µl of each sample was plated
onto BHIS, BHIS containing 0.93 mM taurocholate, or BHIS containing 10 µM of
compound 12a. Colonies that grew on BHIS containing 10 µM of compound 12a were
pooled into 5 ml of degassed BHIS (BHI supplemented with 5 mg/ml yeast extract)
broth, re-sporulated, and the selection process was repeated to enrich the population
for germination-mutants.

4.3. Results and Discussion
4.3.1. Generation of C. difficile ∆csp mutants
Plasmid pMTL-YN3 is an autonomously replicating, segregationally unstable
plasmid that confers thiamphenicol resistance (CatP) in C. difficile (Fig. 4.2) (Ehsaan,
2016). Single-crossover C. difficile clones (individuals with the pMTL-YN3 plasmid
integrated into the chromosome) grow faster on BHISTKC and BHISTUCK15 selective
media than transconjugants carrying a non-integrated, autonomously replicating pMTL127

YN3. Cells carrying catP on the non-integrated plasmid grow slower as the rate of
growth is limited by the rate at which pMTL-YN3 is segregated amongst daughter cells.
Progeny from single-crossover C. difficile clones however, all carry a copy of catP with
each round of chromosomal replication (Fig. 4.3) (Ehsaan, 2016).
Plasmid pMTL-YN3 also contains a pyrE allele isolated from Clostridium
sporogens, which serves as a bidirectional selectable marker. Orotate
phosphoribosyltransferase (PyrE) confers uracil prototrophy and also converts 5-FOA to
5-fluorouracil (5-FU), a toxic byproduct of pyrimidine biosynthesis204. Double-crossover
C. difficile clones (individuals in which the integrated pMTL-YN3 plasmid has
recombined out of the chromosome) lose resistance to thiamphenicol, are uracil
auxotrophs, and are resistant to 5-FOA. As such, double-crossover C. difficile clones
can be selected on CDMMUFOA. Double-crossover C. difficile clones were subsequently
screened for the ∆csp constructs by PCR (Fig. 4.4). Confirmed ∆csp mutants were
subsequently screened by PCR for wild-type contamination (data not shown).

128

Figure 4.2. C. difficile strain 630∆erm ∆pyrE knockout plasmid. The pMTL-YN3 plasmid
contains several components essential for C. difficile strain 630∆erm ∆pyrE knockout: catP
encodes chloramphenicol acetyltransferase, conferring resistance to chloramphenicol and
thiamphenicol in E. coli and C. difficile, respectively; pyrE, isolated from Clostridium
sporogenes, encodes orotate phosphoribosyltransferase allowing de novo pyrimidine
biosynthesis; TraJ is required for the transfer of RP4 based plasmids; RepH is a
segregationally-unstable C. difficile replicon derived from Clostridium butyricum pCB102.
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Figure 4.3. Schematic showing the generation of single- and double-crossover clones.
(A) Design of Knockout plasmid. To generate a knockout construct, homologous regions
upstream (USH) and downstream (DSH) of a gene of interest (GOI) is cloned into pMTL-YN3.
pMTL-YN3 undergoes homologous recombination at USH to generate single-crossover clones.
Recombination can also occur at DSH (not shown). (B) Phenotype of single-crossover
integrants. Single-crossover clones become resistant to thiamphenicol following a singlerecombination event; these clones have a significant growth advantage over transconjugant
clones harboring a non-integrated pMTL-YN3 and can be selected on media supplemented with
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thiamphenicol. (C) Excision of pMTL-YN3 from the chromosome. Single-crossover clones
undergo a second recombination event at DSH, resulting in pMTL-YN3 excision from the
chromosome. Recombination can also occur at USH (not shown), resulting in the wildtype GOI
allele being regenerated. (D) Phenotype of double-crossover clones. Recombinants that
undergo a second crossover event, resulting in pMTL-YN3 excision and subsequent loss,
become resistant to 5-FOA; these clones can be selected on minimal media supplemented with
uracil and 5-FOA. Recombinants grown on CDMMUFOA are screened for the knockout by PCR.

Figure 4.4. Verification of ∆csp mutants by colony PCR. The primers used to screen for the
gene deletions are shown in green. Select molecular weights from a BenchTop 1 kb DNA ladder
are shown for each construct.

4.3.2. ∆csp mutants are unable to germinate or cause disease in hamsters
We wanted to determine whether C. difficile ∆csp mutants would still be able to
germinate in response to taurocholate and glycine. None of the ∆csp mutants were able
to germinate in response to taurocholate and glycine when monitored by optical density
assays (Fig 4.5). These data suggest that CspC, CspB, and CspA are all required for C.
difficile spores to germinate in response to bile acids.
Since C. difficile spore germination is a pre-requisite for disease, we also tested
the ability of these ∆csp mutants to cause disease in antibiotic-treated hamsters.
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Whereas hamsters succumb to disease when administered approximately 100 wild type
C. difficile spores, hamsters receiving a 10-fold increase in the number of spores from
∆csp mutants exhibited no disease symptoms (data not shown). These data, in
conjunction with in vitro germination assays, suggest that C. difficile ∆csp mutants are
unable to germinate in vivo and therefore do not elicit disease.
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Figure 4.5. Germination assay (optical density) of ∆Csp mutants. C. difficile strain 630∆erm
spores were treated with taurocholate and glycine () to a final concentration of 6 mM and 12
mM, respectively; this represents 100% germination. As an additional control, spores were
treated with DMSO () and was set to represent 0% germination. In the presence of
taurocholate and glycine, spores from C. difficile strain 630∆erm ∆cspA (r), ∆cspB (¯), and
∆cspC (£) were unable to germinate. The data represent the averages from three independent
measurements and error bars represent the standard deviations. For clarity, only select
concentrations are shown. Moreover, the graph represents data collected at 2-minute intervals
and only the first 60 minutes are shown.

4.3.3. Screening for natural C. difficile spore mutants
Since we confirmed the essentiality of CspA, CspB, and CspC in regard to
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germination, we questioned whether mutations in these proteins could lead to different
germination phenotypes. However, since chemical and site directed mutagenesis in C.
difficile is a time-consuming process that can led to spurious results, we designed a
series of screens and selections to identify potential individuals with different
germination phenotypes found in C. difficile spore populations. Thus, we attempted to
identify natural mutants that are able to germinate in response to our potent antigermination compounds.

4.3.3.1. C. difficile strain R20291 spores can germinate in response to compound
12a.
C. difficile spores germinate inefficiently on complex media lacking bile acids.
Thus, we examined whether media supplemented with our potent anti-germinant,
compound 12a, could affect spore recovery. Plating onto complex media containing
0.93 mM taurocholate, the natural C. difficile spore germinant, allows us to quantitatively
recover and calculate for the total spore CFU (Fig. 4.6). When C. difficile spores are
plated onto media lacking bile acids, we recovered less than 1% of the total quantity of
spores plated. When plated onto media containing 10-fold less taurocholate (10 µM), we
recovered approximately 20-fold more spores relative to the negative control but this
quantity still amounted to less than 1% of the total population plated. Similarly, when
plated onto media supplemented with 10 µM CamSA, an inactive bile acid analog
against strain R20291 spores, we recovered less than 1% of the total population plated.
These data were expected as the calculated frequencies of recovery approximated to
be roughly 1 in every 106 individuals, in line with average mutation rate occurring in
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bacteria209.
Interestingly, when C. difficile strain R20291 spores were plated onto complex
media supplemented with 10 µM compound 12a, we recovered approximately 5% of the
total population plated (Fig. 4.6). The frequency of recovery using compound 12a was
calculated to be approximately 5 in every 100 individuals. This was an interesting
observation since the frequency is well above the natural bacterial mutation rate and
could suggest that a large subset of strain R20291 spores is able to actively germinate
in response to compound 12a.

Figure 4.6. C. difficile strain R20291 spores can germinate in response to compound 12a.
Total spore CFUs were calculated by plating onto media containing 0.93 mM taurocholate (TC;
white bar). When plated onto media lacking bile acids (DMSO; black bar), C. difficile spores
germinate inefficiently; this serves as a negative control. C. difficile strain R20291 spores also
germinate inefficiently on media containing 10 µM taurocholate (checkered bar) or 10 µM
CamSA (dotted bar). When plated onto media containing 10 µM compound 12a (horizontal bar),
we were able to recover approximately 5% of the total population plated. The data represent the
averages from three independent measurements and error bars represent the standard
deviations.
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4.3.3.2. C. difficile strain R20291 spores germinate spontaneously to compound
12a.
Since a subset of C. difficile strain R20291 spores were able to germinate in
response to compound 12a, we wanted to enrich for individuals able to utilize
compound 12a as a germinant. These individuals could then be sequenced to identify
the variations allowing for an altered germination phenotype. We were, however, unable
to enrich for C. difficile individuals that germinated in response to compound 12a. From
our data, a fraction of the C. difficile strain R20291 spores may be germinating
spontaneously when exposed to compound 12a (Fig. 4.7). Several groups have
proposed that taurocholate-independent germination may occur due to trace amounts of
bile acids found in animal-derived media. Thus, we also attempted to enrich for
individuals that germinate in response to compound 12a on CDMM. We were, however,
unable to recover C. difficile strain R20291 spores from CDMM (data not shown). We
were, however, unable to recover germinated C. difficile strain R20291 spores from
CDMM.
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Figure 4.7. Frequencies of C. difficile strain R20291 spores germinating in response to
compound 12a over time. The frequencies from each sample was calculated by dividing the
CFUs obtained on BHIS containing 10 µM compound 12a, by the total viable CFUs obtained
from spores plated onto BHIS containing 0.93 mM taurocholate.

4.3.3.3. Compound 12a does not trigger germination by disrupting the spore
membrane.
Since we observed spontaneous germination in response to compound 12a
exposure, we hypothesized that compound 12a could be increasing spore recovery by
disrupting the spore membrane. To address this, C. difficile strain R20291 spores were
plated onto solid media containing increasing concentrations of compound 12a. Thus, if
compound 12a is disrupting the spore membrane, higher CFUs should be observed with
higher concentrations of compound 12a. At our highest concentration of compound 12a
tested, we did not observe an increase in spore recovery compared to lower
concentrations of compound 12a used (Fig 4.8).
We also assayed for loss of wet heat resistance following exposure to compound
12a. During germination, spores become heat labile following core re-hydration. Thus, if
136

compound 12a is solubilizing the spore membrane and subsequently triggering
germination, the germinated spores should be susceptible to heat inactivation. In the
presence of taurocholate, we observed a 2-log reduction in CFUs following heat
inactivation, relative to the DMSO-negative control; this signifies 100% germination (Fig.
4.9). However, exposure to saturating concentrations of compound 12a did not affect
spore viability following heat treatment. Thus, our data suggests that compound 12a is
likely not disrupting the spore membrane.

Figure 4.8. Compound 12a does not alter the spore membrane leading to increased spore
recovery. Total spore CFUs were determined by plating onto media containing 0.93 mM
taurocholate (TC; white bar). When plated onto media lacking bile acids (DMSO; black bar), C.
difficile spores germinate inefficiently; this serves as a negative control. Increasing
concentrations of compound 12a does not increase spore recovery, suggesting that the spore
membrane is not being compromised. The data represent the averages from three independent
measurements and error bars represent the standard deviations.
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Figure 4.9. Compound 12a does not alter the spore membrane leading to loss of wet heat
resistance. Following incubation with bile acids, the samples were heat shocked at 68°C to
remove any germinated cells, then plated onto media containing 0.93 mM taurocholate to
determine total spore recovery. A 2-log reduction in total CFUs relative to the DMSO control
suggests that C. difficile strain R20291 spores became susceptible to heat treatment following
exposure to 0.93 mM taurocholate (white bar). In the presence of compound 12a, the CFUs
were comparable to the DMSO control (black bar). These data suggest that compound 12a is
not triggering germination by solubilizing or affecting the spore membrane. The data represent
the averages from three independent measurements and error bars represent the standard
deviations.

4.3.3.4. Compound 12a triggers C. difficile spore germination with unknown
molecules.
Our assays discussed thus far have been based primarily on CFU recovery
following 24-48 hour incubations. We argue, perhaps given the extended incubation
times, our observed CFUs may be due to compound 12a acting as a slow germinant.
Thus, we assayed for C. difficile strain R20291 spore germination in response to
compound 12a as a function of time. An end-point Ca-DPA release assay was used to
monitor the progression of germination. From the Ca-DPA release assay, we were
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unable to show that C. difficile strain R20291 spores germinate in response to
compound 12a over time (Fig. 4.10).

Figure 4.10. Compound 12a is not sufficient for triggering Ca-DPA release from C.
difficile strain R20291 spores. Following incubation with bile acids, an aliquot (30 µl) of the
spore suspension was assayed for Ca-DPA release. Over the course of 22 hours, C. difficile
strain R20291 spores did not germinate or release Ca-DPA when incubated in DMSO (black
bars). Conversely, C. difficile strain R20291 spores germinated slowly and released Ca-DPA
when incubated with taurocholate and glycine (white bars). Incubation with 10 µM taurocholate
and 12 mM glycine was not sufficient to trigger the germination of C. difficile spores (checkered
bars). In contrast with our plate-based assays, incubation with 10 µM compound 12a did not
trigger the germination of C. difficile spores even after 22 hours (horizontal bars). The percent
germination was calculated relative to a boiled sample of C. difficile spores (representing 100%
germination). The data represent the averages from three independent measurements and error
bars represent the standard deviations.

4.3.4. The CspC sequence is conserved throughout C. difficile isolates.
Since we were unable to enrich for C. difficile individuals able to germinate in
response to compound 12a, we attempted to identify the genetic basis for bile acid
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recognition by sequencing cspC from C. difficile isolates with vastly different
germination responses (Table 4.3). Several of these isolates were able to germinate on
BHIS alone, while others required taurocholate. Moreover, several of these strains were
unaffected by chenodeoxycholate-mediated inhibition.
The cspC genes from C. difficile strains 630 and R20291, in addition to the 6
isolates outlined in Table 4.3 were sequenced and aligned. To our surprise, cspC from
strain 630 was identical to cspC sequenced from strains 7004578, 8085054, and
9001966, even though their germination profiles varied widely. Furthermore, cspC from
strain R20291 was identical to cspC sequenced from strains CDC38 and DH1834.
When comparing the strain 630 and strain R20291 isoforms of CspC, the amino acid
differences all exhibited similar chemistries (polar to polar, and non-polar to non-polar
mutations).
When strain 630 was used as the reference strain, CspC from strain R20291
exhibited four distinct mutations: L38V, E151Q, V179A, and N394S. Strain 05-1223-046
exhibited the most divergent CspC but was more closely related to the R20291 CspC
isoform. When aligned against strain R20291, CspC from strain 05-1223-046 exhibited
one additional mutation (G279W).
Interestingly, while CspC from C. difficile strain 630 is identical to CspC from
strains 7004578, 8085054, and 9001966, strain 630 is the only isolate that is inhibited
by CamSA at concentrations below 100 µM (J. Phan, unpublished data). In conjunction
with our data discussed in section 4.3.2, this analysis suggests that although CspC is
essential for C. difficile spore germination in response to taurocholate, it is not readily
apparent that CspC is directly sensing bile acids.
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Strain
9001966
8085054
CDC38
DH1834
05-1223-046
7004578

2 mM TC
47%
72%
42%
58%
74%
46%

2mM CDCA
3%
13%
12%
57%
0%
36%

BHIS
11%
38%
6%
27%
38%
7%

Table 4.3. Germination profiles and loss of optical density of C. difficile isolates. C.
difficile isolates were incubated with either BHIS, BHIS supplemented with 2 mM taurocholate
(TC), or BHIS supplemented with 2 mM taurocholate and 2 mM chenodeoxycholate (CDCA).
Values were obtained from Heeg et al. 2012 and represent the optical density loss percentage
after incubation of C. difficile spores with bile salts after 2 h.

4.4. Conclusions
The efficacy of anti-germination molecules is dependent on the initial recognition
by putative Ger receptors found on the bacterial spores’ inner membrane. Although Ger
receptor homologs have been found in most sporulating bacteria, these receptors are
conspicuously absent from C. difficile’s genome. However, given the physiological
importance of the germination process, C. difficile must encode proteinaceous
machinery that provides a link between the external environment and the initiation of
germination.
The absence of conventional Ger receptor genes suggests that C. difficile likely
encodes receptors that are too divergent from other sporulating bacteria. This could
also suggest that C. difficile recognizes unique germinants. Indeed, several studies
have demonstrated that C. difficile spores recognize bile acids and subsequently
undergo germination. This evidence is further supported by the presence of bile acids
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that can inhibit the process of germination by competing with a putative bile acid binding
site.
Previous studies have suggested that Ger receptors are proteinaceous
heterocomplexes commonly encoded by a tricistron. Moreover, germinant recognition
occurs presumably by the A- and B-subunits of these heterocomplexes42,69. Recently.
Francis et al. suggested that C. difficile spores use CspC, a subtilisin-like
pseudoprotease, to sense bile acids86. Similar to the Ger receptor family of proteins,
CspC is also part of a tricistronic operon. Thus, while CspC may be essential for C.
difficile spore germination, other Csp proteins may be directly sensing bile acids.
In our study, we initially questioned whether the other Csp proteins, CspA and
CspB, are essential for C. difficile spore germination. We generated clean knockouts of
CspA, CspB, CspC, and CspBA. These knockout mutants were unable to germinate in
response to taurocholate and glycine, suggesting that all Csp proteins are essential for
germination (Fig. 4.5). Interestingly, these mutants were also unable to establish
disease in antibiotic-treated hamsters, even when challenged with 10-fold higher titers
than what is necessary to elicit disease. This confirmed that, as previously reported, all
Csp proteins were required for germination under in vitro and in vivo scenarios.
Since the Csp proteins are required for C. difficile spore germination in response
to taurocholate and glycine, we wanted to identify a genetic basis for bile acid
recognition. We used a series of genetic screens and selections in an attempt to identify
C. difficile individuals that have germination phenotypes that vary substantially from the
general population. In our initial attempts to identify these variants, we noticed that a
subset of C. difficile strain R20291 spores could germinate in response to compound
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12a, our lead anti-germination compound (Fig. 4.6).
We were unable to enrich for C. difficile strain R20291 individuals able to
germinate in response to compound 12a (Fig. 4.7). Through these screens and
enrichments, we were further able to characterize compound 12a and demonstrated
that compound 12a does not increase spore recovery by solubilizing the spore
membrane. Interestingly, our plating assays suggest that C. difficile strain R20291
spores germinate in response to compound 12a, with the addition of unknown
molecules found in BHIS. The absence of these unknown molecules from CDMM and
DPA-release assays further support this hypothesis.
At this point, our data suggests that compound 12a is able to activate putative
bile salt receptors and prime the spores for germination without losing wet heat
resistance (Fig. 4.9). If treated with compound 12a and provided ample time in complex
media, a population of spores may be driven to form conies (Fig. 4.6). Under more
restrictive in vitro conditions, such as optical density loss and DPA release assays, the
spores seemingly are unable to germinate (Fig. 4.10).
Since we were unable to isolate C. difficile strain R20291 individuals able to
germinate in response to compound 12a, we undertook a molecular approach to identify
the basis for bile acid recognition. We examined the cspC genes from a panel of C.
difficile isolates that exhibited varying germination responses toward bile acids. We
were, however, unable to establish a correlation between cspC and the different
germination phenotypes. Our data suggests that while CspC is required for germination,
CspC may not be directly involved in sensing bile salts. Through a series of point
mutations, recent work by Rohlfing et al. raised the possibility that CspC could function
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downstream of a bile acid receptor, where the true bile acid receptor still remains
unknown195.
Given the mechanism by which other sporulating bacteria sense their cognate
germinants, CspC may also be part of a heterocomplex formed by CspA and/or CspB,
whereas CspA and CspB could be directly involved in bile acid recognition. Thus, the
genes coding for CspA and CspB could be sequenced from our panel of C. difficile
germination variants in hopes of identifying a genetic basis behind bile acid recognition.
Using our knockout/complementation system, we could also introduce point mutations
into CspA and CspB to further interrogate the function of these proteins.
Given the importance of C. difficile spore germination and its relevance to the
onset of CDI, there is a dire need to identify the receptor involved in bile acid
recognition. By solving the identity of the bile acid receptor, a potential link could be
established between germination phenotype and genes encoding the receptor. We
hypothesize that by elucidating a relationship between putative bile acid receptor genes
and germination phenotype, anti-germinant cocktails could be tailored to each patient
based on which C. difficile strains are eliciting disease. In this study, we verified three
essential germination proteins believed to function in germinant/anti-germinant
recognition. We were, however, unable to establish a correlation between CspC, a
protein believed to function bile acid recognition, and germination phenotype in
response to bile acids.
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
CDIs are the leading cause of antibiotic-associated diarrhea worldwide. In the
United States alone, there are approximately 500,000 CDI cases annually with
associated costs estimating to be about $6.3 billion in treating and managing the
disease. Due to its physiology, C. difficile can only survive outside the host as highly
resistant spores. C. difficile spores, however, do not elicit disease but instead act as
infectious vehicles. Following ingestion by a host, C. difficile spores transit through the
gastrointestinal tract where they can transform into toxin producing, metabolically active
cells through a process known as germination. Since germination from a C. difficile
spore to a toxin producing C. difficile cell is required for the onset of CDI, inhibiting the
process of germination could potentially dictate the course of disease.
The process of germination is triggered by various environmental signals termed
germinants. C. difficile spores germinate in response to taurocholate, a natural bile acid
produced by the mammalian liver. Conversely, chenodeoxycholate, another naturally
occurring bile acid, can inhibit C. difficile spore germination by competing with
taurocholate for a putative binding site. Thus, the delicate balance between taurocholate
and chenodeoxycholate in the gastrointestinal tract often dictates the progression of
CDI.
Chenodeoxycholate was previously been shown to prevent C. difficile spore
germination in vitro. Given the significance of C. difficile spore germination as a
determinant of CDI onset, several studies have evaluated the use of potential antigermination compounds as a form of CDI treatment and prophylaxis85,93. We previously
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synthesized and identified CamSA, a metanilic acid derivative of taurocholate, to be a
potent inhibitor of C. difficile strain 630 spore germination in vitro84. Significantly,
CamSA could prevent CDI in antibiotic-treated mice by inhibiting C. difficile spore
germination in vivo150,151. CamSA, when used with suboptimal concentrations of
vancomycin, could fully protect hamsters when challenged with C. difficile spores; when
used alone, CamSA could double the mean time of death in hamsters156.
The in vitro and in vivo efficacy of CamSA could support the use of CamSA and
other anti-germinants as a form of prophylactic treatment in humans against CDI. We
envision that our anti-germination therapies would be administered to high-risk CDI
patients. These patients would likely be exposed to antibiotics, consequently shifting the
endogenous bile acid populations to one that is conductive of C. difficile spore
germination92.
To be effective in humans, CamSA as well as other anti-germinants, should
demonstrate not only efficacy, but low toxicity, negligible drug-drug interactions, and low
intestinal absorption. Demonstrating limited intestinal absorption would ensure that antigermination compounds are co-localized with C. difficile spores. Low intestinal
absorption would also reduce the possibility that CamSA is distributed to other tissue
and organ groups, where unfavorable side effects could occur. Thus, we initially
determined CamSA’s pharmacokinetic parameters in vivo using an antibiotic-treated
mouse model. Work from our lab demonstrated that CamSA was more stable to the gut
microbiota of antibiotic-treated mice than to the gut microbiota of non-treated mice151.
Furthermore, our lab also confirmed that CamSA, and not its metabolites, was
responsible for preventing CDI onset.
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CamSA demonstrated some unexpected, but very favorable, pharmacokinetic
parameters in our antibiotic-treated mouse model. Since CamSA was able to prevent
CDI onset by co-localizing with C. difficile spores and inhibiting spore germination in
vivo, we hypothesized that a majority of CamSA should be excreted and found in the
feces. We monitored CamSA excretion in the feces up to one week post-administration
and were able to recover approximately 30% of the total dosed CamSA. By monitoring
CamSA from the feces, there were two fascinating observations. First, CamSA did not
exhibit excretion kinetics similar to most drugs where there is a first rapid increase in
drug concentration followed by an exponential decline. Second, CamSA was retained in
the animal’s intestines for, up to, an astounding week post administration.
Since CamSA was retained in the mouse intestines up to a week post
administration, we hypothesized a scenario where CamSA could be absorbed into
systemic circulation and distributed to tissue groups where a CamSA reservoir can be
established. We therefore monitored CamSA from the blood and liver from five predetermined time points over the course of a week following CamSA administration. We
recovered approximately 3% of the total dosed CamSA from the liver samples. Since
CamSA was present in the liver, this suggested to us that CamSA may be absorbed
from the intestinal lumen and subsequently distributed to the liver.
Previous studies using an in vitro Caco-2 assay for intestinal permeability
suggested that CamSA has low intestinal permeability151. Furthermore, the Caco-2
permeability assay also suggested that CamSA would be actively pumped into the
intestinal lumen. In agreement with these data, we were unable to detect or quantify
CamSA from our blood samples.
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The presence and absence of CamSA from the liver and blood, respectively,
suggests a mechanism whereby CamSA bypasses systemic circulation and localizes to
the liver. We propose CamSA undergoes enterohepatic circulation. Enterohepatic
circulation is a process used to recycle bile acids. Bile acids are continually absorbed
from the lower gastrointestinal tract and shuttled back to the liver for reuse. Our feces
data, which demonstrated a wave pattern observed for CamSA’s recovery over the
course of a week, further supports our hypothesis that CamSA undergoes enterohepatic
circulation188. If CamSA is being subjected to enterohepatic circulation, these data,
interestingly, suggest that CamSA is being recognized as a bile acid by the host.
We also assayed for a potential interaction between CamSA and CYP3A4, a
P450 isozyme involved in bile acid metabolism found abundantly in the liver. Using a
fluorescence-based assay, we identified a weak interaction between CamSA and
CYP3A4. While high concentrations of CamSA may inhibit CYP3A4 activity, we do not
expect CamSA to reach toxic concentrations in the liver. While the concentration of
CamSA in the liver of hamsters treated with 300 mg/kg per day for 30 consecutive days
is unknown, these animals displayed no adverse physiological or behavioral effects.
These hamsters also exhibited no histological anomalies and were indistinguishable
from untreated animals, suggesting that CamSA is not readily toxic at the
concentrations used156.
By recirculating between the liver and the intestines, enterohepatic circulation of
CamSA provides a means by which CamSA can be retained in the mouse up to seven
days post-administration. Hence, enterohepatic circulation allows CamSA to be present
in the mouse for extended periods of time after an initial dosage. This also provides
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supporting evidence as to why a single CamSA dose is sufficient to protect mice from
CDI, even though spores remain in the colon for three days post challenge150,151.
Similarly, hamsters challenged with C. difficile spores continually shed C. difficile spores
after cessation of CamSA treatment but do not develop disease156.
While CamSA was able to prevent C. difficile strain 630 spore germination both in
vitro and in vivo, CamSA, however, was unable to prevent the germination of C. difficile
strain R20291 spores. C. difficile strain R20291 is a BI/NAP1/027 hypervirulent strain of
C. difficile and represents a substantial challenge in developing anti-germination
therapies as an alternative form of treatment against CDI. Thus, the emergence of
hypervirulent C. difficile strains has further complicated CDI management in clinical
settings and altered the statistics of CDI.
Since CamSA was inactive against C. difficile strain R20291, we examined
approximately 200 cholate analogs with side chain modifications against spores from
the hypervirulent strain. From an initial chemical library consisting of approximately 70
cholate analogs, we identified compound 12a, a phenyl derivative of cholate, to be a
potent inhibitor of C. difficile strain R20291 spore germination. As a comparison, while
CamSA was active only against strain 630 spores, compound 12a was active against
strain R20291 and strain 630 spores in vitro (J. Phan, unpublished data).
By analyzing compounds from this initial library, our collaborators were able to
determine quantitative structure-activity relationships (QSAR). These QSAR analyses
would be used to design subsequent generations of cholate analogs active against
strain R20291 spores. Our collaborators’ QSAR analyses suggested that active
compounds were more hydrophobic and exhibited smaller molecular surfaces, relative

149

to their inactive counterparts. In our own hands, we were also able to determine
structure activity relationships (SAR) through a closer examination of a subset of
compounds. Our SAR analyses suggested that smaller alkyl linkages between the
amide nitrogen and the cyclic side chain, as well as more constrained rings, exhibited
more potent activity. In our SAR analyses, we also observed a dominant effect of
fluorine substitution on anti-germination activity.
Following the identification of compound 12a, we identified compound SKS-IX01C, an indoline derivative of cholate, to also be a potent germination inhibitor of C.
difficile strain R20291 spores. Compound SKS-IX-01C was in agreement with our SAR
analyses but partly contradicted our collaborators’ QSAR analyses. Re-evaluation of the
compounds used to establish QSAR trends suggested that inactive molecules exhibited
larger molecular surfaces due to their bulky, polar groups. As such, larger molecules
may actually exhibit activity in the absence of polar functional groups.
Since the side chain of compound SKS-IX-01C has a larger framework compared
to compound 12a, and was also active against strain R20291 spores, this allowed us to
develop a new generation of compounds using the indoline side chain as a scaffold.
Currently, our most potent compound identified is compound ARS-I-16C. Compound
ARS-I-16C is a 5-fluoro-indoline derivative of cholate and is over 1,000-fold more potent
that chenodeoxycholate. In line with our SAR analyses, compound ARS-I-16C contains
a planar and rigid indoline side chain bonded directly to the amide nitrogen. Addition of
a fluorine group to the indoline side chain further increased the activity of this
compound, relative to compound SKS-IX-01C.
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Our SAR analyses, as well as QSAR analyses performed by our collaborators,
suggested that hydrophobic compounds were generally more active than their
hydrophilic/polar counterparts. Thus, future anti-germinants could be designed to
contain more nonpolar groups to allow for potent anti-germination activity. These
compounds, however, would likely be insoluble in aqueous solutions and in vivo
scenarios. In order to improve the solubility of our compounds, pro-drug versions of our
anti-germination compounds can be designed. We envision, in one scenario, that our
compounds could contain polar functional groups anchored to esters at positions 3, 7,
and 12 of the cholate backbone. Under in vivo conditions, gastrointestinal esterases and
lipases can hydrolyze the ester bonds, liberating the active anti-germination compounds
at the site of action.
Currently, we have only examined the efficacy of cholate analogs with side chain
modifications. All of the compounds described within this study contain amides that are
susceptible to hydrolysis. In later studies, we hope to increase the in vivo stability of our
anti-germination compounds by designing compounds that lack the amide but can still
exhibit in vitro and in vivo activity. Similarly, we have not yet examined the effect of
modifications along the cholate backbone. We will also design our future generations of
compounds to contain modifications at the 3, 7, and 12 hydroxyl positions to
demonstrate more favorable pharmacokinetic parameters.
We have identified a total of 24 anti-germinants with IC50 values between 0.35
µM and 37 µM against C. difficile strain R20291 spores. While CamSA was inactive
against C. difficile strain R20291 spores, several of the compounds identified in this
study are equally effective against C. difficile strain 630. However, the efficacy of these
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compounds in vivo has not yet been determined. Significantly, to our knowledge,
several compounds identified in this study account for the most potent anti-germinants
described to date against C. difficile.
Since C. difficile strains 630 and R20291 spores exhibited different responses to
CamSA, a major unknown that needs to be addressed is the identity of the C. difficile
bile acid receptor. C. difficile does not encode homologs of conventional germination
receptors found in other sporulating bacteria. However, previous studies performed by
our lab and others have suggested the presence of a bile acid receptor. More recently,
several studies have suggested that C. difficile uses CspC, a catalytically inactive,
subtilisin-like protease, to recognize bile acids.
Interestingly, the gene encoding CspC is part of a tricistron, similar to the Ger
receptor family of proteins found in other sporulating bacteria. Given this, we generated
knockouts of the other Csp proteins (CspA and CspB) and determined their essentiality
as it pertains to C. difficile spore germination. The ∆Csp mutants were unable to
germinate in response to taurocholate and glycine and thus suggests that all Csp
proteins are required for germination. At this point, our data does not reveal the identity
of the bile acid receptor.
We designed a series of screens and enrichments in hopes of identifying C.
difficile individuals with germination phenotypes that deviate from the larger C. difficile
population. We proposed that whole genome sequencing of these variants could
potentially identify mutations that resulted in the germination response differences.
These mutations could have occurred in genes encoding a putative bile acid receptor.
During our initial rounds of screens, our data demonstrated that a large subset of C.
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difficile strain R20291 spores were able to germinate in response to compound 12a, our
potent anti-germinant. From this, we decided to identify individuals that could germinate
robustly when exposed to compound 12a. These individuals would then be sequenced
in parallel to individuals unable to germinate in response to compound 12a.
Unfortunately, we were unable to enrich and isolate for individuals that were able
to germinate in response to compound 12a. Since previous studies suggested that
CspC was the bile acid receptor, we wanted to determine if we could establish a
correlation between the cspC gene and germination phenotype. We sequenced the
gene coding for CspC from a panel of C. difficile isolates with a variety of germination
responses. Our data showed that CspC from strain 630 was identical to CspC from
strains 7004578, 8085054, and 9001966. However, the germination profiles of these
strains, in response to taurocholate and chenodeoxycholate, are highly divergent.
Hence, comparison of strain 630 with strains 7004578, 8085054, and 9001966 suggests
that CspC may not be directly involved in bile acid recognition. Our data also showed
CspC from strain R20291 was identical to CspC from strains CDC38 and DH1834.
Likewise, strains R20291, CDC38, and DH1834 exhibit different germination
phenotypes in response to bile salts despite CspC sequence similarity.
Our research group, and others, have proposed the use of anti-germinants as an
alternative form of treatment and prophylaxis for CDI. This study has allowed for a
better understanding of C. difficile prophylactics, both in vitro and in vivo. Clinically,
while we cannot determine if a reservoir of C. difficile spores is present within a host, we
envision that anti-germination compounds could be continually administered to patients
prior to antibiotic treatment. While depletion of the gastrointestinal microbiota would shift
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the bile acid composition to an environment conductive of C. difficile spore germination,
anti-germinants administered during this time would inhibit this process. Antigermination compounds could also be co-administered with antibiotics following CDI
onset. In these scenarios, the antibiotics would eradicate the toxin-producing cells of C.
difficile, while anti-germinants prevent the subsequent generation of disease-causing
cells from metabolically dormant spores.
Since CDI is an intestinal disease, anti-germination compounds should be
retained in the gastrointestinal lumen where they co-localize with C. difficile spores. Our
Caco-2 in vitro assays suggested that CamSA should be retained in the intestinal
lumen; these data also strongly suggest that CamSA is actively pumped from systemic
circulation into the intestinal lumen. In agreement with this data, we were unable to find
CamSA in the blood from dosed animals. Interestingly, our pharmacokinetic data
suggests that CamSA is being recognized as a bile acid and subjected to enterohepatic
circulation. This was an astonishing result because an anti-germinant reservoir can be
established, thereby preventing disease onset even after cessation of anti-germination
therapy. While a drug reservoir may seem unfavorable by potentiating toxicity, no
toxicity was observed in hamsters even after dosed saturating concentrations of CamSA
over the course of 30 days.
As we develop more potent anti-germination compounds, these pharmacokinetic
parameters must be re-established. All of our anti-germination compounds generated
thus far are cholate analogs. We presume with the cholate backbone, these antigerminants should also be recognized as bile acids and be subjected to enterohepatic
circulation. Our most potent compounds however, in line with our QSAR and SAR
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analyses, exhibit low solubility in aqueous solutions. Thus, our subsequent antigermination compounds must be modified to increase solubility, retain anti-germination
activity in vivo, and still be recognized as a bile acid to undergo enterohepatic
circulation.
Lastly, the expansive repertoire of C. difficile strains poses a significant challenge
for developing anti-germination compounds. This challenge was made noticeable when
CamSA was inactive against R20291, a hypervirulent strain of C. difficile. As progress is
made toward identifying the C. difficile proteins involved in bile acid recognition,
potential anti-germination cocktails could be potentially formulated based on C. difficile
strains infecting a patient.
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